<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Treatment for superficial thrombophlebitis of the leg - Di Nisio, M - 2018 | Cochrane Library</title> <meta content="Treatment for superficial thrombophlebitis of the leg - Di Nisio, M - 2018 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004982.pub6/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Treatment for superficial thrombophlebitis of the leg - Di Nisio, M - 2018 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004982.pub6/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD004982.pub6" name="dc.identifier" scheme="DOI"/> <meta content="Treatment for superficial thrombophlebitis of the leg" name="citation_title"/> <meta content="Marcello Di Nisio" name="citation_author"/> <meta content="mdinisio@unich.it" name="citation_author_email"/> <meta content="Iris M Wichers" name="citation_author"/> <meta content="The Dutch College of General Practitioners" name="citation_author_institution"/> <meta content="Saskia Middeldorp" name="citation_author"/> <meta content="Academic Medical Center" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="2" name="citation_issue"/> <meta content="10.1002/14651858.CD004982.pub6" name="citation_doi"/> <meta content="2018" name="citation_date"/> <meta content="2018/02/25" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004982.pub6/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004982.pub6/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004982.pub6/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Anti‐Inflammatory Agents, Non‐Steroidal [*therapeutic use]; Anticoagulants [*therapeutic use]; Factor Xa Inhibitors [therapeutic use]; Fondaparinux; Hemorrhage [chemically induced]; Heparin, Low‐Molecular‐Weight [*therapeutic use]; Polysaccharides [therapeutic use]; Randomized Controlled Trials as Topic; Rivaroxaban [therapeutic use]; Stockings, Compression; Thrombectomy; Thromboembolism [prevention &amp; control]; Thrombophlebitis [drug therapy, surgery, *therapy]; Venous Thromboembolism [*prevention &amp; control]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004982.pub6&amp;doi=10.1002/14651858.CD004982.pub6&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004982.pub6&amp;doi=10.1002/14651858.CD004982.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004982.pub6&amp;doi=10.1002/14651858.CD004982.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004982.pub6&amp;doi=10.1002/14651858.CD004982.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004982.pub6&amp;doi=10.1002/14651858.CD004982.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004982.pub6&amp;doi=10.1002/14651858.CD004982.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004982.pub6&amp;doi=10.1002/14651858.CD004982.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004982.pub6&amp;doi=10.1002/14651858.CD004982.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004982.pub6&amp;doi=10.1002/14651858.CD004982.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004982.pub6&amp;doi=10.1002/14651858.CD004982.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004982.pub6&amp;doi=10.1002/14651858.CD004982.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004982.pub6&amp;doi=10.1002/14651858.CD004982.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004982.pub6&amp;doi=10.1002/14651858.CD004982.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004982.pub6&amp;doi=10.1002/14651858.CD004982.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004982.pub6&amp;doi=10.1002/14651858.CD004982.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004982.pub6&amp;doi=10.1002/14651858.CD004982.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004982.pub6&amp;doi=10.1002/14651858.CD004982.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004982.pub6&amp;doi=10.1002/14651858.CD004982.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004982.pub6&amp;doi=10.1002/14651858.CD004982.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004982.pub6&amp;doi=10.1002/14651858.CD004982.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004982.pub6&amp;doi=10.1002/14651858.CD004982.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004982.pub6&amp;doi=10.1002/14651858.CD004982.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004982.pub6&amp;doi=10.1002/14651858.CD004982.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="k5rEBE5b";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD004982\x2epub6\x26doi\x3d10\x2e1002\x2f14651858\x2eCD004982\x2epub6\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004982\x2epub6\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004982\x2epub6\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","pt","ms","fa","zh_HANS"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD004982.pub6",title:"Treatment for superficial thrombophlebitis of the leg",firstPublishedDate:"Feb 25, 2018 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Vascular Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=k5rEBE5b&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004982.pub6&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD004982.pub6';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD004982.pub6/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD004982.pub6/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004982.pub6%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD004982.PUB6" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD004982.pub6/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD004982.PUB6" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD004982.pub6/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD004982.pub6/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>10380 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD004982.pub6" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004982.pub6/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004982.pub6/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004982.pub6/full#CD004982-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004982.pub6/full#CD004982-sec-0075"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004982.pub6/full#CD004982-sec-0029"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004982.pub6/full#CD004982-sec-0030"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004982.pub6/full#CD004982-sec-0034"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004982.pub6/full#CD004982-sec-0035"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004982.pub6/full#CD004982-sec-0052"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004982.pub6/full#CD004982-sec-0070"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004982.pub6/appendices#CD004982-sec-0080"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/table_n/CD004982StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/table_n/CD004982StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004982.pub6/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004982.pub6/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004982.pub6/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD004982.pub6/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD004982.pub6/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD004982.pub6/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2018 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Treatment for superficial thrombophlebitis of the leg</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004982.pub6/information#CD004982-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Marcello Di Nisio</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004982.pub6/information#CD004982-cr-0003">Iris M Wichers</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004982.pub6/information#CD004982-cr-0004">Saskia Middeldorp</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/information/en#CD004982-sec-0099">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 25 February 2018 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD004982.pub6">https://doi.org/10.1002/14651858.CD004982.pub6</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD004982-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD004982-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD004982-abs-0006">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD004982-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/pt#CD004982-abs-0002">Português</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD004982-abs-0010">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD004982-abs-0001" lang="en"> <section id="CD004982-sec-0001"> <h3 class="title" id="CD004982-sec-0001">Background</h3> <p>The optimal treatment of superficial thrombophlebitis (ST) of the legs remains poorly defined. While improving or relieving the local painful symptoms, treatment should aim at preventing venous thromboembolism (VTE), which might complicate the natural history of ST. This is the third update of a review first published in 2007. </p> </section> <section id="CD004982-sec-0002"> <h3 class="title" id="CD004982-sec-0002">Objectives</h3> <p>To assess the efficacy and safety of topical, medical, and surgical treatments for ST of the leg in improving local symptoms and decreasing thromboembolic complications. </p> </section> <section id="CD004982-sec-0003"> <h3 class="title" id="CD004982-sec-0003">Search methods</h3> <p>For this update, the Cochrane Vascular Information Specialist searched the Cochrane Vascular Specialised Register (March 2017), CENTRAL (2017, Issue 2), and trials registries (March 2017). We handsearched the reference lists of relevant papers and conference proceedings. </p> </section> <section id="CD004982-sec-0004"> <h3 class="title" id="CD004982-sec-0004">Selection criteria</h3> <p>Randomised controlled trials (RCTs) evaluating topical, medical, and surgical treatments for ST of the legs that included people with a clinical diagnosis of ST of the legs or objective diagnosis of a thrombus in a superficial vein. </p> </section> <section id="CD004982-sec-0005"> <h3 class="title" id="CD004982-sec-0005">Data collection and analysis</h3> <p>Two authors assessed the trials for inclusion in the review, extracted the data, and assessed the quality of the studies. Data were independently extracted from the included studies and any disagreements resolved by consensus. We assessed the quality of the evidence using the GRADE approach. </p> </section> <section id="CD004982-sec-0006"> <h3 class="title" id="CD004982-sec-0006">Main results</h3> <p>We identified three additional trials (613 participants), therefore this update considered 33 studies involving 7296 people with ST of the legs. Treatment included fondaparinux; rivaroxaban; low molecular weight heparin (LMWH); unfractionated heparin (UFH); non‐steroidal anti‐inflammatory drugs (NSAIDs); compression stockings; and topical, intramuscular, or intravenous treatment to surgical interventions such as thrombectomy or ligation. Only a minority of trials compared treatment with placebo rather than an alternative treatment and many studies were small and of poor quality. Pooling of the data was possible for few outcomes, and none were part of a placebo‐controlled trial. In one large, placebo‐controlled RCT of 3002 participants, subcutaneous fondaparinux was associated with a significant reduction in symptomatic VTE (risk ratio (RR) 0.15, 95% confidence interval (CI) 0.04 to 0.50; moderate‐quality evidence), ST extension (RR 0.08, 95% CI 0.03 to 0.22; moderate‐quality evidence), and ST recurrence (RR 0.21, 95% CI 0.08 to 0.54; moderate‐quality evidence) relative to placebo. Major bleeding was infrequent in both groups with very wide CIs around risk estimate (RR 0.99, 95% CI 0.06 to 15.86; moderate‐quality evidence). In one RCT on 472 high‐risk participants with ST, fondaparinux was associated with a non‐significant reduction of symptomatic VTE compared to rivaroxaban 10 mg (RR 0.33, 95% CI 0.03 to 3.18; low‐quality evidence). There were no major bleeding events in either group (low‐quality evidence). In another placebo‐controlled trial, both prophylactic and therapeutic doses of LMWH (prophylactic: RR 0.44, 95% CI 0.26 to 0.74; therapeutic: RR 0.46, 95% CI 0.27 to 0.77) and NSAIDs (RR 0.46, 95% CI 0.27 to 0.78) reduced the extension (low‐quality evidence) and recurrence of ST (low‐quality evidence) in comparison to placebo, with no significant effects on symptomatic VTE (low‐quality evidence) or major bleeding (low‐quality evidence). Overall, topical treatments improved local symptoms compared with placebo, but no data were provided on the effects on VTE and ST extension. Surgical treatment combined with elastic stockings was associated with a lower VTE rate and ST progression compared with elastic stockings alone. However, the majority of studies that compared different oral treatments, topical treatments, or surgery did not report VTE, ST progression, adverse events, or treatment adverse effects. </p> </section> <section id="CD004982-sec-0007"> <h3 class="title" id="CD004982-sec-0007">Authors' conclusions</h3> <p>Prophylactic dose fondaparinux given for 45 days appears to be a valid therapeutic option for ST of the legs for most people. The evidence on topical treatment or surgery is too limited and does not inform clinical practice about the effects of these treatments in terms of VTE. Further research is needed to assess the role of rivaroxaban and other direct oral factor‐X or thrombin inhibitors, LMWH, and NSAIDs; the optimal doses and duration of treatment in people at various risk of recurrence; and whether a combination therapy may be more effective than single treatment. Adequately designed and conducted studies are required to clarify the role of topical and surgical treatments. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD004982-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD004982-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD004982-abs-0007">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD004982-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ms#CD004982-abs-0005">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pt#CD004982-abs-0004">Português</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD004982-abs-0011">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD004982-abs-0003" lang="en"> <h3>Treatment for superficial thrombophlebitis of the leg</h3> <p><b>Background</b> </p> <p>Superficial thrombophlebitis (ST) is a relatively common inflammatory process associated with a blood clot (thrombus) that affects the superficial veins (veins that are close to the surface of the body). Symptoms and signs include local pain, itching, tenderness, reddening of the skin, and hardening of the surrounding tissue. There is some evidence to suggest a link between ST and venous thromboembolism (VTE; a condition where blood clots form (most often) in the deep veins of the leg and can travel in the circulation and lodge in the lungs). Treatment aims to relieve the local symptoms and to prevent the extension of the clot into a deep vein, ST recurrence, or the development of more serious events caused by VTE. This is the third update of a review first published in 2007. The evidence is current to March 2017. </p> <p><b>Study characteristics and key results</b> </p> <p>This update included 33 randomised controlled trials (clinical trials where people are randomly put into one of two or more treatment groups) involving 7296 participants. Treatments included rivaroxaban (a medicine called a direct oral inhibitor of activated factor X), injections of medicines under the skin to prevent blood clotting (e.g. fondaparinux, low molecular weight heparin, or unfractionated heparin), elastic compression stockings, oral non‐steroidal anti‐inflammatory drugs (NSAIDs; a pain killer medicine), topical treatment (medicine applied to the skin), and surgery. </p> <p>One large study, accounting for half of the participants included in the review, showed that treatment with fondaparinux for 45 days was associated with a significant reduction in symptomatic VTE (where symptoms indicate there is a VTE), ST extension (where the clot moves further up the leg), and recurrence of ST (where clots return) compared to placebo. Major bleeding was infrequent in both groups. In one study in people with ST at high risk of recurrent thromboembolic events, fondaparinux was associated with a non‐significant reduction of symptomatic VTE compared to rivaroxaban. There were no major bleeding events in either group. Both low molecular weight heparin and NSAIDs reduced the occurrence of extension or recurrence of ST with no effect on symptomatic VTE or major bleeding. Topical treatments relieved local symptoms but the trials did not report on progression to VTE. Surgical treatment and wearing elastic stockings were associated with a lower rate of VTE and progression of the ST compared with elastic stockings alone. </p> <p><b>Quality of the evidence</b> </p> <p>Overall, the quality of evidence was very low for most treatments due to poor study design, imprecision of results, lack of a placebo (non‐treated) group and only one study in some comparison. The quality of evidence was low to moderate for comparisons in two placebo‐controlled trials. </p> <p>In conclusion, fondaparinux appears to be an adequate treatment for most people with ST. The optimal dose and duration of treatment need to be established in people at high risk as well as people at low risk for recurrent thrombotic events. Further research is needed to assess the role of rivaroxaban and other such medicines, or thrombin, low molecular weight heparin or NSAIDs and to demonstrate the effectiveness, if any, of topical treatment, or surgery in terms of VTE<i>.</i> </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD004982-sec-0075" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD004982-sec-0075"></div> <h3 class="title" id="CD004982-sec-0076">Implications for practice</h3> <section id="CD004982-sec-0076"> <p>Given the available evidence, prophylactic‐dose fondaparinux appears to be a valid treatment option in most people with ST. Fondaparinux should be given at a dose of 2.5 mg subcutaneously once daily for 45 days. Final recommendations cannot be drawn for rivaroxaban, low molecular weight heparin (LMWH), unfractionated heparin, or non‐steroidal anti‐inflammatory drugs (NSAID). Data are still too preliminary to draw firm conclusions on the role of surgery and the topical, oral, and parenteral treatments evaluated this far. </p> </section> <h3 class="title" id="CD004982-sec-0077">Implications for research</h3> <section id="CD004982-sec-0077"> <p>Several questions about the treatment of ST remain unsolved. The role of rivaroxaban and other oral direct factor Xa inhibitors for the management of ST requires further evaluation. As suggested by the results of the SURPRISE study, the efficacy of anticoagulant treatment may vary according to the presence of underlying risk factors for recurrent thromboembolic events (<a href="./references#CD004982-bbs2-0008" title="Beyer‐WestendorfJ , SchellongSM , GerlachH , RabeE , WeitzJI , JersemannK , et al. Prevention of thromboembolic complications in patients with superficial‐vein thrombosis given rivaroxaban or fondaparinux: the open‐label, randomised, non‐inferiority SURPRISE phase 3b trial. Lancet Haematology2017;4(3):e105‐13. WerthS , BauersachsR , GerlachH , RabeE , SchellongS , Beyer‐WestendorfJ . Superficial vein thrombosis treated for 45 days with rivaroxaban versus fondaparinux: rationale and design of the SURPRISE trial. Journal of Thrombosis and Thrombolysis2016;42(2):197‐204. ">Beyer‐Westendorf 2017</a>). Individuals at increased risk could benefit of higher intensity or longer anticoagulant treatment. The usefulness, potential healthcare benefits and cost‐savings of risk stratification tools needs to be evaluated. Additional studies should assess the costs, effects on quality of life, and the cost‐effectiveness of fondaparinux (<a href="./references#CD004982-bbs2-0086" title="GoldmanL , GinsbergJ . Superficial phlebitis and phase 3.5 trials. New England Journal of Medicine2010;363(13):1278‐80. ">Goldman 2010</a>). Large and adequately designed randomised controlled trials would be required to assess the actual role of NSAIDs and LMWH, and how these drugs compare with fondaparinux. Whether topical treatment might add some benefit if given in combination with fondaparinux remains unclear. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD004982-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD004982-sec-0029"></div> <div class="table" id="CD004982-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Fondaparinux compared to placebo for superficial thrombophlebitis of the leg</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Fondaparinux compared to placebo for superficial thrombophlebitis of the leg</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with ST of the leg<br/> <b>Settings:</b> hospitalised or non‐hospitalised<br/> <b>Intervention:</b> fondaparinux<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Fondaparinux</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Symptomatic VTE</b><br/> Ventilation‐perfusion scanning, helical computed tomography, pulmonary angiography, autopsy, ultrasonography, or venography<br/> Follow‐up: 77 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>13 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>2 per 1000</b><br/> (1 to 7) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.15</b> <br/> (0.04 to 0.5) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3002<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Major bleeding</b><br/> Follow‐up: 77 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>1 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>1 per 1000</b><br/> (0 to 11) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.99</b> <br/> (0.06 to 15.86) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2987<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Extension of ST</b><br/> Ultrasonography<br/> Follow‐up: 77 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>34 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>3 per 1000</b><br/> (1 to 7) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.08</b> <br/> (0.03 to 0.22) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3002<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Recurrence of ST</b><br/> Ultrasonography<br/> Follow‐up: 77 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>16 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>3 per 1000</b><br/> (1 to 9) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.21</b> <br/> (0.08 to 0.54) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3002<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mortality</b><br/> Follow‐up: 77 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1 per 1000</b><br/> (0 to 15) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2</b> <br/> (0.18 to 22) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3002<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Minor bleeding</b><br/> Follow‐up: 77 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>4 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>6 per 1000</b><br/> (2 to 17) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.49</b> <br/> (0.53 to 4.17) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2987<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate<sup>1</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects of treatment</b><br/> Follow‐up: 77 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>33 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>37 per 1000</b><br/> (26 to 54) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.13</b> <br/> (0.78 to 1.65) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2987<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>ST:</b> superficial thrombophlebitis; <b>VTE:</b> venous thromboembolism. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Evidence downgraded one level for imprecision due to a low number of events. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD004982-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Prophylactic LMWH versus placebo for superficial thrombophlebitis of the leg</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Prophylactic LMWH versus placebo for superficial thrombophlebitis of the leg</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with ST of the leg<br/> <b>Settings:</b> hospitalised and non‐hospitalised<br/> <b>Intervention:</b> prophylactic LMWH versus placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Prophylactic LMWH</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Symptomatic VTE</b><br/> Follow‐up: 97 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>45 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>54 per 1000</b><br/> (17 to 174) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.22</b> <br/> (0.38 to 3.89) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>222<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Major bleeding</b><br/> Follow‐up: 97 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>222<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 episodes of major bleeding</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Extension or recurrence (or both) of ST</b><br/> Follow‐up: 97 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>330 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>145 per 1000</b><br/> (86 to 244) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.44</b> <br/> (0.26 to 0.74) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>222<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data not available</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Minor bleeding</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data not available</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects of treatment</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data not available</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>LMWH:</b> low molecular weight heparin; <b>RR:</b> risk ratio; <b>ST:</b> superficial thrombophlebitis; <b>VTE:</b> venous thromboembolism. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Evidence downgraded one level due to unclear random sequence generation and incomplete outcome data.<br/> <sup>2</sup>Evidence downgraded one level for imprecision due to a low number of events. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD004982-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Therapeutic LMWH versus placebo for superficial thrombophlebitis of the leg</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Therapeutic LMWH versus placebo for superficial thrombophlebitis of the leg</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with ST of the leg<br/> <b>Settings:</b> hospitalised and non‐hospitalised<br/> <b>Intervention:</b> therapeutic LMWH versus placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>Placebo</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>Therapeutic LMWH</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Symptomatic VTE</b><br/> Follow‐up: 97 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>45 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>38 per 1000</b> </p> <p>(10 to 137)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.85</b> <br/> (0.23 to 3.06) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>218<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Major bleeding</b><br/> Follow‐up: 97 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>218<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No episodes of major bleeding</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Extension or recurrence (or both) of ST</b><br/> Follow‐up: 97 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>330 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>152 per 1000</b> </p> <p>(89 to 254)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.46</b> <br/> (0.27 to 0.77) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>218<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data not available</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Minor bleeding</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data not available</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects of treatment</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data not available</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>LMWH:</b> low molecular weight heparin; <b>RR:</b> risk ratio; <b>ST:</b> superficial thrombophlebitis; <b>VTE:</b> venous thromboembolism. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Evidence downgraded one level due to an unclear random sequence generation and incomplete outcome data.<br/> <sup>2</sup>Evidence downgraded one level for imprecision due to a low number of events. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD004982-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">NSAIDs versus placebo for superficial thrombophlebitis of the leg</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>NSAIDs versus placebo for superficial thrombophlebitis of the leg</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with superficial thrombophlebitis of the leg<br/> <b>Settings:</b> hospitalised and non‐hospitalised<br/> <b>Intervention:</b> NSAIDs versus placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>NSAIDs</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Symptomatic VTE</b><br/> Follow‐up: 97 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>45 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>41 per 1000</b><br/> (11 to 146) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.91</b> <br/> (0.25 to 3.28) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>211<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Major bleeding</b><br/> Follow‐up: 97 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>211<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 episodes of major bleeding</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Extension or recurrence (or both) of ST</b><br/> Follow‐up: 97 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>330 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>152 per 1000</b><br/> (89 to 258) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.46</b> <br/> (0.27 to 0.78) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>211<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data not available</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Minor bleeding</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data not available</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects of treatment</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data not available</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>NSAIDs:</b> non‐steroidal anti‐inflammatory drugs; <b>RR:</b> risk ratio; <b>ST:</b> superficial thrombophlebitis; <b>VTE:</b> venous thromboembolism. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Evidence downgraded one level due to an unclear random sequence generation and incomplete outcome data.<br/> <sup>2</sup>Evidence downgraded one level for imprecision due to a low number of events. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD004982-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD004982-sec-0030"></div> <section id="CD004982-sec-0031"> <h3 class="title" id="CD004982-sec-0031">Description of the condition</h3> <p>The term superficial thrombophlebitis (ST), also known as superficial venous thrombosis, refers to a pathological state characterised by an inflammatory‐thrombotic process in a superficial vein. Distinctive clinical findings include pain and a reddened, warm, tender cord extending along the vein. The surrounding area may show signs of erythema (reddening of the skin) and oedema (swelling of the tissue). ST is a relatively common disease and, although its incidence has never been properly determined, it is estimated to be higher than that of deep vein thrombosis (DVT), which is about 1 per 1000 cases (<a href="./references#CD004982-bbs2-0082" title="DeWeeseMS . Nonoperative treatment of acute superficial thrombophlebitis and deep femoral venous thrombosis. In: ErnstCB , StanleyJC editor(s). Current Therapy in Vascular Surgery. 2nd Edition. Philadelphia (PA): BC Decker, 1991. ">De Weese 1991</a>; <a href="./references#CD004982-bbs2-0097" title="NordstromM , LindbladB , BergqvistD , KjellstromT . A prospective study of the incidence of deep‐vein thrombosis within a defined urban population. Journal of Internal Medicine1992;232(2):155‐60. ">Nordstrom 1992</a>). In one community‐based study conducted in a population of 265,687 adults in France, the annual diagnosis rate of symptomatic, confirmed ST was 0.64% (95% confidence interval (CI) 0.55% to 0.74%) (<a href="./references#CD004982-bbs2-0085" title="FrappéP , Buchmuller‐CordierA , BertolettiL , Bonithon‐KoppC , CouzanS , LafondP , et al. Annual diagnosis rate of superficial vein thrombosis of the lower limbs: the STEPH community‐based study. Journal of Thrombosis and Haemostasis2014;12(6):831‐8. ">Frappé 2014</a>). </p> <p>While the majority of ST occurs in varicose veins, additional predisposing risk factors similar to those for venous thromboembolism (VTE) include immobilisation, trauma, postoperative states, pregnancy, puerperium (the period immediately following childbirth), active malignancy, autoimmune diseases, use of oral contraceptive pills or hormonal replacement therapy, advanced age, obesity, and a history of previous VTE (<a href="./references#CD004982-bbs2-0075" title="BarrelierMT . Superficial venous thrombosis of the legs. Phlebologie1993;46(4):633‐9. ">Barrelier 1993</a>; <a href="./references#CD004982-bbs2-0076" title="BergqvistD , JaroszewskiH . Deep venous thrombosis in patients with superficial thrombophlebitis of the leg. British Medical Journal1986;292(6521):658‐9. ">Bergqvist 1986</a>; <a href="./references#CD004982-bbs2-0080" title="ChengelisDL , BendickPJ , GloverJL , BrownOW , RanvalTJ . Progression of superficial venous thrombosis to deep vein thrombosis. Journal of Vascular Surgery1996;24(5):745‐9. ">Chengelis 1996</a>; <a href="./references#CD004982-bbs2-0081" title="deMoerlooseP , WutschertR , HeinzmannM , PernegerT , ReberG , BounameauxH . Superficial vein thrombosis of lower limbs: influence of factor V Leiden, Factor II G20210A and overweight. Thrombosis and Haemostasis1998;80(2):239‐41. ">de Moerloose 1998</a>; <a href="./references#CD004982-bbs2-0095" title="LutterKS , KerrTM , RoedersheimerLR , LohrJM , SampsonMG . Superficial thrombophlebitis diagnosed by duplex scanning. Surgery1991;110(1):42‐6. ">Lutter 1991</a>; <a href="./references#CD004982-bbs2-0102" title="SamlaskaCP , JamesWD . Superficial thrombophlebitis II. Secondary hypercoagulable states. Journal of the American Academy of Dermatology1990;23(1):1‐18. ">Samlaska 1990a</a>). Furthermore, the presence of inherited thrombophilia (a disorder where there is a tendency for thrombosis to occur, for example factor V Leiden, the prothrombin 20210A mutation, and deficiencies of the natural anticoagulant proteins C and S) in ST suggests a similar pathophysiology as VTE (<a href="./references#CD004982-bbs2-0081" title="deMoerlooseP , WutschertR , HeinzmannM , PernegerT , ReberG , BounameauxH . Superficial vein thrombosis of lower limbs: influence of factor V Leiden, Factor II G20210A and overweight. Thrombosis and Haemostasis1998;80(2):239‐41. ">de Moerloose 1998</a>; <a href="./references#CD004982-bbs2-0089" title="HansonJN , AscherE , DePippoP , LorensenE , ScheinmanM , YorkovichW , et al. Saphenous vein thrombophlebitis (SVT): a deceptively benign disease. Journal of Vascular Surgery1998;27(4):677‐80. ">Hanson 1998</a>; <a href="./references#CD004982-bbs2-0096" title="MartinelliI , CattaneoM , TaioliE , DeStefanoV , ChiusoloP , MannucciPM . Genetic risk factors for superficial vein thrombosis. Thrombosis and Haemostasis1999;82(4):1215‐7. ">Martinelli 1999</a>; <a href="./references#CD004982-bbs2-0102" title="SamlaskaCP , JamesWD . Superficial thrombophlebitis II. Secondary hypercoagulable states. Journal of the American Academy of Dermatology1990;23(1):1‐18. ">Samlaska 1990a</a>; <a href="./references#CD004982-bbs2-0103" title="SamlaskaCP , JamesWD . Superficial thrombophlebitis I. Primary hypercoagulable states. Journal of the American Academy of Dermatology1990;22(6 Pt 1):975‐89. ">Samlaska 1990b</a>). Traditionally, ST has been considered a relatively benign disease, but several studies have described an association between ST and VTE (<a href="./references#CD004982-bbs2-0076" title="BergqvistD , JaroszewskiH . Deep venous thrombosis in patients with superficial thrombophlebitis of the leg. British Medical Journal1986;292(6521):658‐9. ">Bergqvist 1986</a>; <a href="./references#CD004982-bbs2-0077" title="BlumenbergRM , BartonE , GelfandML , SkudderP , BrennanJ . Occult deep venous thrombosis complicating superficial thrombophlebitis. Journal of Vascular Surgery1998;27(2):338‐43. ">Blumenberg 1998</a>; <a href="./references#CD004982-bbs2-0078" title="BounameauxH , Reber‐WasemMA . Superficial thrombophlebitis and deep venous thrombosis. A controversial association. Archives of Internal Medicine1997;157(16):1822‐4. ">Bounameaux 1997</a>; <a href="./references#CD004982-bbs2-0080" title="ChengelisDL , BendickPJ , GloverJL , BrownOW , RanvalTJ . Progression of superficial venous thrombosis to deep vein thrombosis. Journal of Vascular Surgery1996;24(5):745‐9. ">Chengelis 1996</a>; <a href="./references#CD004982-bbs2-0092" title="JorgensenJO , HanelKC , MorganAM , HuntJM . The incidence of deep venous thrombosis in patients with superficial thrombophlebitis of the lower limbs. Journal of Vascular Surgery1993;18(1):70‐3. ">Jorgensen 1993</a>; <a href="./references#CD004982-bbs2-0094" title="KrunesU , LindnerF , LindnerR , GnutzmannJ . Is the physical diagnosis of below‐knee superficial thrombophlebitis reliable?. Phlebologie1999;28(3):93‐6. ">Krunes 1999</a>; <a href="./references#CD004982-bbs2-0095" title="LutterKS , KerrTM , RoedersheimerLR , LohrJM , SampsonMG . Superficial thrombophlebitis diagnosed by duplex scanning. Surgery1991;110(1):42‐6. ">Lutter 1991</a>; <a href="./references#CD004982-bbs2-0099" title="QuenetS , LaporteS , DecoususH , LeizoroviczA , EpinatM , MismettiP , STENOX Group. Factors predictive of venous thrombotic complications in patients with isolated superficial vein thrombosis. Journal of Vascular Surgery2003;38(5):944‐9. ">Quenet 2003</a>; <a href="./references#CD004982-bbs2-0106" title="UnnoN , MitsuokaH , UchiyamaT , YamamotoN , SaitoT , IshimaruK , et al. Superficial thrombophlebitis of the lower limbs in patients with varicose veins. Surgery Today2002;32(5):397‐401. ">Unno 2002</a>; <a href="./references#CD004982-bbs2-0107" title="VerlatoF , ZucchettaP , PrandoniP , CamporeseG , MarzolaMC , SalmistraroG , et al. An expectedly high rate of pulmonary embolism in patients with superficial thrombophlebitis of the thigh. Journal of Vascular Surgery1999;30(6):1113‐5. ">Verlato 1999</a>). In people with a diagnosis of ST, 6% to 44% have an associated (or develop) DVT, 20% to 33% have asymptomatic pulmonary embolism (PE), and 2% to 13% have symptomatic PE (<a href="./references#CD004982-bbs2-0076" title="BergqvistD , JaroszewskiH . Deep venous thrombosis in patients with superficial thrombophlebitis of the leg. British Medical Journal1986;292(6521):658‐9. ">Bergqvist 1986</a>; <a href="./references#CD004982-bbs2-0077" title="BlumenbergRM , BartonE , GelfandML , SkudderP , BrennanJ . Occult deep venous thrombosis complicating superficial thrombophlebitis. Journal of Vascular Surgery1998;27(2):338‐43. ">Blumenberg 1998</a>; <a href="./references#CD004982-bbs2-0078" title="BounameauxH , Reber‐WasemMA . Superficial thrombophlebitis and deep venous thrombosis. A controversial association. Archives of Internal Medicine1997;157(16):1822‐4. ">Bounameaux 1997</a>; <a href="./references#CD004982-bbs2-0080" title="ChengelisDL , BendickPJ , GloverJL , BrownOW , RanvalTJ . Progression of superficial venous thrombosis to deep vein thrombosis. Journal of Vascular Surgery1996;24(5):745‐9. ">Chengelis 1996</a>; <a href="./references#CD004982-bbs2-0085" title="FrappéP , Buchmuller‐CordierA , BertolettiL , Bonithon‐KoppC , CouzanS , LafondP , et al. Annual diagnosis rate of superficial vein thrombosis of the lower limbs: the STEPH community‐based study. Journal of Thrombosis and Haemostasis2014;12(6):831‐8. ">Frappé 2014</a>; <a href="./references#CD004982-bbs2-0092" title="JorgensenJO , HanelKC , MorganAM , HuntJM . The incidence of deep venous thrombosis in patients with superficial thrombophlebitis of the lower limbs. Journal of Vascular Surgery1993;18(1):70‐3. ">Jorgensen 1993</a>; <a href="./references#CD004982-bbs2-0094" title="KrunesU , LindnerF , LindnerR , GnutzmannJ . Is the physical diagnosis of below‐knee superficial thrombophlebitis reliable?. Phlebologie1999;28(3):93‐6. ">Krunes 1999</a>; <a href="./references#CD004982-bbs2-0095" title="LutterKS , KerrTM , RoedersheimerLR , LohrJM , SampsonMG . Superficial thrombophlebitis diagnosed by duplex scanning. Surgery1991;110(1):42‐6. ">Lutter 1991</a>; <a href="./references#CD004982-bbs2-0098" title="PlateG , EklofB , JensenR , OhlinP . Deep venous thrombosis, pulmonary embolism and acute surgery in thrombophlebitis of the long saphenous vein. Acta Chirurgica Scandinavica1985;151(3):241‐4. ">Plate 1985</a>; <a href="./references#CD004982-bbs2-0099" title="QuenetS , LaporteS , DecoususH , LeizoroviczA , EpinatM , MismettiP , STENOX Group. Factors predictive of venous thrombotic complications in patients with isolated superficial vein thrombosis. Journal of Vascular Surgery2003;38(5):944‐9. ">Quenet 2003</a>; <a href="./references#CD004982-bbs2-0104" title="SkillmanJJ , KentKC , PorterDH , KimD . Simultaneous occurrence of superficial and deep thrombophlebitis in the lower extremity. Journal of Vascular Surgery1990;11(6):818‐23. ">Skillman 1990</a>; <a href="./references#CD004982-bbs2-0106" title="UnnoN , MitsuokaH , UchiyamaT , YamamotoN , SaitoT , IshimaruK , et al. Superficial thrombophlebitis of the lower limbs in patients with varicose veins. Surgery Today2002;32(5):397‐401. ">Unno 2002</a>; <a href="./references#CD004982-bbs2-0107" title="VerlatoF , ZucchettaP , PrandoniP , CamporeseG , MarzolaMC , SalmistraroG , et al. An expectedly high rate of pulmonary embolism in patients with superficial thrombophlebitis of the thigh. Journal of Vascular Surgery1999;30(6):1113‐5. ">Verlato 1999</a>). ST located in the saphenous main trunk seems to have the strongest association with VTE (<a href="./references#CD004982-bbs2-0076" title="BergqvistD , JaroszewskiH . Deep venous thrombosis in patients with superficial thrombophlebitis of the leg. British Medical Journal1986;292(6521):658‐9. ">Bergqvist 1986</a>; <a href="./references#CD004982-bbs2-0077" title="BlumenbergRM , BartonE , GelfandML , SkudderP , BrennanJ . Occult deep venous thrombosis complicating superficial thrombophlebitis. Journal of Vascular Surgery1998;27(2):338‐43. ">Blumenberg 1998</a>; <a href="./references#CD004982-bbs2-0080" title="ChengelisDL , BendickPJ , GloverJL , BrownOW , RanvalTJ . Progression of superficial venous thrombosis to deep vein thrombosis. Journal of Vascular Surgery1996;24(5):745‐9. ">Chengelis 1996</a>; <a href="./references#CD004982-bbs2-0092" title="JorgensenJO , HanelKC , MorganAM , HuntJM . The incidence of deep venous thrombosis in patients with superficial thrombophlebitis of the lower limbs. Journal of Vascular Surgery1993;18(1):70‐3. ">Jorgensen 1993</a>; <a href="./references#CD004982-bbs2-0095" title="LutterKS , KerrTM , RoedersheimerLR , LohrJM , SampsonMG . Superficial thrombophlebitis diagnosed by duplex scanning. Surgery1991;110(1):42‐6. ">Lutter 1991</a>; <a href="./references#CD004982-bbs2-0099" title="QuenetS , LaporteS , DecoususH , LeizoroviczA , EpinatM , MismettiP , STENOX Group. Factors predictive of venous thrombotic complications in patients with isolated superficial vein thrombosis. Journal of Vascular Surgery2003;38(5):944‐9. ">Quenet 2003</a>; <a href="./references#CD004982-bbs2-0106" title="UnnoN , MitsuokaH , UchiyamaT , YamamotoN , SaitoT , IshimaruK , et al. Superficial thrombophlebitis of the lower limbs in patients with varicose veins. Surgery Today2002;32(5):397‐401. ">Unno 2002</a>; <a href="./references#CD004982-bbs2-0107" title="VerlatoF , ZucchettaP , PrandoniP , CamporeseG , MarzolaMC , SalmistraroG , et al. An expectedly high rate of pulmonary embolism in patients with superficial thrombophlebitis of the thigh. Journal of Vascular Surgery1999;30(6):1113‐5. ">Verlato 1999</a>). The variations in estimates reported in the literature are probably due to the retrospective design of most studies, the small number of participants included, and the fact that ST was often diagnosed in vascular laboratories where people were referred for suspected DVT. In one cross‐sectional and prospective epidemiological cohort study, ST at diagnosis was associated with VTE in 25% of the cases (<a href="./references#CD004982-bbs2-0083" title="DecoususH , QuéréI , PreslesE , BeckerF , BarrellierM , ChanutM , et al. POST (Prospective Observational Superficial Thrombophlebitis) Study Group. Superficial venous thrombosis and venous thromboembolism. Annals of Internal Medicine2010;152(4):218‐24. ">Decousus 2010a</a>). During a three‐month follow‐up, 10% of people with ST developed thromboembolic complications despite 90% having received anticoagulant drugs, and about 98% had used elastic compression stockings. In one nationwide population‐based cohort study of 10,973 people with a first diagnosis of ST, the incidence of VTE in the first three months after ST diagnosis was 3.4%, which was estimated to be over 70 times higher compared to the general population without ST (<a href="./references#CD004982-bbs2-0079" title="CannegieterSC , Horvath‐PuhòE , SchmidtM , DekkersOM , PedersenL , VandenbrouckeJP , et al. Risk of venous and arterial thrombotic events in patients diagnosed with superficial vein thrombosis: a nationwide cohort study. Blood2015;125(2):229‐35. ">Cannegieter 2015</a>). </p> </section> <section id="CD004982-sec-0032"> <h3 class="title" id="CD004982-sec-0032">Description of the intervention</h3> <p>There is no consensus on the optimal treatment of ST in clinical practice as suggested by a survey in 2011 among practitioners mostly from North America showing a large variability in the management of ST (<a href="./references#CD004982-bbs2-0084" title="DuaA , HellerJA , PatelB , DesaiSS . Variability in the management of superficial venous thrombophlebitis across practitioners based in North America and the global community. Thrombosis2014;2014:306018. [DOI: 10.1155/2014/306018] ">Dua 2014</a>). Several therapies have been proposed in the literature, including surgery (ligation or stripping of the affected veins), elastic stockings, non‐steroidal anti‐inflammatory drugs (NSAIDs) that aim to reduce pain and inflammation, and several anticoagulant agents. It is unclear whether different locations of ST may influence the choice of treatment. The thrombus location in trunks of either the great saphenous vein (saphena magna) or small saphenous vein (saphena parva) may have the highest risk of extension into the deep vein system and thus could require an aggressive form of treatment, whereas other locations may be associated with a lower risk of extension and thus may warrant a less aggressive approach. Validated risk stratification tools based on ST location and patient characteristics are currently unavailable. </p> </section> <section id="CD004982-sec-0033"> <h3 class="title" id="CD004982-sec-0033">Why it is important to do this review</h3> <p>While the estimates of VTE prevalence in people with ST vary, management of ST should consider the prevention of this scaring complication beyond the mere resolution of local symptoms (<a href="./references#CD004982-bbs2-0079" title="CannegieterSC , Horvath‐PuhòE , SchmidtM , DekkersOM , PedersenL , VandenbrouckeJP , et al. Risk of venous and arterial thrombotic events in patients diagnosed with superficial vein thrombosis: a nationwide cohort study. Blood2015;125(2):229‐35. ">Cannegieter 2015</a>; <a href="./references#CD004982-bbs2-0083" title="DecoususH , QuéréI , PreslesE , BeckerF , BarrellierM , ChanutM , et al. POST (Prospective Observational Superficial Thrombophlebitis) Study Group. Superficial venous thrombosis and venous thromboembolism. Annals of Internal Medicine2010;152(4):218‐24. ">Decousus 2010a</a>; <a href="./references#CD004982-bbs2-0108" title="WichersIM , DiNisioM , BullerHR , MiddeldorpS . Treatment of superficial vein thrombosis to prevent deep vein thrombosis and pulmonary embolism: a systematic review. Haematologica2005;90(5):672‐7. ">Wichers 2005</a>). Conservative management, mainly focusing on the painful symptoms of disease, might therefore be insufficient. While provision of adequate treatment for ST may help prevent (fatal) VTE, the efficacy of the intervention needs to be balanced against the potential associated risks, such as (major) bleeding events with anticoagulants. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD004982-sec-0034" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD004982-sec-0034"></div> <p>To assess the efficacy and safety of topical, medical, and surgical treatments for ST of the leg in improving local symptoms and decreasing thromboembolic complications. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD004982-sec-0035" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD004982-sec-0035"></div> <section id="CD004982-sec-0036"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD004982-sec-0037"> <h4 class="title">Types of studies</h4> <p>Randomised controlled trials (RCTs) evaluating topical, medical, and surgical treatments for ST of the legs. </p> </section> <section id="CD004982-sec-0038"> <h4 class="title">Types of participants</h4> <p>Hospitalised and non‐hospitalised people with a diagnosis of ST of the lower extremities based on signs and symptoms of ST (e.g. pain, tenderness, induration (hardening of the tissue), or erythema (redness of the skin)) in a superficial vein, and objective diagnosis of the thrombus in the superficial vein by means of compression ultrasonography that excludes any concomitant DVT. </p> </section> <section id="CD004982-sec-0039"> <h4 class="title">Types of interventions</h4> <p>Interventions included any treatment to relieve the symptoms and signs or to prevent complications of ST, such as topical treatments, compression stockings, compression bandages, leg elevation, medical treatments (e.g. NSAIDs, anticoagulants such as fondaparinux, low molecular weight heparin (LMWH) or the oral direct inhibitors of factor Xa or thrombin), and surgical intervention (e.g. ligation, vein stripping, crossectomy). Each treatment could be compared with another form of treatment, placebo, or no intervention. Combinations of therapies could be used. </p> </section> <section id="CD004982-sec-0040"> <h4 class="title">Types of outcome measures</h4> <p>We included RCTs assessing any of the following outcome measures for any of the reviewed interventions. </p> <section id="CD004982-sec-0041"> <h5 class="title">Primary outcomes</h5> <p>Primary efficacy outcome:</p> <p> <ul id="CD004982-list-0001"> <li> <p>symptomatic VTE (i.e. the combined of symptomatic PE and symptomatic DVT).</p> </li> </ul> </p> <p>Primary safety outcome:</p> <p> <ul id="CD004982-list-0002"> <li> <p>major bleeding.</p> </li> </ul> </p> <p>The presence of PE or DVT had to be confirmed by an objective test, namely pulmonary angiography, ventilation/perfusion lung scan, or spiral computed tomography for PE; and ultrasonography, venography, or plethysmography for DVT. </p> </section> <section id="CD004982-sec-0042"> <h5 class="title">Secondary outcomes</h5> <p>The secondary outcomes considered for the review were:</p> <p> <ul id="CD004982-list-0003"> <li> <p>symptomatic PE;</p> </li> <li> <p>symptomatic DVT or the progression of ST into DVT;</p> </li> <li> <p>extension (symptomatic and asymptomatic) of ST;</p> </li> <li> <p>recurrence (symptomatic and asymptomatic) of ST;</p> </li> <li> <p>symptoms (e.g. pain);</p> </li> <li> <p>signs (e.g. induration and erythema);</p> </li> <li> <p>quality of life (assessed by means of disease‐specific and non‐specific questionnaires);</p> </li> <li> <p>mortality;</p> </li> <li> <p>adverse effects of treatment (e.g. minor bleeding, thrombocytopenia (reduced platelet count), allergic reactions, or surgery complications); </p> </li> <li> <p>arterial thromboembolic events.</p> </li> </ul> </p> </section> </section> </section> <section id="CD004982-sec-0043"> <h3 class="title">Search methods for identification of studies</h3> <p>We searched for RCTs comparing any treatment versus placebo or another treatment in people with ST of the legs. There was no restriction on language. </p> <section id="CD004982-sec-0044"> <h4 class="title">Electronic searches</h4> <p>For this update, the Cochrane Vascular Information Specialist (CIS) searched the following databases for relevant trials: </p> <p> <ul id="CD004982-list-0004"> <li> <p>Cochrane Vascular Specialised Register (March 2017);</p> </li> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL; 2017, Issue 2) via the Cochrane Register of Studies Online. </p> </li> </ul> </p> <p>See <a href="./appendices#CD004982-sec-0081">Appendix 1</a> for details of the search strategy used to search CENTRAL. </p> <p>The Cochrane Vascular Specialised Register is maintained by the CIS and is constructed from weekly electronic searches of MEDLINE Ovid, Embase Ovid, CINAHL, and AMED, and through handsearching of relevant journals. The full list of the databases, journals, and conference proceedings that have been searched, as well as the search strategies used, are described in the <a href="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/PVD/frame.html" target="_blank">Specialised Register</a> section of the Cochrane Vascular module in the Cochrane Library (<a href="http://www.cochranelibrary.com/" target="_blank">www.cochranelibrary.com</a>). </p> <p>The CIS searched the following trials registries for details of ongoing and unpublished studies in March 2017: </p> <p> <ul id="CD004982-list-0005"> <li> <p>ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>); </p> </li> <li> <p>World Health Organization International Clinical Trials Registry Platform (<a href="http://www.who.int/ictrp/search/en/" target="_blank">www.who.int/trialsearch</a>); </p> </li> <li> <p>ISRCTN Register (<a href="http://www.isrctn.com/" target="_blank">www.isrctn.com/</a>). </p> </li> </ul> </p> <p>See <a href="./appendices#CD004982-sec-0082">Appendix 2</a>. </p> </section> <section id="CD004982-sec-0045"> <h4 class="title">Searching other resources</h4> <p>We searched reference lists of relevant papers and conference proceedings of the International Society for Thrombosis and Hemostasis (2003 to 2016) and American Society of Hematology (2004 to 2014), and we attempted to contact known experts in the field. </p> </section> </section> <section id="CD004982-sec-0046"> <h3 class="title" id="CD004982-sec-0046">Data collection and analysis</h3> <section id="CD004982-sec-0047"> <h4 class="title">Selection of studies</h4> <p>Two authors (MDN and IMW) independently reviewed titles and abstracts identified from the database searches to determine whether the inclusion criteria were satisfied. Two authors (MDN and IMW) independently assessed trials for inclusion in the review, and resolved any disagreements through discussion or involvement of a third author (SM). We independently reviewed the full text of identified articles, including those where there was disagreement in the initial title or abstract scanning stage, to ensure that the inclusion criteria were met. We obtained hard copies of the full text of studies that fulfilled the selection criteria. We were not blinded to the journal, institution, or results of the study. Titles and abstracts of non‐English articles were translated into English and assessed for inclusion. We documented reasons for excluding studies and resolved disagreements by consensus. One author (MDN) scanned conference proceedings, identified articles from other sources (experts or reference lists), and contacted trialists for further information if required. </p> </section> <section id="CD004982-sec-0048"> <h4 class="title">Data extraction and management</h4> <p>Two authors (MDN and IMW) independently extracted the data from the included studies using an agreed format. We resolved any disagreements by consensus and, if necessary, by the involvement of the third author (SM). For any study published twice, we extracted the data from the more complete study. Collected information included methodological quality, characteristics of participants, type of intervention and control, and outcomes. </p> </section> <section id="CD004982-sec-0049"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two authors independently assessed randomisation, blinding, and adequacy of analyses (<a href="./references#CD004982-bbs2-0093" title="JuniP , AltmanDG , EggerM . Systematic reviews in health care: assessing the quality of controlled clinical trials. BMJ2001;323(7303):42‐6. ">Juni 2001</a>). We resolved disagreements by consensus. </p> <p>Two components of randomisation were assessed: generation of allocation sequences and concealment of allocation. Generation of allocation sequences was considered adequate if it resulted in an unpredictable allocation schedule. Mechanisms considered adequate included random‐number tables, computer‐generated random numbers, minimisation, coin tossing, shuffling cards, and drawing lots. Trials using an unpredictable allocation sequence were considered randomised. Trials using potentially predictable allocation mechanisms, such as alternation or the allocation of participants according to date of birth, were considered quasi‐randomised. </p> <p>Concealment of allocation was considered adequate if participants and investigators responsible for participants selection were unable to predict, before allocation, which treatment was next. Methods considered adequate included central randomisation; pharmacy‐controlled randomisation using identical prenumbered containers; and sequentially numbered, sealed, opaque envelopes. </p> <p>Blinding of participants and therapists was considered adequate if experimental and control preparations were explicitly described as indistinguishable or if a double‐dummy technique was used. Assessors were considered blinded if this was explicitly mentioned by the investigators. </p> <p>Analyses were considered adequate if all randomised participants were included in the analysis according to the intention‐to‐treat (ITT) principle. The item 'free of selective reporting' was classified as at 'low risk of bias' if we had both the protocol and the full report of a given study, where the full report presented results for all outcomes listed in the protocol. We classified a study as at 'high risk of bias' if a report did not present data on all outcomes reported in either the protocol or the methods section. The risk of bias item 'free of other bias' was not considered in this review. We assessed the reporting of primary outcomes and sample size calculations. </p> </section> <section id="CD004982-sec-0050"> <h4 class="title">Data synthesis</h4> <p>Prior to obtaining the global effect estimators (a balanced mean of the effect in different trials), we planned to evaluate the heterogeneity of treatment effects between trials using the I<sup>2</sup> statistic (<a href="./references#CD004982-bbs2-0090" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327(7414):557‐60. ">Higgins 2003</a>), which describes the percentage of total variation across trials that is attributable to heterogeneity rather than chance. I<sup>2</sup> values of 25%, 50%, and 75% may be interpreted as low, moderate, and high between‐trial heterogeneity, although the interpretation of the I<sup>2</sup> statistic depends on the size and number of trials included (<a href="./references#CD004982-bbs2-0101" title="RückerG , SchwarzerG , CarpenterJR , SchumacherM . Undue reliance on I2 in assessing heterogeneity may mislead. BMC Medical Research Methodology2008;8:79. ">Rücker 2008</a>). In the presence of no or low heterogeneity, we planned to use the fixed‐effect model (Mantel‐Haenszel method) and the random‐effects model to pool and analyse summary effect sizes. Where possible, we presented results as summary risk ratios (RR) or hazard ratios (HRs) for dichotomous variables and mean differences (MD) for all continuous variables. We determined the 95% CI for each estimate. The unit of analysis was the number of participants with the outcome of interest. Where possible, we analysed the results by ITT, including every individual in the randomly assigned treatment group regardless of whether they completed the treatment or withdrew from the trial. </p> <p>We planned to evaluate publication bias and other biases related to small study size using funnel plots, plotting effect sizes on the vertical axis against their standard errors on the horizontal axis. We planned to assess asymmetry using the asymmetry coefficient: the difference in effect size per unit increase in standard error (<a href="./references#CD004982-bbs2-0105" title="SterneJA , EggerM . Funnel plots for detecting bias in meta‐analysis: guidelines on choice of axis. Journal of Clinical Epidemiology2001;54(10):1046‐55. ">Sterne 2001</a>), which is mainly a surrogate for sample size. Symmetry would be expected in the absence of any bias related to small study size. </p> <p>We used Review Manager 5 for data analysis (<a href="./references#CD004982-bbs2-0100" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). </p> <section id="CD004982-sec-0051"> <h5 class="title">'Summary of findings' tables</h5> <p>We presented the main findings of the review concerning the quality of evidence and the magnitude of treatment effects in the 'Summary of findings' tables, according to the GRADE principles described by <a href="./references#CD004982-bbs2-0091" title="HigginsJPT , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org. ">Higgins 2011</a> and <a href="./references#CD004982-bbs2-0088" title="GuyattGH , OxmanAD , VistGE , KunzR , Falck‐YtterY , Alonso‐CoelloP , et al. GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ2008;336:924‐6. ">Guyatt 2008</a>. We used GRADEproGDT software (<a href="./references#CD004982-bbs2-0087" title="McMaster University. GRADEpro GDT. Version accessed May 2017. Hamilton (ON): McMaster University, 2015. ">GRADEproGDT 2015</a>) to create the tables. We included the primary efficacy and safety outcomes of the review as well as the major secondary outcomes (i.e. extension and recurrence of ST, minor bleeding, adverse effects of treatment, and mortality). We focused on the active treatments fondaparinux, LMWH, and NSAIDs with placebo as comparator and at least one primary outcome comparison. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD004982-sec-0052" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD004982-sec-0052"></div> <section id="CD004982-sec-0053"> <h3 class="title">Description of studies</h3> <p>See <a href="./references#CD004982-sec-0105" title="">Characteristics of included studies</a>; <a href="./references#CD004982-sec-0106" title="">Characteristics of excluded studies</a>; and <a href="./references#CD004982-sec-0108" title="">Characteristics of ongoing studies</a> tables. </p> <section id="CD004982-sec-0054"> <h4 class="title">Results of the search</h4> <p>See <a href="#CD004982-fig-0001">Figure 1</a>. </p> <div class="figure" id="CD004982-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD004982-fig-0001" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> <p>There were three new included studies (<a href="./references#CD004982-bbs2-0008" title="Beyer‐WestendorfJ , SchellongSM , GerlachH , RabeE , WeitzJI , JersemannK , et al. Prevention of thromboembolic complications in patients with superficial‐vein thrombosis given rivaroxaban or fondaparinux: the open‐label, randomised, non‐inferiority SURPRISE phase 3b trial. Lancet Haematology2017;4(3):e105‐13. WerthS , BauersachsR , GerlachH , RabeE , SchellongS , Beyer‐WestendorfJ . Superficial vein thrombosis treated for 45 days with rivaroxaban versus fondaparinux: rationale and design of the SURPRISE trial. Journal of Thrombosis and Thrombolysis2016;42(2):197‐204. ">Beyer‐Westendorf 2017</a>; <a href="./references#CD004982-bbs2-0009" title="BoehlerK , KittlerH , StolkovichS , TzanevaS . Therapeutic effect of compression stockings versus no compression on isolated superficial vein thrombosis of the legs: a randomized clinical trial. European Journal of Vascular and Endovascular Surgery2014;48(4):465‐71. ">Boehler 2014</a>; <a href="./references#CD004982-bbs2-0028" title="SpirkoskaA , JezovnikMK , PoredosP . Time course and the recanalization rate of superficial vein thrombosis treated with low‐molecular‐weight heparin. Angiology2015;66:381‐6. ">Spirkoska 2015</a>). </p> </section> <section id="CD004982-sec-0055"> <h4 class="title">Included studies</h4> <p>Three additional studies were included in this third update (<a href="./references#CD004982-bbs2-0008" title="Beyer‐WestendorfJ , SchellongSM , GerlachH , RabeE , WeitzJI , JersemannK , et al. Prevention of thromboembolic complications in patients with superficial‐vein thrombosis given rivaroxaban or fondaparinux: the open‐label, randomised, non‐inferiority SURPRISE phase 3b trial. Lancet Haematology2017;4(3):e105‐13. WerthS , BauersachsR , GerlachH , RabeE , SchellongS , Beyer‐WestendorfJ . Superficial vein thrombosis treated for 45 days with rivaroxaban versus fondaparinux: rationale and design of the SURPRISE trial. Journal of Thrombosis and Thrombolysis2016;42(2):197‐204. ">Beyer‐Westendorf 2017</a>; <a href="./references#CD004982-bbs2-0009" title="BoehlerK , KittlerH , StolkovichS , TzanevaS . Therapeutic effect of compression stockings versus no compression on isolated superficial vein thrombosis of the legs: a randomized clinical trial. European Journal of Vascular and Endovascular Surgery2014;48(4):465‐71. ">Boehler 2014</a>; <a href="./references#CD004982-bbs2-0028" title="SpirkoskaA , JezovnikMK , PoredosP . Time course and the recanalization rate of superficial vein thrombosis treated with low‐molecular‐weight heparin. Angiology2015;66:381‐6. ">Spirkoska 2015</a>), giving a total of 33 studies involving 7296 participants (<a href="./references#CD004982-bbs2-0001" title="AndreozziGM , SignorelliS , DiPinoL , MartiniR , MarchitelliE , PintoA , et al. Tolerability and clinical efficacy of desmin in the treatment of superficial varicothrombophlebitis. Angiology1996;47(9):887‐94. ">Andreozzi 1996</a>; <a href="./references#CD004982-bbs2-0002" title="Anonymous . Indomethacin in superficial thrombophlebitis. Practitioner1970;205(227):369‐72. ">Anonymous 1970</a>; <a href="./references#CD004982-bbs2-0003" title="ArcherDS , FowlerPD . Comparison of oxyphenbutazone and placebo in the treatment of superficial thrombophlebitis: an object lesson in clinical trial design. Practitioner1977;218:712‐75. ">Archer 1977</a>; <a href="./references#CD004982-bbs2-0004" title="BelcaroG , ErrichiBM , LauroraG , CesaroneMR , CandianiC . Treatment of acute superficial thrombosis and follow‐up by computerized thermography. VASA. Zeitschrift fur Gefasskrankheiten. Journal for Vascular Diseases1989;18(3):227‐34. ">Belcaro 1989</a>; <a href="./references#CD004982-bbs2-0005" title="BelcaroG . Evolution of superficial vein thrombosis treated with defibrotide: comparison with low dose subcutaneous heparin. International Journal of Tissue Reactions1990;12(5):319‐24. ">Belcaro 1990</a>; <a href="./references#CD004982-bbs2-0006" title="BelcaroG , NicolaidesAN , ErrichiBM , CesaroneMR , DeSanctisMT , IncandelaL , et al. Superficial thrombophlebitis of the legs: a randomized, controlled, follow‐up study. Angiology1999;50(7):523‐9. ">Belcaro 1999</a>; <a href="./references#CD004982-bbs2-0007" title="BelcaroG , CesaroneMR , DugallM , FeragalliB , IppolitoE , CorsiM , et al. Topical formulation of heparin is effective in reducing the symptoms of superficial venous thrombosis: a monocenter, observer‐blind, placebo‐controlled randomized study. Panminerva Medica2011;53(3 Suppl 1):3‐11. ">Belcaro 2011</a>; <a href="./references#CD004982-bbs2-0008" title="Beyer‐WestendorfJ , SchellongSM , GerlachH , RabeE , WeitzJI , JersemannK , et al. Prevention of thromboembolic complications in patients with superficial‐vein thrombosis given rivaroxaban or fondaparinux: the open‐label, randomised, non‐inferiority SURPRISE phase 3b trial. Lancet Haematology2017;4(3):e105‐13. WerthS , BauersachsR , GerlachH , RabeE , SchellongS , Beyer‐WestendorfJ . Superficial vein thrombosis treated for 45 days with rivaroxaban versus fondaparinux: rationale and design of the SURPRISE trial. Journal of Thrombosis and Thrombolysis2016;42(2):197‐204. ">Beyer‐Westendorf 2017</a>; <a href="./references#CD004982-bbs2-0009" title="BoehlerK , KittlerH , StolkovichS , TzanevaS . Therapeutic effect of compression stockings versus no compression on isolated superficial vein thrombosis of the legs: a randomized clinical trial. European Journal of Vascular and Endovascular Surgery2014;48(4):465‐71. ">Boehler 2014</a>; <a href="./references#CD004982-bbs2-0010" title="CosmiB . Risk factors for recurrent events in subjects with superficial vein thrombosis in the randomized clinical trial SteFlux (Superficial Thromboembolism Fluxum). Thrombosis Research2014;133(2):196‐202. CosmiB , FilippiniM , TontiD , AvruscioG , GhirarduzziA , BucheriniE , et al. A randomized double‐blind study of low‐molecular‐weight heparin (parnaparin) for superficial vein thrombosis: STEFLUX (Superficial ThromboEmbolism and Fluxum). Journal of Thrombosis and Haemostasis2012;10(6):1026‐35. CosmiB , FilippiniM , TontiD , GhirarduzziA , AvruscioG , ImbertiD , et al. Risk factors for recurrent events in subjects with superficial vein thrombosis in the randomized clinical trial Steflux (Superficial Thromboembolism Fluxum). Hamostaseologie2012;32:A29. CosmiB , FilippiniM , TontiD , GhirarduzziA , AvruscioG , ImbertiD , et al. The Steflux (Superficial Thromboembolism and Fluxum) randomized double blind clinical study of different treatment doses and duration of low molecular weight heparin (parnaparin) in superficial vein thrombosis. Hamostaseologie2012;32:A28. ">Cosmi 2012</a>; <a href="./references#CD004982-bbs2-0011" title="BauersachsRM . The CALISTO‐study. Phlebologie2011;40(2):79‐83. DecoususH . Fondaparinux reduced a composite of VTE complications or death in superficial leg‐vein thrombosis. Annals of Internal Medicine2011;154(4):JC2‐3. DecoususH , PrandoniP , MismettiP , BauersachsRM , BodaZ , BrennerB , et al. CALISTO Study Group. Fondaparinux for the treatment of superficial‐vein thrombosis in the legs. New England Journal of Medicine2010;363(13):1222‐32. LeizoroviczA , BeckerF , BuchmullerA , QuereI , PrandoniP , DecoususH , et al. Clinical relevance of symptomatic superficial‐vein thrombosis extension: lessons from the CALISTO study. Blood2013;122(10):1724‐9. LeizoroviczA , PrandoniP , DecoususH . Fondaparinux reduces all types of symptomatic thromboembolic complications in patients with superficial‐vein thrombosis in the legs: data from the CALISTO study. ASH Annual Meeting Abstracts2011;118:2310. ">Decousus 2010b</a>; <a href="./references#CD004982-bbs2-0012" title="DeSanctisMT , CesaroneMR , IncandelaL , BelcaroG , GriffinM . Treatment of superficial vein thrombosis with standardized application of Essaven gel ‐ a placebo‐controlled, randomized study. Angiology2001;52 Suppl 3:S57‐62. ">De Sanctis 2001</a>; <a href="./references#CD004982-bbs2-0013" title="FerrariE , PratesiC , ScaricabarozziI , TrezzaniR . A clinical study of efficacy and tolerability of nimesulide compared with diclofenac sodium in the treatment of acute superficial thrombophlebitis [Studio clinico sull'efficacia terapeutica e la tollerabilità della nimesulide in confronto a diclofenac sodio nel trattamento delle tromboflebiti acute superficiali]. Minerva Cardioangiologica1992;40(11):455‐60. ">Ferrari 1992</a>; <a href="./references#CD004982-bbs2-0014" title="GorskiG , SzopinskiP , MichalakJ , MarianowskaA , BorkowskiM , GeremekM , et al. Liposomal heparin spray: a new formula in adjunctive treatment of superficial venous thrombosis. Angiology2005;56(1):9‐17. ">Gorski 2005</a>; <a href="./references#CD004982-bbs2-0015" title="HolzgreveA , KleineW , StegmannW . Local treatment of superficial thrombophlebitis with nonsteroidal antiinflammatory agents. Zeitschrift fur Allgemeinmedizin1989;65(27):663‐7. ">Holzgreve 1989</a>; <a href="./references#CD004982-bbs2-0016" title="IncandelaL , DeSanctisMT , CesaroneMR , RicciA , ErrichiBM , DugalM , et al. Treatment of superficial vein thrombosis: clinical evaluation of essaven gel ‐ a placebo‐controlled, 8‐week, randomized study. Angiology2001;52 Suppl 3:69‐72. ">Incandela 2001</a>; <a href="./references#CD004982-bbs2-0017" title="KatzenschlagerR , UgurluogluA , MinarE , HirschlM . Liposomal heparin‐spraygel in comparison with subcutaneous low molecular weight heparin in patients with superficial venous thrombosis. A randomized, controlled, open multicentre study. Journal fur Kardiologie2003;10(9):375‐8. ">Katzenschlager 2003</a>; <a href="./references#CD004982-bbs2-0018" title="KoshkinVM , KirienkoAI . Systemic enzyme therapy in the treatment of acute thrombosis of superficial veins in the lower extremities and postthrombophlebitic disease. International Journal of Immunotherapy2001;17(2‐4):121‐4. ">Koshkin 2001</a>; <a href="./references#CD004982-bbs2-0019" title="KuhlweinA . Drug treatment of superficial thrombophlebitides [Medikamentose behandlung oberflachlicher thrombophlebitiden]. Therapiewoche1985;35(36):4067‐70. ">Kuhlwein 1985</a>; <a href="./references#CD004982-bbs2-0020" title="LozanoFS , AlmazanA . Low‐molecular‐weight heparin versus saphenofemoral disconnection for the treatment of above‐knee greater saphenous thrombophlebitis: a prospective study. Vascular and Endovascular Surgery2003;37(6):415‐20. ">Lozano 2003</a>; <a href="./references#CD004982-bbs2-0021" title="MarchioriA , VerlatoF , SabbionP , CamporeseG , RossoF , MosenaL , et al. High versus low doses of unfractionated heparin for the treatment of superficial thrombophlebitis of the leg. A prospective, controlled, randomized study. Haematologica2002;87(5):523‐7. ">Marchiori 2002</a>; <a href="./references#CD004982-bbs2-0022" title="MarshallM , KleineM‐W . Efficacy and tolerability of an oral enzyme therapy in the treatment of painful acute superficial thrombophlebitis [Wirksamkeit und vertraglichkeit einer oralen enzymtherapie bei der schmerzhaften akuten thrombophlebitis superficialis]. Phlebologie2001;30(2):36‐43. ">Marshall 2001</a>; <a href="./references#CD004982-bbs2-0023" title="MessaG , LaPlacaG , PuccettiL , DiPerriT . Heparansulphate. Effectiveness and tolerability of heparan sulphate in the treatment of superficial thrombophlebitis. Controlled clinical study vs sulodexide [Efficacia e tollerabilità dell'eparansolfato nel trattamento della tromboflebite superficiale. Studio clinico controllato vs sulodexide]. Minerva Cardioangiologica1997;45(4):147‐53. ">Messa 1997</a>; <a href="./references#CD004982-bbs2-0024" title="DiebschlagW , NockerW . Lokal treatment for superficial thrombophlebitis. Die Medizinische Welt1990;41:651‐5. NockerW , DiebschlagW , LehmacherW . The efficacy of a diclofenac gel compared with placebo and heparin gel in the local treatment of superficial thrombophlebitis [Lokaltherapie bei oberflachlicher thrombophlebitis. Wirksamkeit eines diclofenac‐natrium‐gels im vergleich zu placebo‐ und heparin‐gel]. Zeitschrift fur Allgemeinmedizin1991;67:2214‐22. ">Nocker 1991</a>; <a href="./references#CD004982-bbs2-0025" title="NusserC‐J , SchareW , BernardI . The treatment of superficial thrombophlebitis with nonsteroidal antiphlogistic agents [Therapie superfizieller thrombophlebitiden mit nichtsteroidalen antiphlogistika]. Therapiewoche1991;41(9):541‐4. ">Nusser 1991</a>; <a href="./references#CD004982-bbs2-0026" title="PintoG , GalatiD , BompianiGD , CorcioneF , CalifanoG , ColucciS , et al. Topical 5'‐methylthioadenosine in the treatment of symptomatic chronic venous insufficiency, haemorrhoids and superficial phlebitis. A double‐blind placebo‐controlled trial. Drug Investigation1992;4(3):205‐14. ">Pinto 1992</a>; <a href="./references#CD004982-bbs2-0027" title="RathbunSW , AstonCE , WhitsettTL . A randomized trial of dalteparin compared with ibuprofen for the treatment of superficial thrombophlebitis. Journal of Thrombosis and Haemostasis2012;10(5):833‐9. ">Rathbun 2012</a>; <a href="./references#CD004982-bbs2-0028" title="SpirkoskaA , JezovnikMK , PoredosP . Time course and the recanalization rate of superficial vein thrombosis treated with low‐molecular‐weight heparin. Angiology2015;66:381‐6. ">Spirkoska 2015</a>; <a href="./references#CD004982-bbs2-0029" title="Superficial Thrombophlebitis Treated by Enoxaparin Study Group. A pilot randomized double‐blind comparison of a low‐molecular‐weight heparin, a nonsteroidal anti‐inflammatory agent, and placebo in the treatment of superficial vein thrombosis. Archives of Internal Medicine2003;163(14):1657‐63. ">Stenox Group 2003</a>; <a href="./references#CD004982-bbs2-0030" title="TitonJP , AugerD , GrangeP , HecquetJP , RemondA , UlliacP , et al. Therapeutic management of superficial venous thrombosis with calcium nadroparin. Dosage testing and comparison with an non‐steroidal anti‐inflammatory agent [Traitement curatif des thromboses veineuses superficielles par nadroparine calcique. Recherche posologique et comparaison à un anti‐inflammatoire non stéroidien]. Annales de Cardiologie et d'Angeiologie1994;43(3):160‐6. ">Titon 1994</a>; <a href="./references#CD004982-bbs2-0031" title="UncuH . A comparison of low‐molecular‐weight heparin and combined therapy of low‐molecular‐weight heparin with an anti‐inflammatory agent in the treatment of superficial vein thrombosis. Phlebology2009;24(2):56‐60. ">Uncu 2009</a>; <a href="./references#CD004982-bbs2-0032" title="PrandoniP . High versus low doses of low‐molecular‐weight heparin for the treatment of superficial vein thrombosis of the legs. A double‐blind, randomized trial. Journal of Thrombosis and Haemostasis2005;3 (Suppl 1):Abstract number OR145. [http://onlinelibrary.wiley.com/doi/10.1111/j.1538‐7836.2005.0300b.x/full] PrandoniP , TormeneD , PesaventoR , Vesalio Investigators Group. High vs. low doses of low‐molecular‐weight heparin for the treatment of superficial vein thrombosis of the legs: a double‐blind, randomized trial. Journal of Thrombosis and Haemostasis2005;3(6):1152‐7. ">Vesalio Group 2005</a>; <a href="./references#CD004982-bbs2-0033" title="WinterWR , RauhutK , ArnoldS , BabiakD , StoidnerB . Local therapy of thrombophlebitis superficialis ‐ an inter‐individual comparison of Voltaren‐Emulgel versus a gel containing heparin [Lokale therapie der thrombophlebitis superficialis ‐ Ein individueller vergleich von Voltaren‐emulgel versus ein heparin‐haltiges gel]. Zeitschrift fur Rheumatologie1986;45:180‐1. ">Winter 1986</a>). Nine studies reported data for 50 participants or fewer, 13 trials for 50 to 100 participants, and 11 studies for 100 participants or more. </p> <p>Interventions and comparisons varied greatly among the studies. Nine trials included a topical treatment group (<a href="./references#CD004982-bbs2-0007" title="BelcaroG , CesaroneMR , DugallM , FeragalliB , IppolitoE , CorsiM , et al. Topical formulation of heparin is effective in reducing the symptoms of superficial venous thrombosis: a monocenter, observer‐blind, placebo‐controlled randomized study. Panminerva Medica2011;53(3 Suppl 1):3‐11. ">Belcaro 2011</a>; <a href="./references#CD004982-bbs2-0012" title="DeSanctisMT , CesaroneMR , IncandelaL , BelcaroG , GriffinM . Treatment of superficial vein thrombosis with standardized application of Essaven gel ‐ a placebo‐controlled, randomized study. Angiology2001;52 Suppl 3:S57‐62. ">De Sanctis 2001</a>; <a href="./references#CD004982-bbs2-0014" title="GorskiG , SzopinskiP , MichalakJ , MarianowskaA , BorkowskiM , GeremekM , et al. Liposomal heparin spray: a new formula in adjunctive treatment of superficial venous thrombosis. Angiology2005;56(1):9‐17. ">Gorski 2005</a>; <a href="./references#CD004982-bbs2-0015" title="HolzgreveA , KleineW , StegmannW . Local treatment of superficial thrombophlebitis with nonsteroidal antiinflammatory agents. Zeitschrift fur Allgemeinmedizin1989;65(27):663‐7. ">Holzgreve 1989</a>; <a href="./references#CD004982-bbs2-0016" title="IncandelaL , DeSanctisMT , CesaroneMR , RicciA , ErrichiBM , DugalM , et al. Treatment of superficial vein thrombosis: clinical evaluation of essaven gel ‐ a placebo‐controlled, 8‐week, randomized study. Angiology2001;52 Suppl 3:69‐72. ">Incandela 2001</a>; <a href="./references#CD004982-bbs2-0017" title="KatzenschlagerR , UgurluogluA , MinarE , HirschlM . Liposomal heparin‐spraygel in comparison with subcutaneous low molecular weight heparin in patients with superficial venous thrombosis. A randomized, controlled, open multicentre study. Journal fur Kardiologie2003;10(9):375‐8. ">Katzenschlager 2003</a>; <a href="./references#CD004982-bbs2-0024" title="DiebschlagW , NockerW . Lokal treatment for superficial thrombophlebitis. Die Medizinische Welt1990;41:651‐5. NockerW , DiebschlagW , LehmacherW . The efficacy of a diclofenac gel compared with placebo and heparin gel in the local treatment of superficial thrombophlebitis [Lokaltherapie bei oberflachlicher thrombophlebitis. Wirksamkeit eines diclofenac‐natrium‐gels im vergleich zu placebo‐ und heparin‐gel]. Zeitschrift fur Allgemeinmedizin1991;67:2214‐22. ">Nocker 1991</a>; <a href="./references#CD004982-bbs2-0026" title="PintoG , GalatiD , BompianiGD , CorcioneF , CalifanoG , ColucciS , et al. Topical 5'‐methylthioadenosine in the treatment of symptomatic chronic venous insufficiency, haemorrhoids and superficial phlebitis. A double‐blind placebo‐controlled trial. Drug Investigation1992;4(3):205‐14. ">Pinto 1992</a>; <a href="./references#CD004982-bbs2-0033" title="WinterWR , RauhutK , ArnoldS , BabiakD , StoidnerB . Local therapy of thrombophlebitis superficialis ‐ an inter‐individual comparison of Voltaren‐Emulgel versus a gel containing heparin [Lokale therapie der thrombophlebitis superficialis ‐ Ein individueller vergleich von Voltaren‐emulgel versus ein heparin‐haltiges gel]. Zeitschrift fur Rheumatologie1986;45:180‐1. ">Winter 1986</a>); three used a surgical treatment group (<a href="./references#CD004982-bbs2-0004" title="BelcaroG , ErrichiBM , LauroraG , CesaroneMR , CandianiC . Treatment of acute superficial thrombosis and follow‐up by computerized thermography. VASA. Zeitschrift fur Gefasskrankheiten. Journal for Vascular Diseases1989;18(3):227‐34. ">Belcaro 1989</a>; <a href="./references#CD004982-bbs2-0006" title="BelcaroG , NicolaidesAN , ErrichiBM , CesaroneMR , DeSanctisMT , IncandelaL , et al. Superficial thrombophlebitis of the legs: a randomized, controlled, follow‐up study. Angiology1999;50(7):523‐9. ">Belcaro 1999</a>; <a href="./references#CD004982-bbs2-0020" title="LozanoFS , AlmazanA . Low‐molecular‐weight heparin versus saphenofemoral disconnection for the treatment of above‐knee greater saphenous thrombophlebitis: a prospective study. Vascular and Endovascular Surgery2003;37(6):415‐20. ">Lozano 2003</a>); 14 used LMWH (<a href="./references#CD004982-bbs2-0004" title="BelcaroG , ErrichiBM , LauroraG , CesaroneMR , CandianiC . Treatment of acute superficial thrombosis and follow‐up by computerized thermography. VASA. Zeitschrift fur Gefasskrankheiten. Journal for Vascular Diseases1989;18(3):227‐34. ">Belcaro 1989</a>; <a href="./references#CD004982-bbs2-0005" title="BelcaroG . Evolution of superficial vein thrombosis treated with defibrotide: comparison with low dose subcutaneous heparin. International Journal of Tissue Reactions1990;12(5):319‐24. ">Belcaro 1990</a>; <a href="./references#CD004982-bbs2-0006" title="BelcaroG , NicolaidesAN , ErrichiBM , CesaroneMR , DeSanctisMT , IncandelaL , et al. Superficial thrombophlebitis of the legs: a randomized, controlled, follow‐up study. Angiology1999;50(7):523‐9. ">Belcaro 1999</a>; <a href="./references#CD004982-bbs2-0010" title="CosmiB . Risk factors for recurrent events in subjects with superficial vein thrombosis in the randomized clinical trial SteFlux (Superficial Thromboembolism Fluxum). Thrombosis Research2014;133(2):196‐202. CosmiB , FilippiniM , TontiD , AvruscioG , GhirarduzziA , BucheriniE , et al. A randomized double‐blind study of low‐molecular‐weight heparin (parnaparin) for superficial vein thrombosis: STEFLUX (Superficial ThromboEmbolism and Fluxum). Journal of Thrombosis and Haemostasis2012;10(6):1026‐35. CosmiB , FilippiniM , TontiD , GhirarduzziA , AvruscioG , ImbertiD , et al. Risk factors for recurrent events in subjects with superficial vein thrombosis in the randomized clinical trial Steflux (Superficial Thromboembolism Fluxum). Hamostaseologie2012;32:A29. CosmiB , FilippiniM , TontiD , GhirarduzziA , AvruscioG , ImbertiD , et al. The Steflux (Superficial Thromboembolism and Fluxum) randomized double blind clinical study of different treatment doses and duration of low molecular weight heparin (parnaparin) in superficial vein thrombosis. Hamostaseologie2012;32:A28. ">Cosmi 2012</a>; <a href="./references#CD004982-bbs2-0014" title="GorskiG , SzopinskiP , MichalakJ , MarianowskaA , BorkowskiM , GeremekM , et al. Liposomal heparin spray: a new formula in adjunctive treatment of superficial venous thrombosis. Angiology2005;56(1):9‐17. ">Gorski 2005</a>; <a href="./references#CD004982-bbs2-0017" title="KatzenschlagerR , UgurluogluA , MinarE , HirschlM . Liposomal heparin‐spraygel in comparison with subcutaneous low molecular weight heparin in patients with superficial venous thrombosis. A randomized, controlled, open multicentre study. Journal fur Kardiologie2003;10(9):375‐8. ">Katzenschlager 2003</a>; <a href="./references#CD004982-bbs2-0020" title="LozanoFS , AlmazanA . Low‐molecular‐weight heparin versus saphenofemoral disconnection for the treatment of above‐knee greater saphenous thrombophlebitis: a prospective study. Vascular and Endovascular Surgery2003;37(6):415‐20. ">Lozano 2003</a>; <a href="./references#CD004982-bbs2-0021" title="MarchioriA , VerlatoF , SabbionP , CamporeseG , RossoF , MosenaL , et al. High versus low doses of unfractionated heparin for the treatment of superficial thrombophlebitis of the leg. A prospective, controlled, randomized study. Haematologica2002;87(5):523‐7. ">Marchiori 2002</a>; <a href="./references#CD004982-bbs2-0027" title="RathbunSW , AstonCE , WhitsettTL . A randomized trial of dalteparin compared with ibuprofen for the treatment of superficial thrombophlebitis. Journal of Thrombosis and Haemostasis2012;10(5):833‐9. ">Rathbun 2012</a>; <a href="./references#CD004982-bbs2-0028" title="SpirkoskaA , JezovnikMK , PoredosP . Time course and the recanalization rate of superficial vein thrombosis treated with low‐molecular‐weight heparin. Angiology2015;66:381‐6. ">Spirkoska 2015</a>; <a href="./references#CD004982-bbs2-0029" title="Superficial Thrombophlebitis Treated by Enoxaparin Study Group. A pilot randomized double‐blind comparison of a low‐molecular‐weight heparin, a nonsteroidal anti‐inflammatory agent, and placebo in the treatment of superficial vein thrombosis. Archives of Internal Medicine2003;163(14):1657‐63. ">Stenox Group 2003</a>; <a href="./references#CD004982-bbs2-0030" title="TitonJP , AugerD , GrangeP , HecquetJP , RemondA , UlliacP , et al. Therapeutic management of superficial venous thrombosis with calcium nadroparin. Dosage testing and comparison with an non‐steroidal anti‐inflammatory agent [Traitement curatif des thromboses veineuses superficielles par nadroparine calcique. Recherche posologique et comparaison à un anti‐inflammatoire non stéroidien]. Annales de Cardiologie et d'Angeiologie1994;43(3):160‐6. ">Titon 1994</a>; <a href="./references#CD004982-bbs2-0031" title="UncuH . A comparison of low‐molecular‐weight heparin and combined therapy of low‐molecular‐weight heparin with an anti‐inflammatory agent in the treatment of superficial vein thrombosis. Phlebology2009;24(2):56‐60. ">Uncu 2009</a>; <a href="./references#CD004982-bbs2-0032" title="PrandoniP . High versus low doses of low‐molecular‐weight heparin for the treatment of superficial vein thrombosis of the legs. A double‐blind, randomized trial. Journal of Thrombosis and Haemostasis2005;3 (Suppl 1):Abstract number OR145. [http://onlinelibrary.wiley.com/doi/10.1111/j.1538‐7836.2005.0300b.x/full] PrandoniP , TormeneD , PesaventoR , Vesalio Investigators Group. High vs. low doses of low‐molecular‐weight heparin for the treatment of superficial vein thrombosis of the legs: a double‐blind, randomized trial. Journal of Thrombosis and Haemostasis2005;3(6):1152‐7. ">Vesalio Group 2005</a>); six used NSAIDs (<a href="./references#CD004982-bbs2-0002" title="Anonymous . Indomethacin in superficial thrombophlebitis. Practitioner1970;205(227):369‐72. ">Anonymous 1970</a>; <a href="./references#CD004982-bbs2-0013" title="FerrariE , PratesiC , ScaricabarozziI , TrezzaniR . A clinical study of efficacy and tolerability of nimesulide compared with diclofenac sodium in the treatment of acute superficial thrombophlebitis [Studio clinico sull'efficacia terapeutica e la tollerabilità della nimesulide in confronto a diclofenac sodio nel trattamento delle tromboflebiti acute superficiali]. Minerva Cardioangiologica1992;40(11):455‐60. ">Ferrari 1992</a>; <a href="./references#CD004982-bbs2-0025" title="NusserC‐J , SchareW , BernardI . The treatment of superficial thrombophlebitis with nonsteroidal antiphlogistic agents [Therapie superfizieller thrombophlebitiden mit nichtsteroidalen antiphlogistika]. Therapiewoche1991;41(9):541‐4. ">Nusser 1991</a>; <a href="./references#CD004982-bbs2-0027" title="RathbunSW , AstonCE , WhitsettTL . A randomized trial of dalteparin compared with ibuprofen for the treatment of superficial thrombophlebitis. Journal of Thrombosis and Haemostasis2012;10(5):833‐9. ">Rathbun 2012</a>; <a href="./references#CD004982-bbs2-0029" title="Superficial Thrombophlebitis Treated by Enoxaparin Study Group. A pilot randomized double‐blind comparison of a low‐molecular‐weight heparin, a nonsteroidal anti‐inflammatory agent, and placebo in the treatment of superficial vein thrombosis. Archives of Internal Medicine2003;163(14):1657‐63. ">Stenox Group 2003</a>; <a href="./references#CD004982-bbs2-0030" title="TitonJP , AugerD , GrangeP , HecquetJP , RemondA , UlliacP , et al. Therapeutic management of superficial venous thrombosis with calcium nadroparin. Dosage testing and comparison with an non‐steroidal anti‐inflammatory agent [Traitement curatif des thromboses veineuses superficielles par nadroparine calcique. Recherche posologique et comparaison à un anti‐inflammatoire non stéroidien]. Annales de Cardiologie et d'Angeiologie1994;43(3):160‐6. ">Titon 1994</a>); two used fondaparinux (<a href="./references#CD004982-bbs2-0008" title="Beyer‐WestendorfJ , SchellongSM , GerlachH , RabeE , WeitzJI , JersemannK , et al. Prevention of thromboembolic complications in patients with superficial‐vein thrombosis given rivaroxaban or fondaparinux: the open‐label, randomised, non‐inferiority SURPRISE phase 3b trial. Lancet Haematology2017;4(3):e105‐13. WerthS , BauersachsR , GerlachH , RabeE , SchellongS , Beyer‐WestendorfJ . Superficial vein thrombosis treated for 45 days with rivaroxaban versus fondaparinux: rationale and design of the SURPRISE trial. Journal of Thrombosis and Thrombolysis2016;42(2):197‐204. ">Beyer‐Westendorf 2017</a>; <a href="./references#CD004982-bbs2-0011" title="BauersachsRM . The CALISTO‐study. Phlebologie2011;40(2):79‐83. DecoususH . Fondaparinux reduced a composite of VTE complications or death in superficial leg‐vein thrombosis. Annals of Internal Medicine2011;154(4):JC2‐3. DecoususH , PrandoniP , MismettiP , BauersachsRM , BodaZ , BrennerB , et al. CALISTO Study Group. Fondaparinux for the treatment of superficial‐vein thrombosis in the legs. New England Journal of Medicine2010;363(13):1222‐32. LeizoroviczA , BeckerF , BuchmullerA , QuereI , PrandoniP , DecoususH , et al. Clinical relevance of symptomatic superficial‐vein thrombosis extension: lessons from the CALISTO study. Blood2013;122(10):1724‐9. LeizoroviczA , PrandoniP , DecoususH . Fondaparinux reduces all types of symptomatic thromboembolic complications in patients with superficial‐vein thrombosis in the legs: data from the CALISTO study. ASH Annual Meeting Abstracts2011;118:2310. ">Decousus 2010b</a>); one used rivaroxaban (<a href="./references#CD004982-bbs2-0008" title="Beyer‐WestendorfJ , SchellongSM , GerlachH , RabeE , WeitzJI , JersemannK , et al. Prevention of thromboembolic complications in patients with superficial‐vein thrombosis given rivaroxaban or fondaparinux: the open‐label, randomised, non‐inferiority SURPRISE phase 3b trial. Lancet Haematology2017;4(3):e105‐13. WerthS , BauersachsR , GerlachH , RabeE , SchellongS , Beyer‐WestendorfJ . Superficial vein thrombosis treated for 45 days with rivaroxaban versus fondaparinux: rationale and design of the SURPRISE trial. Journal of Thrombosis and Thrombolysis2016;42(2):197‐204. ">Beyer‐Westendorf 2017</a>), and nine studies used another oral (<a href="./references#CD004982-bbs2-0003" title="ArcherDS , FowlerPD . Comparison of oxyphenbutazone and placebo in the treatment of superficial thrombophlebitis: an object lesson in clinical trial design. Practitioner1977;218:712‐75. ">Archer 1977</a>; <a href="./references#CD004982-bbs2-0004" title="BelcaroG , ErrichiBM , LauroraG , CesaroneMR , CandianiC . Treatment of acute superficial thrombosis and follow‐up by computerized thermography. VASA. Zeitschrift fur Gefasskrankheiten. Journal for Vascular Diseases1989;18(3):227‐34. ">Belcaro 1989</a>; <a href="./references#CD004982-bbs2-0006" title="BelcaroG , NicolaidesAN , ErrichiBM , CesaroneMR , DeSanctisMT , IncandelaL , et al. Superficial thrombophlebitis of the legs: a randomized, controlled, follow‐up study. Angiology1999;50(7):523‐9. ">Belcaro 1999</a>; <a href="./references#CD004982-bbs2-0018" title="KoshkinVM , KirienkoAI . Systemic enzyme therapy in the treatment of acute thrombosis of superficial veins in the lower extremities and postthrombophlebitic disease. International Journal of Immunotherapy2001;17(2‐4):121‐4. ">Koshkin 2001</a>; <a href="./references#CD004982-bbs2-0019" title="KuhlweinA . Drug treatment of superficial thrombophlebitides [Medikamentose behandlung oberflachlicher thrombophlebitiden]. Therapiewoche1985;35(36):4067‐70. ">Kuhlwein 1985</a>; <a href="./references#CD004982-bbs2-0023" title="MessaG , LaPlacaG , PuccettiL , DiPerriT . Heparansulphate. Effectiveness and tolerability of heparan sulphate in the treatment of superficial thrombophlebitis. Controlled clinical study vs sulodexide [Efficacia e tollerabilità dell'eparansolfato nel trattamento della tromboflebite superficiale. Studio clinico controllato vs sulodexide]. Minerva Cardioangiologica1997;45(4):147‐53. ">Messa 1997</a>), intramuscular (<a href="./references#CD004982-bbs2-0001" title="AndreozziGM , SignorelliS , DiPinoL , MartiniR , MarchitelliE , PintoA , et al. Tolerability and clinical efficacy of desmin in the treatment of superficial varicothrombophlebitis. Angiology1996;47(9):887‐94. ">Andreozzi 1996</a>), intravenous (<a href="./references#CD004982-bbs2-0022" title="MarshallM , KleineM‐W . Efficacy and tolerability of an oral enzyme therapy in the treatment of painful acute superficial thrombophlebitis [Wirksamkeit und vertraglichkeit einer oralen enzymtherapie bei der schmerzhaften akuten thrombophlebitis superficialis]. Phlebologie2001;30(2):36‐43. ">Marshall 2001</a>), or non‐pharmacological (<a href="./references#CD004982-bbs2-0009" title="BoehlerK , KittlerH , StolkovichS , TzanevaS . Therapeutic effect of compression stockings versus no compression on isolated superficial vein thrombosis of the legs: a randomized clinical trial. European Journal of Vascular and Endovascular Surgery2014;48(4):465‐71. ">Boehler 2014</a>) treatment. </p> </section> <section id="CD004982-sec-0056"> <h4 class="title">Excluded studies</h4> <p>Two additional studies were excluded in this update (<a href="./references#CD004982-bbs2-0056" title="NgIHL . Best treatment modality for superficial phlebitis. Annals of the Academy of Medicine Singapore2010:S210. ">Ng 2010</a>; <a href="./references#CD004982-bbs2-0067" title="SupeA , SubnisBM , RajeevRM , PanchalVH , LakhaniRJ , MehtaliaB , et al. Novel topical quick penetrating solution of heparin in management of superficial thrombophlebitis: results of randomized active controlled trial. International Journal of Pharmaceutical Sciences and Research2013;4(11):4442‐7. ">Supe 2013</a>) and one study which had previously been in the <a href="./references#CD004982-bbs1-0003" title="">Studies awaiting classification</a> section (<a href="./references#CD004982-bbs2-0042" title="BijuanL . Observation of aloe pigmentum in treatment of phlebitis. Nanfang Journal of Nursing2003:3. ">Bijuan 2003</a>) was also excluded making a total of 37 excluded studies. The reasons for exclusion are listed in the <a href="./references#CD004982-sec-0106" title="">Characteristics of excluded studies</a> table. Twenty‐one studies included a mixed population and it was not possible to extract data separately for ST (<a href="./references#CD004982-bbs2-0035" title="AllegraC , PollariG , CriscuoloA , BonifacioM , TabassiD . Centella asiatica extract in venous disorders of the lower limbs. Comparative clinical‐instrumental trial against a placebo [L'estratto di centella asiatica nelle flebopatie degli arti inferiori. Ricerca clinico‐strumentale comparativa con un placebo]. Clinica Terapeutica1981;99:507‐13. ">Allegra 1981</a>; <a href="./references#CD004982-bbs2-0036" title="AnnoniF , DeStefanoA , PabischS , FlorestaM , MagnaniP , LiettiF , et al. Efficacy and safety of topical treatment with heparan sulfate in superficial phlebitis. A double‐blind placebo‐controlled trial. Acta Therapeutica1991;17:263‐72. ">Annoni 1991</a>; <a href="./references#CD004982-bbs2-0037" title="ArgenteriA , VittoriF , LongoniA . Flurbiprofen and thrombophlebitis of lower limbs: a controlled clinical trial [Terapia antiinfiammatoria delle tromboflebiti degli arti inferiori con flurbiprofen: studio clinico controllato]. Giornale Italiano di Angiologia1983;3:203‐8. ">Argenteri 1983</a>; <a href="./references#CD004982-bbs2-0038" title="BaglianiA , LaRosaA , SarchiC . A new anti‐inflammatory drug, suprofen, in the treatment of thrombophlebitis [Un nuovo farmaco antiinfiammatorio, il suprofen, nel trattamento delle tromboflebiti]. Giornale Italiano di Angiologia1983;3:57‐64. ">Bagliani 1983</a>; <a href="./references#CD004982-bbs2-0039" title="BecherucciA , BagiletD , MarenghiniJ , DiabM , BiancardiH . Effect of topical and oral diclofenac on superficial thrombophlebitis caused by intravenous infusion [Efecto del diclofenaco topico y oral sobre la tromboflebitis superficial inducida por infusion intravenosa]. Medicina Clinica2000;114(10):371‐3. ">Becherucci 2000</a>; <a href="./references#CD004982-bbs2-0040" title="BergqvistD , BrunkwallJ , JensenN , PerssonNH . Treatment of superficial thrombophlebitis. A comparative trial between placebo, hirudoid cream and piroxicam gel. Annales Chirurgiae et Gynaecologiae1990;79(2):92‐6. ">Bergqvist 1990</a>; <a href="./references#CD004982-bbs2-0043" title="BracaleG , SelvetellaL . Controlled clinical trial comparing seaprose S to serratio‐peptidase in venous inflammatory disease. Efficacy and safety [Studio clinico sull'efficacia e la tollerabilità del seaprose S nelle flebopatie infiammatorie. Studio controllato verso serratio‐peptidasi]. Minerva Cardioangiologica1996;44(10):515‐24. ">Bracale 1996</a>; <a href="./references#CD004982-bbs2-0044" title="BruniM , Quarti TrevanoGM , LochisD , BaresiA , SolettiL . Double‐blind assessment of the clinical and pharmacological results of administration of a preparation with trypsin/chymotrypsin and tetracycline hydrochloride base in cases of acute phlebitis [Analisi in doppio cieco dei risultati clinici e farmacologici dopom somministrazione di un preparato a base di tripsina/chimotripsina e tetraciclina cloridrato nelle flebiti acute]. Gazzetta Medica Italiana1979;138(11):567‐70. ">Bruni 1979</a>; <a href="./references#CD004982-bbs2-0045" title="Della MarchinaM , RenziG , PalazziniE . Treatment of phlebopathies with low molecular weight heparin as compared to heparin calcium. Riforma Medica1989;104(4):99‐104. ">Della Marchina 1989</a>; <a href="./references#CD004982-bbs2-0051" title="LuttichauU , PalazziniE . Antithrombotic therapy in phlebopathies of lower limbs: a controlled study of low molecular weight heparin versus heparin calcium. Rivista Europea Per Le Scienze Mediche e Farmacologiche1989;11(4):351‐8. ">Luttichau 1989</a>; <a href="./references#CD004982-bbs2-0052" title="MariF , CerretaG , NardiV , DialtiL . Piroxicam as antiinflammatory therapy in thrombophlebitis: clinical experience [Il piroxicam nella terapia antiflogistica delle tromboflebiti. Nostra esperienza clinica]. Gazzetta Medica Italiana1982;141(5):243‐5. ">Mari 1982</a>; <a href="./references#CD004982-bbs2-0053" title="MarsalaF . A controlled double‐blind cross‐over study of a calcium heparin preparation [Studio controllato in doppio cieco cross‐over su un preparato a base di calcio‐eparina]. Clinica Terapeutica1985;113(6):473‐7. ">Marsala 1985</a>; <a href="./references#CD004982-bbs2-0054" title="MauroM , FerraroG , PalmieriG . Profibrinolytic and antithrombotic effects of sulodexide oral administration: a double‐blind, cross‐over, placebo‐controlled study. Current Therapeutic Research, Clinical and Experimental1992;51(3):342‐50. ">Mauro 1992</a>; <a href="./references#CD004982-bbs2-0057" title="PaciaroniE , MariniM . Topical therapy for phlebophaties. Results of a controlled clinical study [Sulla terapia topica delle flebopatie. Risultati di uno studio clinico controllato]. Policlinico Sezione Medica1982;89(3):255‐64. ">Paciaroni 1982</a>; <a href="./references#CD004982-bbs2-0058" title="PortersJ , RoekaertsF , ReyntjensA . R 41 468, a specific serotonin antagonist, relieves symptoms of acute superficial thrombophlebitis. Current Therapeutic Research, Clinical and Experimental1981;30(4):499‐506. ">Porters 1981</a>; <a href="./references#CD004982-bbs2-0059" title="PozzaE , MenghiR , PansiniGC , DuattiA , CarnovaliM . Clinical trial with BPH 689 for the treatment of superficial phlebitis [Impiego clinico del BPH 689 nel trattamento delle flebiti superficiali]. Acta Chirurgica Italiana1980;36(2):157‐66. ">Pozza 1980</a>; <a href="./references#CD004982-bbs2-0063" title="SecciaM , BortolottiP , BellominiMG , BucciantiP , ChiarugiM , CavinaE . Use of defibrotide in the treatment of acute superficial thrombophlebitis of the legs [Impiego del defibrotide nel trattamento delle tromboflebiti acute superficiali degli arti]. Minerva Chirurgica1989;44(9):1379‐84. ">Seccia 1989</a>; <a href="./references#CD004982-bbs2-0064" title="SeghezziR , BorriP , ChierichettiS , FerrariP . Controlled clinical trial of 4‐prenyl‐1,2‐diphenyl‐3,5‐pyrazolidinedione (DA2370) and oxyphenbutazone in thrombophlebitis. Arzneimittel‐Forschung1972;22(1):272‐4. ">Seghezzi 1972</a>; <a href="./references#CD004982-bbs2-0065" title="SeligmanB . Oral bromelains as adjuncts in the treatment of acute thrombophlebitis. Angiology1969;20(1):22‐6. ">Seligman 1969</a>; <a href="./references#CD004982-bbs2-0066" title="StolleA . Treatment of superficial thrombophlebitis with a new emulsion gel [Behandlung der thrombophlebitis superficialis mit einem neuartigen emulsiongel]. Die Medizinische Welt1986;37:700‐2. ">Stolle 1986</a>; <a href="./references#CD004982-bbs2-0068" title="TomamichelM , ReinerM . Treatment of thrombophlebitis and superficial phlebitis. A comparison of nimesulide and oxyphenbutazone. Clinical Trials Journal1983;20(3):148‐57. ">Tomamichel 1983</a>). In one study it was not possible to extract outcome data separately for the two study treatment groups (<a href="./references#CD004982-bbs2-0034" title="AgusGB , deAngelisR , MondaniP , MoiaR . Double‐blind comparison of nimesulide and diclofenac in the treatment of superficial thrombophlebitis with telethermographic assessment. Drugs1993;46 Suppl 1:200‐3. ">Agus 1993</a>). Four studies included people without a diagnosis of ST of the legs (<a href="./references#CD004982-bbs2-0041" title="BernicotJ . The value of Eucatex in venous pathology in the young woman [Interet d'eucatex dans la pathologie veineuse de la jeune femme]. Quest Medical1980;33(5):221‐2. ">Bernicot 1980</a>; <a href="./references#CD004982-bbs2-0047" title="GandhiDB , PalmarJR , LewisB , SchraibmanIG . Clinical comparison of elastic supports for venous diseases of the lower limbs. Postgraduate Medical Journal1984;60:349‐52. ">Gandhi 1984</a>; <a href="./references#CD004982-bbs2-0061" title="RestaV . Clinical comparative experiment on 2 ointments of different extractive heparinoid concentrations (double blind test). Arzneimittel‐Forschung1967;17(8):1078‐82. ">Resta 1967</a>; <a href="./references#CD004982-bbs2-0069" title="vanCauwenbergeH . Double‐blind study of the efficacy of a soluble rutoside derivative in the treatment of venous disease [Etude n double aveugle de l'efficacité de l'O‐(beta‐hydroxyéthyl)‐rutosides dans le traitement des affections veineuses]. Archives Internationales de Pharmacodynamie et de Therapie1972;196:122‐8. ">van Cauwenberge 1972</a>), and two studies included people with DVT (<a href="./references#CD004982-bbs2-0046" title="DiPerriT , VittoriaA , MessaGL , CappelliR . Defibrotide therapy for thrombophlebitis ‐ controlled clinical trial. Haemostasis1986;16 Suppl 1:42‐7. ">Di Perri 1986</a>; <a href="./references#CD004982-bbs2-0060" title="ReaWJ , PetersDW , SmileyRE , EdgarR , GreenbergM , FenyvesE . Recurrent environmentally triggered thrombophlebitis: a five‐year follow‐up. Annals of Allergy1981;47(5):338‐44. ">Rea 1981</a>). In one study, it was unclear whether the study was randomised or not (<a href="./references#CD004982-bbs2-0048" title="GiorgettiPL , BortolaniEM , MorbidelliA , VandonePL , GhilardiG , MattioliA , et al. Use of a new anti‐inflammatory drug in the treatment of varicophlebitis of the lower limbs [L'uso di un nuovo farmaco antiinflammatorio nel trattamento delle varicoflebiti degli arti inferiori]. Minerva Chirurgica1990;45(12):883‐6. ">Giorgetti 1990</a>). Six studies included people with ST of the arm (<a href="./references#CD004982-bbs2-0049" title="GoupingZ , Wan‐ErT , Xue‐LingW , Min‐QianX , KunF , TuraleS , et al. Notoginseny cream in the treatment of phlebitis. Journal of Infusion Nursing2003;26(1):49‐54. ">Gouping 2003</a>; <a href="./references#CD004982-bbs2-0055" title="MehtaPP , SagarS , KakkarVV . Treatment of superficial thrombophlebitis: a randomized double‐blind trial of heparinoid cream. BMJ1975;3(5984):614‐6. ">Mehta 1975</a>; <a href="./references#CD004982-bbs2-0056" title="NgIHL . Best treatment modality for superficial phlebitis. Annals of the Academy of Medicine Singapore2010:S210. ">Ng 2010</a>; <a href="./references#CD004982-bbs2-0062" title="RozsosI , KollarL , ScholzME . The topical treatment of infusion thrombophlebitis with pentosan polysulfate sodium ointment. A randomised double‐blind study. Annals of Hematology1994;68 Suppl 1:A92. ">Rozsos 1994</a>; <a href="./references#CD004982-bbs2-0067" title="SupeA , SubnisBM , RajeevRM , PanchalVH , LakhaniRJ , MehtaliaB , et al. Novel topical quick penetrating solution of heparin in management of superficial thrombophlebitis: results of randomized active controlled trial. International Journal of Pharmaceutical Sciences and Research2013;4(11):4442‐7. ">Supe 2013</a>; <a href="./references#CD004982-bbs2-0070" title="van derKnaapJH , denOttolanderGJH , vanHeerdeLR . Research into efficacy of heparinoid cream [Onderzoek naar de effectiviteit van heparinodezalf]. Pharmaceutisch Weekblad1988;123:973‐5. ">van der Knaap 1988</a>), and in one study, the evaluated outcomes were not among those considered in the present review (<a href="./references#CD004982-bbs2-0050" title="Ibanez‐BermudezS , Perez MartinezF , Llamas del CastilloMD , Sevilla JiménezJC , Gonzalez GonzalezEM . Randomized double‐blind clinical study on the efficacy of topical sodium heparin versus sodium polysulphate pentosan [Estudio clinico randomizado y doble ciego sobre la eficacia de heparina sodica topica frente a pentosan polisulfato sodico en patologias venosas superficiales]. Farmacia Clinica1996;13(2):110‐5. ">Ibanez‐Bermudez 1996</a>). For one study, we were unable to retrieve sufficient information to judge eligibility fully (<a href="./references#CD004982-bbs2-0042" title="BijuanL . Observation of aloe pigmentum in treatment of phlebitis. Nanfang Journal of Nursing2003:3. ">Bijuan 2003</a>). </p> <section id="CD004982-sec-0057"> <h5 class="title">Ongoing studies</h5> <p>One study is still ongoing (<a href="./references#CD004982-bbs2-0074" title="RabeE . DAPS‐dalteparin in patients with superficial leg vein phlebitis in addition to compression treatment ‐ a placebo‐controlled phase‐III study. XVIth World Meeting of the Union Internationale de Phlébologie (UIP); 2009 Aug 31‐Sept 4; Principality of Monaco. ">Rabe 2009</a>). See <a href="./references#CD004982-sec-0108" title="">Characteristics of ongoing studies</a> table. </p> </section> </section> </section> <section id="CD004982-sec-0058"> <h3 class="title">Risk of bias in included studies</h3> <p>Details of the methodological quality for each trial are reported in the <a href="./references#CD004982-sec-0105" title="">Characteristics of included studies</a> table. A risk of bias summary is presented in <a href="#CD004982-fig-0002">Figure 2</a>. </p> <div class="figure" id="CD004982-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD004982-fig-0002" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD004982-sec-0059"> <h4 class="title">Allocation</h4> <p>Thirteen studies adequately generated the randomisation sequence (<a href="./references#CD004982-bbs2-0007" title="BelcaroG , CesaroneMR , DugallM , FeragalliB , IppolitoE , CorsiM , et al. Topical formulation of heparin is effective in reducing the symptoms of superficial venous thrombosis: a monocenter, observer‐blind, placebo‐controlled randomized study. Panminerva Medica2011;53(3 Suppl 1):3‐11. ">Belcaro 2011</a>; <a href="./references#CD004982-bbs2-0008" title="Beyer‐WestendorfJ , SchellongSM , GerlachH , RabeE , WeitzJI , JersemannK , et al. Prevention of thromboembolic complications in patients with superficial‐vein thrombosis given rivaroxaban or fondaparinux: the open‐label, randomised, non‐inferiority SURPRISE phase 3b trial. Lancet Haematology2017;4(3):e105‐13. WerthS , BauersachsR , GerlachH , RabeE , SchellongS , Beyer‐WestendorfJ . Superficial vein thrombosis treated for 45 days with rivaroxaban versus fondaparinux: rationale and design of the SURPRISE trial. Journal of Thrombosis and Thrombolysis2016;42(2):197‐204. ">Beyer‐Westendorf 2017</a>; <a href="./references#CD004982-bbs2-0010" title="CosmiB . Risk factors for recurrent events in subjects with superficial vein thrombosis in the randomized clinical trial SteFlux (Superficial Thromboembolism Fluxum). Thrombosis Research2014;133(2):196‐202. CosmiB , FilippiniM , TontiD , AvruscioG , GhirarduzziA , BucheriniE , et al. A randomized double‐blind study of low‐molecular‐weight heparin (parnaparin) for superficial vein thrombosis: STEFLUX (Superficial ThromboEmbolism and Fluxum). Journal of Thrombosis and Haemostasis2012;10(6):1026‐35. CosmiB , FilippiniM , TontiD , GhirarduzziA , AvruscioG , ImbertiD , et al. Risk factors for recurrent events in subjects with superficial vein thrombosis in the randomized clinical trial Steflux (Superficial Thromboembolism Fluxum). Hamostaseologie2012;32:A29. CosmiB , FilippiniM , TontiD , GhirarduzziA , AvruscioG , ImbertiD , et al. The Steflux (Superficial Thromboembolism and Fluxum) randomized double blind clinical study of different treatment doses and duration of low molecular weight heparin (parnaparin) in superficial vein thrombosis. Hamostaseologie2012;32:A28. ">Cosmi 2012</a>; <a href="./references#CD004982-bbs2-0011" title="BauersachsRM . The CALISTO‐study. Phlebologie2011;40(2):79‐83. DecoususH . Fondaparinux reduced a composite of VTE complications or death in superficial leg‐vein thrombosis. Annals of Internal Medicine2011;154(4):JC2‐3. DecoususH , PrandoniP , MismettiP , BauersachsRM , BodaZ , BrennerB , et al. CALISTO Study Group. Fondaparinux for the treatment of superficial‐vein thrombosis in the legs. New England Journal of Medicine2010;363(13):1222‐32. LeizoroviczA , BeckerF , BuchmullerA , QuereI , PrandoniP , DecoususH , et al. Clinical relevance of symptomatic superficial‐vein thrombosis extension: lessons from the CALISTO study. Blood2013;122(10):1724‐9. LeizoroviczA , PrandoniP , DecoususH . Fondaparinux reduces all types of symptomatic thromboembolic complications in patients with superficial‐vein thrombosis in the legs: data from the CALISTO study. ASH Annual Meeting Abstracts2011;118:2310. ">Decousus 2010b</a>; <a href="./references#CD004982-bbs2-0014" title="GorskiG , SzopinskiP , MichalakJ , MarianowskaA , BorkowskiM , GeremekM , et al. Liposomal heparin spray: a new formula in adjunctive treatment of superficial venous thrombosis. Angiology2005;56(1):9‐17. ">Gorski 2005</a>; <a href="./references#CD004982-bbs2-0017" title="KatzenschlagerR , UgurluogluA , MinarE , HirschlM . Liposomal heparin‐spraygel in comparison with subcutaneous low molecular weight heparin in patients with superficial venous thrombosis. A randomized, controlled, open multicentre study. Journal fur Kardiologie2003;10(9):375‐8. ">Katzenschlager 2003</a>; <a href="./references#CD004982-bbs2-0021" title="MarchioriA , VerlatoF , SabbionP , CamporeseG , RossoF , MosenaL , et al. High versus low doses of unfractionated heparin for the treatment of superficial thrombophlebitis of the leg. A prospective, controlled, randomized study. Haematologica2002;87(5):523‐7. ">Marchiori 2002</a>; <a href="./references#CD004982-bbs2-0022" title="MarshallM , KleineM‐W . Efficacy and tolerability of an oral enzyme therapy in the treatment of painful acute superficial thrombophlebitis [Wirksamkeit und vertraglichkeit einer oralen enzymtherapie bei der schmerzhaften akuten thrombophlebitis superficialis]. Phlebologie2001;30(2):36‐43. ">Marshall 2001</a>; <a href="./references#CD004982-bbs2-0023" title="MessaG , LaPlacaG , PuccettiL , DiPerriT . Heparansulphate. Effectiveness and tolerability of heparan sulphate in the treatment of superficial thrombophlebitis. Controlled clinical study vs sulodexide [Efficacia e tollerabilità dell'eparansolfato nel trattamento della tromboflebite superficiale. Studio clinico controllato vs sulodexide]. Minerva Cardioangiologica1997;45(4):147‐53. ">Messa 1997</a>; <a href="./references#CD004982-bbs2-0027" title="RathbunSW , AstonCE , WhitsettTL . A randomized trial of dalteparin compared with ibuprofen for the treatment of superficial thrombophlebitis. Journal of Thrombosis and Haemostasis2012;10(5):833‐9. ">Rathbun 2012</a>; <a href="./references#CD004982-bbs2-0028" title="SpirkoskaA , JezovnikMK , PoredosP . Time course and the recanalization rate of superficial vein thrombosis treated with low‐molecular‐weight heparin. Angiology2015;66:381‐6. ">Spirkoska 2015</a>; <a href="./references#CD004982-bbs2-0032" title="PrandoniP . High versus low doses of low‐molecular‐weight heparin for the treatment of superficial vein thrombosis of the legs. A double‐blind, randomized trial. Journal of Thrombosis and Haemostasis2005;3 (Suppl 1):Abstract number OR145. [http://onlinelibrary.wiley.com/doi/10.1111/j.1538‐7836.2005.0300b.x/full] PrandoniP , TormeneD , PesaventoR , Vesalio Investigators Group. High vs. low doses of low‐molecular‐weight heparin for the treatment of superficial vein thrombosis of the legs: a double‐blind, randomized trial. Journal of Thrombosis and Haemostasis2005;3(6):1152‐7. ">Vesalio Group 2005</a>; <a href="./references#CD004982-bbs2-0033" title="WinterWR , RauhutK , ArnoldS , BabiakD , StoidnerB . Local therapy of thrombophlebitis superficialis ‐ an inter‐individual comparison of Voltaren‐Emulgel versus a gel containing heparin [Lokale therapie der thrombophlebitis superficialis ‐ Ein individueller vergleich von Voltaren‐emulgel versus ein heparin‐haltiges gel]. Zeitschrift fur Rheumatologie1986;45:180‐1. ">Winter 1986</a>), one was not adequate (<a href="./references#CD004982-bbs2-0031" title="UncuH . A comparison of low‐molecular‐weight heparin and combined therapy of low‐molecular‐weight heparin with an anti‐inflammatory agent in the treatment of superficial vein thrombosis. Phlebology2009;24(2):56‐60. ">Uncu 2009</a>), and the remaining 18 studies were unclear. Eighteen studies adequately concealed allocation (<a href="./references#CD004982-bbs2-0007" title="BelcaroG , CesaroneMR , DugallM , FeragalliB , IppolitoE , CorsiM , et al. Topical formulation of heparin is effective in reducing the symptoms of superficial venous thrombosis: a monocenter, observer‐blind, placebo‐controlled randomized study. Panminerva Medica2011;53(3 Suppl 1):3‐11. ">Belcaro 2011</a>; <a href="./references#CD004982-bbs2-0008" title="Beyer‐WestendorfJ , SchellongSM , GerlachH , RabeE , WeitzJI , JersemannK , et al. Prevention of thromboembolic complications in patients with superficial‐vein thrombosis given rivaroxaban or fondaparinux: the open‐label, randomised, non‐inferiority SURPRISE phase 3b trial. Lancet Haematology2017;4(3):e105‐13. WerthS , BauersachsR , GerlachH , RabeE , SchellongS , Beyer‐WestendorfJ . Superficial vein thrombosis treated for 45 days with rivaroxaban versus fondaparinux: rationale and design of the SURPRISE trial. Journal of Thrombosis and Thrombolysis2016;42(2):197‐204. ">Beyer‐Westendorf 2017</a>; <a href="./references#CD004982-bbs2-0010" title="CosmiB . Risk factors for recurrent events in subjects with superficial vein thrombosis in the randomized clinical trial SteFlux (Superficial Thromboembolism Fluxum). Thrombosis Research2014;133(2):196‐202. CosmiB , FilippiniM , TontiD , AvruscioG , GhirarduzziA , BucheriniE , et al. A randomized double‐blind study of low‐molecular‐weight heparin (parnaparin) for superficial vein thrombosis: STEFLUX (Superficial ThromboEmbolism and Fluxum). Journal of Thrombosis and Haemostasis2012;10(6):1026‐35. CosmiB , FilippiniM , TontiD , GhirarduzziA , AvruscioG , ImbertiD , et al. Risk factors for recurrent events in subjects with superficial vein thrombosis in the randomized clinical trial Steflux (Superficial Thromboembolism Fluxum). Hamostaseologie2012;32:A29. CosmiB , FilippiniM , TontiD , GhirarduzziA , AvruscioG , ImbertiD , et al. The Steflux (Superficial Thromboembolism and Fluxum) randomized double blind clinical study of different treatment doses and duration of low molecular weight heparin (parnaparin) in superficial vein thrombosis. Hamostaseologie2012;32:A28. ">Cosmi 2012</a>; <a href="./references#CD004982-bbs2-0011" title="BauersachsRM . The CALISTO‐study. Phlebologie2011;40(2):79‐83. DecoususH . Fondaparinux reduced a composite of VTE complications or death in superficial leg‐vein thrombosis. Annals of Internal Medicine2011;154(4):JC2‐3. DecoususH , PrandoniP , MismettiP , BauersachsRM , BodaZ , BrennerB , et al. CALISTO Study Group. Fondaparinux for the treatment of superficial‐vein thrombosis in the legs. New England Journal of Medicine2010;363(13):1222‐32. LeizoroviczA , BeckerF , BuchmullerA , QuereI , PrandoniP , DecoususH , et al. Clinical relevance of symptomatic superficial‐vein thrombosis extension: lessons from the CALISTO study. Blood2013;122(10):1724‐9. LeizoroviczA , PrandoniP , DecoususH . Fondaparinux reduces all types of symptomatic thromboembolic complications in patients with superficial‐vein thrombosis in the legs: data from the CALISTO study. ASH Annual Meeting Abstracts2011;118:2310. ">Decousus 2010b</a>; <a href="./references#CD004982-bbs2-0022" title="MarshallM , KleineM‐W . Efficacy and tolerability of an oral enzyme therapy in the treatment of painful acute superficial thrombophlebitis [Wirksamkeit und vertraglichkeit einer oralen enzymtherapie bei der schmerzhaften akuten thrombophlebitis superficialis]. Phlebologie2001;30(2):36‐43. ">Marshall 2001</a>; <a href="./references#CD004982-bbs2-0027" title="RathbunSW , AstonCE , WhitsettTL . A randomized trial of dalteparin compared with ibuprofen for the treatment of superficial thrombophlebitis. Journal of Thrombosis and Haemostasis2012;10(5):833‐9. ">Rathbun 2012</a>; <a href="./references#CD004982-bbs2-0028" title="SpirkoskaA , JezovnikMK , PoredosP . Time course and the recanalization rate of superficial vein thrombosis treated with low‐molecular‐weight heparin. Angiology2015;66:381‐6. ">Spirkoska 2015</a>; <a href="./references#CD004982-bbs2-0029" title="Superficial Thrombophlebitis Treated by Enoxaparin Study Group. A pilot randomized double‐blind comparison of a low‐molecular‐weight heparin, a nonsteroidal anti‐inflammatory agent, and placebo in the treatment of superficial vein thrombosis. Archives of Internal Medicine2003;163(14):1657‐63. ">Stenox Group 2003</a>), and the remaining 25 studies were unclear. </p> </section> <section id="CD004982-sec-0060"> <h4 class="title">Blinding</h4> <p>Ten studies had a double‐blinded design (<a href="./references#CD004982-bbs2-0010" title="CosmiB . Risk factors for recurrent events in subjects with superficial vein thrombosis in the randomized clinical trial SteFlux (Superficial Thromboembolism Fluxum). Thrombosis Research2014;133(2):196‐202. CosmiB , FilippiniM , TontiD , AvruscioG , GhirarduzziA , BucheriniE , et al. A randomized double‐blind study of low‐molecular‐weight heparin (parnaparin) for superficial vein thrombosis: STEFLUX (Superficial ThromboEmbolism and Fluxum). Journal of Thrombosis and Haemostasis2012;10(6):1026‐35. CosmiB , FilippiniM , TontiD , GhirarduzziA , AvruscioG , ImbertiD , et al. Risk factors for recurrent events in subjects with superficial vein thrombosis in the randomized clinical trial Steflux (Superficial Thromboembolism Fluxum). Hamostaseologie2012;32:A29. CosmiB , FilippiniM , TontiD , GhirarduzziA , AvruscioG , ImbertiD , et al. The Steflux (Superficial Thromboembolism and Fluxum) randomized double blind clinical study of different treatment doses and duration of low molecular weight heparin (parnaparin) in superficial vein thrombosis. Hamostaseologie2012;32:A28. ">Cosmi 2012</a>; <a href="./references#CD004982-bbs2-0011" title="BauersachsRM . The CALISTO‐study. Phlebologie2011;40(2):79‐83. DecoususH . Fondaparinux reduced a composite of VTE complications or death in superficial leg‐vein thrombosis. Annals of Internal Medicine2011;154(4):JC2‐3. DecoususH , PrandoniP , MismettiP , BauersachsRM , BodaZ , BrennerB , et al. CALISTO Study Group. Fondaparinux for the treatment of superficial‐vein thrombosis in the legs. New England Journal of Medicine2010;363(13):1222‐32. LeizoroviczA , BeckerF , BuchmullerA , QuereI , PrandoniP , DecoususH , et al. Clinical relevance of symptomatic superficial‐vein thrombosis extension: lessons from the CALISTO study. Blood2013;122(10):1724‐9. LeizoroviczA , PrandoniP , DecoususH . Fondaparinux reduces all types of symptomatic thromboembolic complications in patients with superficial‐vein thrombosis in the legs: data from the CALISTO study. ASH Annual Meeting Abstracts2011;118:2310. ">Decousus 2010b</a>; <a href="./references#CD004982-bbs2-0012" title="DeSanctisMT , CesaroneMR , IncandelaL , BelcaroG , GriffinM . Treatment of superficial vein thrombosis with standardized application of Essaven gel ‐ a placebo‐controlled, randomized study. Angiology2001;52 Suppl 3:S57‐62. ">De Sanctis 2001</a>; <a href="./references#CD004982-bbs2-0016" title="IncandelaL , DeSanctisMT , CesaroneMR , RicciA , ErrichiBM , DugalM , et al. Treatment of superficial vein thrombosis: clinical evaluation of essaven gel ‐ a placebo‐controlled, 8‐week, randomized study. Angiology2001;52 Suppl 3:69‐72. ">Incandela 2001</a>; <a href="./references#CD004982-bbs2-0022" title="MarshallM , KleineM‐W . Efficacy and tolerability of an oral enzyme therapy in the treatment of painful acute superficial thrombophlebitis [Wirksamkeit und vertraglichkeit einer oralen enzymtherapie bei der schmerzhaften akuten thrombophlebitis superficialis]. Phlebologie2001;30(2):36‐43. ">Marshall 2001</a>; <a href="./references#CD004982-bbs2-0025" title="NusserC‐J , SchareW , BernardI . The treatment of superficial thrombophlebitis with nonsteroidal antiphlogistic agents [Therapie superfizieller thrombophlebitiden mit nichtsteroidalen antiphlogistika]. Therapiewoche1991;41(9):541‐4. ">Nusser 1991</a>; <a href="./references#CD004982-bbs2-0026" title="PintoG , GalatiD , BompianiGD , CorcioneF , CalifanoG , ColucciS , et al. Topical 5'‐methylthioadenosine in the treatment of symptomatic chronic venous insufficiency, haemorrhoids and superficial phlebitis. A double‐blind placebo‐controlled trial. Drug Investigation1992;4(3):205‐14. ">Pinto 1992</a>; <a href="./references#CD004982-bbs2-0027" title="RathbunSW , AstonCE , WhitsettTL . A randomized trial of dalteparin compared with ibuprofen for the treatment of superficial thrombophlebitis. Journal of Thrombosis and Haemostasis2012;10(5):833‐9. ">Rathbun 2012</a>; <a href="./references#CD004982-bbs2-0029" title="Superficial Thrombophlebitis Treated by Enoxaparin Study Group. A pilot randomized double‐blind comparison of a low‐molecular‐weight heparin, a nonsteroidal anti‐inflammatory agent, and placebo in the treatment of superficial vein thrombosis. Archives of Internal Medicine2003;163(14):1657‐63. ">Stenox Group 2003</a>; <a href="./references#CD004982-bbs2-0032" title="PrandoniP . High versus low doses of low‐molecular‐weight heparin for the treatment of superficial vein thrombosis of the legs. A double‐blind, randomized trial. Journal of Thrombosis and Haemostasis2005;3 (Suppl 1):Abstract number OR145. [http://onlinelibrary.wiley.com/doi/10.1111/j.1538‐7836.2005.0300b.x/full] PrandoniP , TormeneD , PesaventoR , Vesalio Investigators Group. High vs. low doses of low‐molecular‐weight heparin for the treatment of superficial vein thrombosis of the legs: a double‐blind, randomized trial. Journal of Thrombosis and Haemostasis2005;3(6):1152‐7. ">Vesalio Group 2005</a>), and in nine studies it was unclear whether blinding was attempted (<a href="./references#CD004982-bbs2-0002" title="Anonymous . Indomethacin in superficial thrombophlebitis. Practitioner1970;205(227):369‐72. ">Anonymous 1970</a>; <a href="./references#CD004982-bbs2-0003" title="ArcherDS , FowlerPD . Comparison of oxyphenbutazone and placebo in the treatment of superficial thrombophlebitis: an object lesson in clinical trial design. Practitioner1977;218:712‐75. ">Archer 1977</a>; <a href="./references#CD004982-bbs2-0013" title="FerrariE , PratesiC , ScaricabarozziI , TrezzaniR . A clinical study of efficacy and tolerability of nimesulide compared with diclofenac sodium in the treatment of acute superficial thrombophlebitis [Studio clinico sull'efficacia terapeutica e la tollerabilità della nimesulide in confronto a diclofenac sodio nel trattamento delle tromboflebiti acute superficiali]. Minerva Cardioangiologica1992;40(11):455‐60. ">Ferrari 1992</a>; <a href="./references#CD004982-bbs2-0018" title="KoshkinVM , KirienkoAI . Systemic enzyme therapy in the treatment of acute thrombosis of superficial veins in the lower extremities and postthrombophlebitic disease. International Journal of Immunotherapy2001;17(2‐4):121‐4. ">Koshkin 2001</a>; <a href="./references#CD004982-bbs2-0019" title="KuhlweinA . Drug treatment of superficial thrombophlebitides [Medikamentose behandlung oberflachlicher thrombophlebitiden]. Therapiewoche1985;35(36):4067‐70. ">Kuhlwein 1985</a>; <a href="./references#CD004982-bbs2-0021" title="MarchioriA , VerlatoF , SabbionP , CamporeseG , RossoF , MosenaL , et al. High versus low doses of unfractionated heparin for the treatment of superficial thrombophlebitis of the leg. A prospective, controlled, randomized study. Haematologica2002;87(5):523‐7. ">Marchiori 2002</a>; <a href="./references#CD004982-bbs2-0024" title="DiebschlagW , NockerW . Lokal treatment for superficial thrombophlebitis. Die Medizinische Welt1990;41:651‐5. NockerW , DiebschlagW , LehmacherW . The efficacy of a diclofenac gel compared with placebo and heparin gel in the local treatment of superficial thrombophlebitis [Lokaltherapie bei oberflachlicher thrombophlebitis. Wirksamkeit eines diclofenac‐natrium‐gels im vergleich zu placebo‐ und heparin‐gel]. Zeitschrift fur Allgemeinmedizin1991;67:2214‐22. ">Nocker 1991</a>; <a href="./references#CD004982-bbs2-0028" title="SpirkoskaA , JezovnikMK , PoredosP . Time course and the recanalization rate of superficial vein thrombosis treated with low‐molecular‐weight heparin. Angiology2015;66:381‐6. ">Spirkoska 2015</a>; <a href="./references#CD004982-bbs2-0033" title="WinterWR , RauhutK , ArnoldS , BabiakD , StoidnerB . Local therapy of thrombophlebitis superficialis ‐ an inter‐individual comparison of Voltaren‐Emulgel versus a gel containing heparin [Lokale therapie der thrombophlebitis superficialis ‐ Ein individueller vergleich von Voltaren‐emulgel versus ein heparin‐haltiges gel]. Zeitschrift fur Rheumatologie1986;45:180‐1. ">Winter 1986</a>). The remaining 14 studies did not attempt to blind the assessment of the outcomes or did not report whether blinding was used. </p> </section> <section id="CD004982-sec-0061"> <h4 class="title">Incomplete outcome data</h4> <p>Seven studies performed the analysis according to the ITT principle (<a href="./references#CD004982-bbs2-0008" title="Beyer‐WestendorfJ , SchellongSM , GerlachH , RabeE , WeitzJI , JersemannK , et al. Prevention of thromboembolic complications in patients with superficial‐vein thrombosis given rivaroxaban or fondaparinux: the open‐label, randomised, non‐inferiority SURPRISE phase 3b trial. Lancet Haematology2017;4(3):e105‐13. WerthS , BauersachsR , GerlachH , RabeE , SchellongS , Beyer‐WestendorfJ . Superficial vein thrombosis treated for 45 days with rivaroxaban versus fondaparinux: rationale and design of the SURPRISE trial. Journal of Thrombosis and Thrombolysis2016;42(2):197‐204. ">Beyer‐Westendorf 2017</a>; <a href="./references#CD004982-bbs2-0011" title="BauersachsRM . The CALISTO‐study. Phlebologie2011;40(2):79‐83. DecoususH . Fondaparinux reduced a composite of VTE complications or death in superficial leg‐vein thrombosis. Annals of Internal Medicine2011;154(4):JC2‐3. DecoususH , PrandoniP , MismettiP , BauersachsRM , BodaZ , BrennerB , et al. CALISTO Study Group. Fondaparinux for the treatment of superficial‐vein thrombosis in the legs. New England Journal of Medicine2010;363(13):1222‐32. LeizoroviczA , BeckerF , BuchmullerA , QuereI , PrandoniP , DecoususH , et al. Clinical relevance of symptomatic superficial‐vein thrombosis extension: lessons from the CALISTO study. Blood2013;122(10):1724‐9. LeizoroviczA , PrandoniP , DecoususH . Fondaparinux reduces all types of symptomatic thromboembolic complications in patients with superficial‐vein thrombosis in the legs: data from the CALISTO study. ASH Annual Meeting Abstracts2011;118:2310. ">Decousus 2010b</a>; <a href="./references#CD004982-bbs2-0012" title="DeSanctisMT , CesaroneMR , IncandelaL , BelcaroG , GriffinM . Treatment of superficial vein thrombosis with standardized application of Essaven gel ‐ a placebo‐controlled, randomized study. Angiology2001;52 Suppl 3:S57‐62. ">De Sanctis 2001</a>; <a href="./references#CD004982-bbs2-0019" title="KuhlweinA . Drug treatment of superficial thrombophlebitides [Medikamentose behandlung oberflachlicher thrombophlebitiden]. Therapiewoche1985;35(36):4067‐70. ">Kuhlwein 1985</a>; <a href="./references#CD004982-bbs2-0021" title="MarchioriA , VerlatoF , SabbionP , CamporeseG , RossoF , MosenaL , et al. High versus low doses of unfractionated heparin for the treatment of superficial thrombophlebitis of the leg. A prospective, controlled, randomized study. Haematologica2002;87(5):523‐7. ">Marchiori 2002</a>; <a href="./references#CD004982-bbs2-0023" title="MessaG , LaPlacaG , PuccettiL , DiPerriT . Heparansulphate. Effectiveness and tolerability of heparan sulphate in the treatment of superficial thrombophlebitis. Controlled clinical study vs sulodexide [Efficacia e tollerabilità dell'eparansolfato nel trattamento della tromboflebite superficiale. Studio clinico controllato vs sulodexide]. Minerva Cardioangiologica1997;45(4):147‐53. ">Messa 1997</a>; <a href="./references#CD004982-bbs2-0024" title="DiebschlagW , NockerW . Lokal treatment for superficial thrombophlebitis. Die Medizinische Welt1990;41:651‐5. NockerW , DiebschlagW , LehmacherW . The efficacy of a diclofenac gel compared with placebo and heparin gel in the local treatment of superficial thrombophlebitis [Lokaltherapie bei oberflachlicher thrombophlebitis. Wirksamkeit eines diclofenac‐natrium‐gels im vergleich zu placebo‐ und heparin‐gel]. Zeitschrift fur Allgemeinmedizin1991;67:2214‐22. ">Nocker 1991</a>; <a href="./references#CD004982-bbs2-0032" title="PrandoniP . High versus low doses of low‐molecular‐weight heparin for the treatment of superficial vein thrombosis of the legs. A double‐blind, randomized trial. Journal of Thrombosis and Haemostasis2005;3 (Suppl 1):Abstract number OR145. [http://onlinelibrary.wiley.com/doi/10.1111/j.1538‐7836.2005.0300b.x/full] PrandoniP , TormeneD , PesaventoR , Vesalio Investigators Group. High vs. low doses of low‐molecular‐weight heparin for the treatment of superficial vein thrombosis of the legs: a double‐blind, randomized trial. Journal of Thrombosis and Haemostasis2005;3(6):1152‐7. ">Vesalio Group 2005</a>); in nine this was unclear, while in the remaining studies the percentage of participants randomised and subsequently excluded from the analysis ranged from 2% to 33% (<a href="./references#CD004982-bbs2-0002" title="Anonymous . Indomethacin in superficial thrombophlebitis. Practitioner1970;205(227):369‐72. ">Anonymous 1970</a>; <a href="./references#CD004982-bbs2-0003" title="ArcherDS , FowlerPD . Comparison of oxyphenbutazone and placebo in the treatment of superficial thrombophlebitis: an object lesson in clinical trial design. Practitioner1977;218:712‐75. ">Archer 1977</a>; <a href="./references#CD004982-bbs2-0004" title="BelcaroG , ErrichiBM , LauroraG , CesaroneMR , CandianiC . Treatment of acute superficial thrombosis and follow‐up by computerized thermography. VASA. Zeitschrift fur Gefasskrankheiten. Journal for Vascular Diseases1989;18(3):227‐34. ">Belcaro 1989</a>; <a href="./references#CD004982-bbs2-0006" title="BelcaroG , NicolaidesAN , ErrichiBM , CesaroneMR , DeSanctisMT , IncandelaL , et al. Superficial thrombophlebitis of the legs: a randomized, controlled, follow‐up study. Angiology1999;50(7):523‐9. ">Belcaro 1999</a>; <a href="./references#CD004982-bbs2-0007" title="BelcaroG , CesaroneMR , DugallM , FeragalliB , IppolitoE , CorsiM , et al. Topical formulation of heparin is effective in reducing the symptoms of superficial venous thrombosis: a monocenter, observer‐blind, placebo‐controlled randomized study. Panminerva Medica2011;53(3 Suppl 1):3‐11. ">Belcaro 2011</a>; <a href="./references#CD004982-bbs2-0009" title="BoehlerK , KittlerH , StolkovichS , TzanevaS . Therapeutic effect of compression stockings versus no compression on isolated superficial vein thrombosis of the legs: a randomized clinical trial. European Journal of Vascular and Endovascular Surgery2014;48(4):465‐71. ">Boehler 2014</a>; <a href="./references#CD004982-bbs2-0010" title="CosmiB . Risk factors for recurrent events in subjects with superficial vein thrombosis in the randomized clinical trial SteFlux (Superficial Thromboembolism Fluxum). Thrombosis Research2014;133(2):196‐202. CosmiB , FilippiniM , TontiD , AvruscioG , GhirarduzziA , BucheriniE , et al. A randomized double‐blind study of low‐molecular‐weight heparin (parnaparin) for superficial vein thrombosis: STEFLUX (Superficial ThromboEmbolism and Fluxum). Journal of Thrombosis and Haemostasis2012;10(6):1026‐35. CosmiB , FilippiniM , TontiD , GhirarduzziA , AvruscioG , ImbertiD , et al. Risk factors for recurrent events in subjects with superficial vein thrombosis in the randomized clinical trial Steflux (Superficial Thromboembolism Fluxum). Hamostaseologie2012;32:A29. CosmiB , FilippiniM , TontiD , GhirarduzziA , AvruscioG , ImbertiD , et al. The Steflux (Superficial Thromboembolism and Fluxum) randomized double blind clinical study of different treatment doses and duration of low molecular weight heparin (parnaparin) in superficial vein thrombosis. Hamostaseologie2012;32:A28. ">Cosmi 2012</a>; <a href="./references#CD004982-bbs2-0013" title="FerrariE , PratesiC , ScaricabarozziI , TrezzaniR . A clinical study of efficacy and tolerability of nimesulide compared with diclofenac sodium in the treatment of acute superficial thrombophlebitis [Studio clinico sull'efficacia terapeutica e la tollerabilità della nimesulide in confronto a diclofenac sodio nel trattamento delle tromboflebiti acute superficiali]. Minerva Cardioangiologica1992;40(11):455‐60. ">Ferrari 1992</a>; <a href="./references#CD004982-bbs2-0014" title="GorskiG , SzopinskiP , MichalakJ , MarianowskaA , BorkowskiM , GeremekM , et al. Liposomal heparin spray: a new formula in adjunctive treatment of superficial venous thrombosis. Angiology2005;56(1):9‐17. ">Gorski 2005</a>; <a href="./references#CD004982-bbs2-0015" title="HolzgreveA , KleineW , StegmannW . Local treatment of superficial thrombophlebitis with nonsteroidal antiinflammatory agents. Zeitschrift fur Allgemeinmedizin1989;65(27):663‐7. ">Holzgreve 1989</a>; <a href="./references#CD004982-bbs2-0017" title="KatzenschlagerR , UgurluogluA , MinarE , HirschlM . Liposomal heparin‐spraygel in comparison with subcutaneous low molecular weight heparin in patients with superficial venous thrombosis. A randomized, controlled, open multicentre study. Journal fur Kardiologie2003;10(9):375‐8. ">Katzenschlager 2003</a>; <a href="./references#CD004982-bbs2-0020" title="LozanoFS , AlmazanA . Low‐molecular‐weight heparin versus saphenofemoral disconnection for the treatment of above‐knee greater saphenous thrombophlebitis: a prospective study. Vascular and Endovascular Surgery2003;37(6):415‐20. ">Lozano 2003</a>; <a href="./references#CD004982-bbs2-0022" title="MarshallM , KleineM‐W . Efficacy and tolerability of an oral enzyme therapy in the treatment of painful acute superficial thrombophlebitis [Wirksamkeit und vertraglichkeit einer oralen enzymtherapie bei der schmerzhaften akuten thrombophlebitis superficialis]. Phlebologie2001;30(2):36‐43. ">Marshall 2001</a>; <a href="./references#CD004982-bbs2-0028" title="SpirkoskaA , JezovnikMK , PoredosP . Time course and the recanalization rate of superficial vein thrombosis treated with low‐molecular‐weight heparin. Angiology2015;66:381‐6. ">Spirkoska 2015</a>; <a href="./references#CD004982-bbs2-0029" title="Superficial Thrombophlebitis Treated by Enoxaparin Study Group. A pilot randomized double‐blind comparison of a low‐molecular‐weight heparin, a nonsteroidal anti‐inflammatory agent, and placebo in the treatment of superficial vein thrombosis. Archives of Internal Medicine2003;163(14):1657‐63. ">Stenox Group 2003</a>; <a href="./references#CD004982-bbs2-0030" title="TitonJP , AugerD , GrangeP , HecquetJP , RemondA , UlliacP , et al. Therapeutic management of superficial venous thrombosis with calcium nadroparin. Dosage testing and comparison with an non‐steroidal anti‐inflammatory agent [Traitement curatif des thromboses veineuses superficielles par nadroparine calcique. Recherche posologique et comparaison à un anti‐inflammatoire non stéroidien]. Annales de Cardiologie et d'Angeiologie1994;43(3):160‐6. ">Titon 1994</a>). In <a href="./references#CD004982-bbs2-0008" title="Beyer‐WestendorfJ , SchellongSM , GerlachH , RabeE , WeitzJI , JersemannK , et al. Prevention of thromboembolic complications in patients with superficial‐vein thrombosis given rivaroxaban or fondaparinux: the open‐label, randomised, non‐inferiority SURPRISE phase 3b trial. Lancet Haematology2017;4(3):e105‐13. WerthS , BauersachsR , GerlachH , RabeE , SchellongS , Beyer‐WestendorfJ . Superficial vein thrombosis treated for 45 days with rivaroxaban versus fondaparinux: rationale and design of the SURPRISE trial. Journal of Thrombosis and Thrombolysis2016;42(2):197‐204. ">Beyer‐Westendorf 2017</a> the primary analysis was originally planned as ITT analysis, but later modified into a per‐protocol analysis. Although 7.6% (36/471) participants randomised were excluded from the primary analysis authors report results also according to the ITT principle. </p> </section> <section id="CD004982-sec-0062"> <h4 class="title">Selective reporting</h4> <p>Most studies were free of selective reporting except <a href="./references#CD004982-bbs2-0002" title="Anonymous . Indomethacin in superficial thrombophlebitis. Practitioner1970;205(227):369‐72. ">Anonymous 1970</a>; <a href="./references#CD004982-bbs2-0007" title="BelcaroG , CesaroneMR , DugallM , FeragalliB , IppolitoE , CorsiM , et al. Topical formulation of heparin is effective in reducing the symptoms of superficial venous thrombosis: a monocenter, observer‐blind, placebo‐controlled randomized study. Panminerva Medica2011;53(3 Suppl 1):3‐11. ">Belcaro 2011</a>; <a href="./references#CD004982-bbs2-0020" title="LozanoFS , AlmazanA . Low‐molecular‐weight heparin versus saphenofemoral disconnection for the treatment of above‐knee greater saphenous thrombophlebitis: a prospective study. Vascular and Endovascular Surgery2003;37(6):415‐20. ">Lozano 2003</a>; <a href="./references#CD004982-bbs2-0028" title="SpirkoskaA , JezovnikMK , PoredosP . Time course and the recanalization rate of superficial vein thrombosis treated with low‐molecular‐weight heparin. Angiology2015;66:381‐6. ">Spirkoska 2015</a>; and <a href="./references#CD004982-bbs2-0031" title="UncuH . A comparison of low‐molecular‐weight heparin and combined therapy of low‐molecular‐weight heparin with an anti‐inflammatory agent in the treatment of superficial vein thrombosis. Phlebology2009;24(2):56‐60. ">Uncu 2009</a> (all high risk), which did not provide data on some of the specified outcomes and <a href="./references#CD004982-bbs2-0033" title="WinterWR , RauhutK , ArnoldS , BabiakD , StoidnerB . Local therapy of thrombophlebitis superficialis ‐ an inter‐individual comparison of Voltaren‐Emulgel versus a gel containing heparin [Lokale therapie der thrombophlebitis superficialis ‐ Ein individueller vergleich von Voltaren‐emulgel versus ein heparin‐haltiges gel]. Zeitschrift fur Rheumatologie1986;45:180‐1. ">Winter 1986</a> (unclear risk), which was reported as an abstract only and did not prespecify outcomes. </p> </section> </section> <section id="CD004982-sec-0063"> <h3 class="title" id="CD004982-sec-0063">Effects of interventions</h3> <p>See: <a href="./full#CD004982-tbl-0001"><b>Summary of findings for the main comparison</b> Fondaparinux compared to placebo for superficial thrombophlebitis of the leg</a>; <a href="./full#CD004982-tbl-0002"><b>Summary of findings 2</b> Prophylactic LMWH versus placebo for superficial thrombophlebitis of the leg</a>; <a href="./full#CD004982-tbl-0003"><b>Summary of findings 3</b> Therapeutic LMWH versus placebo for superficial thrombophlebitis of the leg</a>; <a href="./full#CD004982-tbl-0004"><b>Summary of findings 4</b> NSAIDs versus placebo for superficial thrombophlebitis of the leg</a> </p> <p>None of the studies evaluated similar treatments on the same study outcomes. Treatment included fondaparinux, rivaroxaban, LMWH, unfractionated heparin (UFH), NSAIDs, topical treatment, oral treatment, intramuscular treatment, and intravenous treatment to surgery. </p> <section id="CD004982-sec-0064"> <h4 class="title">Fondaparinux</h4> <p>The CALISTO study, a large double‐blinded, placebo‐controlled RCT, evaluated a prophylactic dose (2.5 mg subcutaneously (sc) once daily) of fondaparinux given for 45 days (<a href="./references#CD004982-bbs2-0011" title="BauersachsRM . The CALISTO‐study. Phlebologie2011;40(2):79‐83. DecoususH . Fondaparinux reduced a composite of VTE complications or death in superficial leg‐vein thrombosis. Annals of Internal Medicine2011;154(4):JC2‐3. DecoususH , PrandoniP , MismettiP , BauersachsRM , BodaZ , BrennerB , et al. CALISTO Study Group. Fondaparinux for the treatment of superficial‐vein thrombosis in the legs. New England Journal of Medicine2010;363(13):1222‐32. LeizoroviczA , BeckerF , BuchmullerA , QuereI , PrandoniP , DecoususH , et al. Clinical relevance of symptomatic superficial‐vein thrombosis extension: lessons from the CALISTO study. Blood2013;122(10):1724‐9. LeizoroviczA , PrandoniP , DecoususH . Fondaparinux reduces all types of symptomatic thromboembolic complications in patients with superficial‐vein thrombosis in the legs: data from the CALISTO study. ASH Annual Meeting Abstracts2011;118:2310. ">Decousus 2010b</a>). The primary efficacy outcome of this RCT (i.e. composite of death from any cause, symptomatic PE, symptomatic DVT, or symptomatic extension to the saphenofemoral junction or symptomatic recurrence of ST up to day 47) was reduced by 85% by fondaparinux (RR 0.15, 95% CI 0.08 to 0.26) with a number needed to treat for an additional beneficial outcome (NNTB) of 20. The incidence of each component of the primary efficacy outcome was significantly reduced in the fondaparinux group compared with the placebo group except for the incidence of PE and of death, which did not differ significantly between the two groups (<a href="./references#CD004982-fig-0003" title="">Analysis 1.1</a>; <a href="./references#CD004982-fig-0008" title="">Analysis 1.6</a>). The risk of the composite of symptomatic DVT or PE was reduced by 85% with fondaparinux compared with placebo (RR 0.15, 95% CI 0.04 to 0.50) with a NNTB of 88. Fondaparinux was associated with lower rates of extension (RR 0.08, 95% CI 0.03 to 0.22) and recurrence of ST (RR 0.21, 95% CI 0.08 to 0.54). By day 47, major bleeding had occurred in one participant (0.1%) in each group (RR 0.99, 95% CI 0.06 to 15.86; P = 1.00). The rate of clinically relevant non‐major, minor, and total bleeding; arterial thromboembolic complications; and adverse effects of treatment did not differ significantly between the two groups. </p> <p>In the SURPRISE study, 472 people with ST and one or more risk factors for thromboembolic complications (older than 65 years, male sex, previous ST or DVT or PE, active cancer or history of cancer, autoimmune disease, or involvement of non‐varicose veins) were randomised to fondaparinux (2.5 mg sc once daily) or the oral direct factor Xa inhibitor rivaroxaban (10 mg once daily) (<a href="./references#CD004982-bbs2-0008" title="Beyer‐WestendorfJ , SchellongSM , GerlachH , RabeE , WeitzJI , JersemannK , et al. Prevention of thromboembolic complications in patients with superficial‐vein thrombosis given rivaroxaban or fondaparinux: the open‐label, randomised, non‐inferiority SURPRISE phase 3b trial. Lancet Haematology2017;4(3):e105‐13. WerthS , BauersachsR , GerlachH , RabeE , SchellongS , Beyer‐WestendorfJ . Superficial vein thrombosis treated for 45 days with rivaroxaban versus fondaparinux: rationale and design of the SURPRISE trial. Journal of Thrombosis and Thrombolysis2016;42(2):197‐204. ">Beyer‐Westendorf 2017</a>). In the per‐protocol analysis, the incidence of the primary efficacy outcome (i.e. composite of symptomatic DVT or PE, progression or recurrence of ST, and all‐cause mortality at 45 days) was comparable in the rivaroxaban and fondaparinux groups at day 45 (3% with rivaroxaban versus 2% with fondaparinux; HR 1.9, 95% CI 0.6 to 6.4) and at 90 days, (7% with rivaroxaban versus 7% with fondaparinux; HR 1.1, 95% CI 0.5 to 2.2). </p> <p>There were similar results when the analysis was performed according to the ITT principle. Fondaparinux was associated with a non‐statistically significant reduction of symptomatic VTE, DVT, recurrence of ST, mortality, clinically relevant non‐major bleeding, serious adverse events, or adverse effects of treatment compared with rivaroxaban (<a href="./references#CD004982-fig-0016" title="">Analysis 2.2</a>; <a href="./references#CD004982-fig-0017" title="">Analysis 2.3</a>; <a href="./references#CD004982-fig-0019" title="">Analysis 2.5</a>; <a href="./references#CD004982-fig-0020" title="">Analysis 2.6</a>; <a href="./references#CD004982-fig-0022" title="">Analysis 2.8</a>; <a href="./references#CD004982-fig-0024" title="">Analysis 2.10</a>; <a href="./references#CD004982-fig-0025" title="">Analysis 2.11</a>). There were no cases of PE, extension of ST or major bleeding in either treatment arm. </p> </section> <section id="CD004982-sec-0065"> <h4 class="title">Low molecular weight heparin and unfractionated heparin</h4> <p>Fourteen studies included a LMWH group (<a href="./references#CD004982-bbs2-0004" title="BelcaroG , ErrichiBM , LauroraG , CesaroneMR , CandianiC . Treatment of acute superficial thrombosis and follow‐up by computerized thermography. VASA. Zeitschrift fur Gefasskrankheiten. Journal for Vascular Diseases1989;18(3):227‐34. ">Belcaro 1989</a>; <a href="./references#CD004982-bbs2-0005" title="BelcaroG . Evolution of superficial vein thrombosis treated with defibrotide: comparison with low dose subcutaneous heparin. International Journal of Tissue Reactions1990;12(5):319‐24. ">Belcaro 1990</a>; <a href="./references#CD004982-bbs2-0006" title="BelcaroG , NicolaidesAN , ErrichiBM , CesaroneMR , DeSanctisMT , IncandelaL , et al. Superficial thrombophlebitis of the legs: a randomized, controlled, follow‐up study. Angiology1999;50(7):523‐9. ">Belcaro 1999</a>; <a href="./references#CD004982-bbs2-0010" title="CosmiB . Risk factors for recurrent events in subjects with superficial vein thrombosis in the randomized clinical trial SteFlux (Superficial Thromboembolism Fluxum). Thrombosis Research2014;133(2):196‐202. CosmiB , FilippiniM , TontiD , AvruscioG , GhirarduzziA , BucheriniE , et al. A randomized double‐blind study of low‐molecular‐weight heparin (parnaparin) for superficial vein thrombosis: STEFLUX (Superficial ThromboEmbolism and Fluxum). Journal of Thrombosis and Haemostasis2012;10(6):1026‐35. CosmiB , FilippiniM , TontiD , GhirarduzziA , AvruscioG , ImbertiD , et al. Risk factors for recurrent events in subjects with superficial vein thrombosis in the randomized clinical trial Steflux (Superficial Thromboembolism Fluxum). Hamostaseologie2012;32:A29. CosmiB , FilippiniM , TontiD , GhirarduzziA , AvruscioG , ImbertiD , et al. The Steflux (Superficial Thromboembolism and Fluxum) randomized double blind clinical study of different treatment doses and duration of low molecular weight heparin (parnaparin) in superficial vein thrombosis. Hamostaseologie2012;32:A28. ">Cosmi 2012</a>; <a href="./references#CD004982-bbs2-0014" title="GorskiG , SzopinskiP , MichalakJ , MarianowskaA , BorkowskiM , GeremekM , et al. Liposomal heparin spray: a new formula in adjunctive treatment of superficial venous thrombosis. Angiology2005;56(1):9‐17. ">Gorski 2005</a>; <a href="./references#CD004982-bbs2-0017" title="KatzenschlagerR , UgurluogluA , MinarE , HirschlM . Liposomal heparin‐spraygel in comparison with subcutaneous low molecular weight heparin in patients with superficial venous thrombosis. A randomized, controlled, open multicentre study. Journal fur Kardiologie2003;10(9):375‐8. ">Katzenschlager 2003</a>; <a href="./references#CD004982-bbs2-0020" title="LozanoFS , AlmazanA . Low‐molecular‐weight heparin versus saphenofemoral disconnection for the treatment of above‐knee greater saphenous thrombophlebitis: a prospective study. Vascular and Endovascular Surgery2003;37(6):415‐20. ">Lozano 2003</a>; <a href="./references#CD004982-bbs2-0021" title="MarchioriA , VerlatoF , SabbionP , CamporeseG , RossoF , MosenaL , et al. High versus low doses of unfractionated heparin for the treatment of superficial thrombophlebitis of the leg. A prospective, controlled, randomized study. Haematologica2002;87(5):523‐7. ">Marchiori 2002</a>; <a href="./references#CD004982-bbs2-0027" title="RathbunSW , AstonCE , WhitsettTL . A randomized trial of dalteparin compared with ibuprofen for the treatment of superficial thrombophlebitis. Journal of Thrombosis and Haemostasis2012;10(5):833‐9. ">Rathbun 2012</a>; <a href="./references#CD004982-bbs2-0028" title="SpirkoskaA , JezovnikMK , PoredosP . Time course and the recanalization rate of superficial vein thrombosis treated with low‐molecular‐weight heparin. Angiology2015;66:381‐6. ">Spirkoska 2015</a>; <a href="./references#CD004982-bbs2-0029" title="Superficial Thrombophlebitis Treated by Enoxaparin Study Group. A pilot randomized double‐blind comparison of a low‐molecular‐weight heparin, a nonsteroidal anti‐inflammatory agent, and placebo in the treatment of superficial vein thrombosis. Archives of Internal Medicine2003;163(14):1657‐63. ">Stenox Group 2003</a>; <a href="./references#CD004982-bbs2-0030" title="TitonJP , AugerD , GrangeP , HecquetJP , RemondA , UlliacP , et al. Therapeutic management of superficial venous thrombosis with calcium nadroparin. Dosage testing and comparison with an non‐steroidal anti‐inflammatory agent [Traitement curatif des thromboses veineuses superficielles par nadroparine calcique. Recherche posologique et comparaison à un anti‐inflammatoire non stéroidien]. Annales de Cardiologie et d'Angeiologie1994;43(3):160‐6. ">Titon 1994</a>; <a href="./references#CD004982-bbs2-0031" title="UncuH . A comparison of low‐molecular‐weight heparin and combined therapy of low‐molecular‐weight heparin with an anti‐inflammatory agent in the treatment of superficial vein thrombosis. Phlebology2009;24(2):56‐60. ">Uncu 2009</a>; <a href="./references#CD004982-bbs2-0032" title="PrandoniP . High versus low doses of low‐molecular‐weight heparin for the treatment of superficial vein thrombosis of the legs. A double‐blind, randomized trial. Journal of Thrombosis and Haemostasis2005;3 (Suppl 1):Abstract number OR145. [http://onlinelibrary.wiley.com/doi/10.1111/j.1538‐7836.2005.0300b.x/full] PrandoniP , TormeneD , PesaventoR , Vesalio Investigators Group. High vs. low doses of low‐molecular‐weight heparin for the treatment of superficial vein thrombosis of the legs: a double‐blind, randomized trial. Journal of Thrombosis and Haemostasis2005;3(6):1152‐7. ">Vesalio Group 2005</a>). </p> <p>Although not statistically significant, the incidence of VTE tended to be lower with both prophylactic and therapeutic LMWH compared with placebo shortly after treatment (prophylactic: RR 0.25, 95% CI 0.03 to 2.24; therapeutic: RR 0.26, 95% CI 0.03 to 2.33). However, at the end of the three‐month follow‐up, this difference was even less evident suggesting a catch‐up phenomenon (<a href="./references#CD004982-fig-0027" title="">Analysis 3.2</a>; <a href="./references#CD004982-fig-0032" title="">Analysis 4.2</a>) (<a href="./references#CD004982-bbs2-0029" title="Superficial Thrombophlebitis Treated by Enoxaparin Study Group. A pilot randomized double‐blind comparison of a low‐molecular‐weight heparin, a nonsteroidal anti‐inflammatory agent, and placebo in the treatment of superficial vein thrombosis. Archives of Internal Medicine2003;163(14):1657‐63. ">Stenox Group 2003</a>). Prophylactic and therapeutic LMWH given for eight to 12 days significantly reduced ST extension or recurrence, or both, compared with placebo (prophylactic: RR 0.44, 95% CI 0.26 to 0.74; therapeutic: RR 0.46, 95% CI 0.27 to 0.77). There were no episodes of major bleeding or heparin‐induced thrombocytopenia (HIT) in any treatment group (<a href="./references#CD004982-bbs2-0029" title="Superficial Thrombophlebitis Treated by Enoxaparin Study Group. A pilot randomized double‐blind comparison of a low‐molecular‐weight heparin, a nonsteroidal anti‐inflammatory agent, and placebo in the treatment of superficial vein thrombosis. Archives of Internal Medicine2003;163(14):1657‐63. ">Stenox Group 2003</a>). </p> <p>Combined therapy with LMWH plus elastic compression stockings seemed to reduce the incidence of VTE and ST extension or recurrence, or both, compared with elastic stockings alone (VTE: RR 0.08, 95% CI 0.00 to 1.38; ST extension or recurrence, or both: RR 0.08, 95% CI 0.01 to 0.59), although the former difference was not statistically significant (<a href="./references#CD004982-bbs2-0006" title="BelcaroG , NicolaidesAN , ErrichiBM , CesaroneMR , DeSanctisMT , IncandelaL , et al. Superficial thrombophlebitis of the legs: a randomized, controlled, follow‐up study. Angiology1999;50(7):523‐9. ">Belcaro 1999</a>). This study did not provide data on safety outcomes. </p> <p>Two studies randomised participants to topical treatment with heparin spray gel or LMWH (<a href="./references#CD004982-bbs2-0014" title="GorskiG , SzopinskiP , MichalakJ , MarianowskaA , BorkowskiM , GeremekM , et al. Liposomal heparin spray: a new formula in adjunctive treatment of superficial venous thrombosis. Angiology2005;56(1):9‐17. ">Gorski 2005</a>; <a href="./references#CD004982-bbs2-0017" title="KatzenschlagerR , UgurluogluA , MinarE , HirschlM . Liposomal heparin‐spraygel in comparison with subcutaneous low molecular weight heparin in patients with superficial venous thrombosis. A randomized, controlled, open multicentre study. Journal fur Kardiologie2003;10(9):375‐8. ">Katzenschlager 2003</a>). There was a non‐significant decrease in DVT with LMWH (RR 0.30, 95% CI 0.03 to 2.70) and relief of local symptoms of ST was similar between both treatments at 21 days (<a href="./references#CD004982-bbs2-0014" title="GorskiG , SzopinskiP , MichalakJ , MarianowskaA , BorkowskiM , GeremekM , et al. Liposomal heparin spray: a new formula in adjunctive treatment of superficial venous thrombosis. Angiology2005;56(1):9‐17. ">Gorski 2005</a>). </p> <p>One study evaluated LMWH versus surgical treatment (saphenofemoral disconnection) (<a href="./references#CD004982-bbs2-0020" title="LozanoFS , AlmazanA . Low‐molecular‐weight heparin versus saphenofemoral disconnection for the treatment of above‐knee greater saphenous thrombophlebitis: a prospective study. Vascular and Endovascular Surgery2003;37(6):415‐20. ">Lozano 2003</a>). There was a comparable reduction of VTE events and a similar safety profile in the two study groups. There were numerically more cases of ST extension or recurrence with LMWH, although numbers were low and differences were not statistically significant (RR 3.00, 95% CI 0.33 to 27.23). </p> <p>Three studies evaluated LMWH versus NSAIDs (<a href="./references#CD004982-bbs2-0027" title="RathbunSW , AstonCE , WhitsettTL . A randomized trial of dalteparin compared with ibuprofen for the treatment of superficial thrombophlebitis. Journal of Thrombosis and Haemostasis2012;10(5):833‐9. ">Rathbun 2012</a>; <a href="./references#CD004982-bbs2-0029" title="Superficial Thrombophlebitis Treated by Enoxaparin Study Group. A pilot randomized double‐blind comparison of a low‐molecular‐weight heparin, a nonsteroidal anti‐inflammatory agent, and placebo in the treatment of superficial vein thrombosis. Archives of Internal Medicine2003;163(14):1657‐63. ">Stenox Group 2003</a>; <a href="./references#CD004982-bbs2-0030" title="TitonJP , AugerD , GrangeP , HecquetJP , RemondA , UlliacP , et al. Therapeutic management of superficial venous thrombosis with calcium nadroparin. Dosage testing and comparison with an non‐steroidal anti‐inflammatory agent [Traitement curatif des thromboses veineuses superficielles par nadroparine calcique. Recherche posologique et comparaison à un anti‐inflammatoire non stéroidien]. Annales de Cardiologie et d'Angeiologie1994;43(3):160‐6. ">Titon 1994</a>). Compared to NSAIDs, both fixed‐dose LMWH and weight‐adjusted LMWH seemed to have a similar effect on VTE (RR 0.93, 95% CI 0.24 to 3.63) and ST recurrence (RR 1.01, 95% CI 0.58 to 1.78). In the study by <a href="./references#CD004982-bbs2-0027" title="RathbunSW , AstonCE , WhitsettTL . A randomized trial of dalteparin compared with ibuprofen for the treatment of superficial thrombophlebitis. Journal of Thrombosis and Haemostasis2012;10(5):833‐9. ">Rathbun 2012</a>, there was one case of ST progression into the posterior tibial veins and one symptomatic PE, both in the LMWH group. <a href="./references#CD004982-bbs2-0027" title="RathbunSW , AstonCE , WhitsettTL . A randomized trial of dalteparin compared with ibuprofen for the treatment of superficial thrombophlebitis. Journal of Thrombosis and Haemostasis2012;10(5):833‐9. ">Rathbun 2012</a> was not pooled with the other two studies for the outcome VTE since the administration of therapeutic LMWH in any person with thrombus progression during follow‐up could have introduced significant confounding. In <a href="./references#CD004982-bbs2-0029" title="Superficial Thrombophlebitis Treated by Enoxaparin Study Group. A pilot randomized double‐blind comparison of a low‐molecular‐weight heparin, a nonsteroidal anti‐inflammatory agent, and placebo in the treatment of superficial vein thrombosis. Archives of Internal Medicine2003;163(14):1657‐63. ">Stenox Group 2003</a>, which used placebo as a control group, an indirect comparison between prophylactic LMWH and NSAIDs suggested a non‐statistically significant reduction in VTE at the end of treatment (RR 0.45, 95% CI 0.04 to 4.89). There were no major bleeding events or HIT in either group. <a href="./references#CD004982-bbs2-0027" title="RathbunSW , AstonCE , WhitsettTL . A randomized trial of dalteparin compared with ibuprofen for the treatment of superficial thrombophlebitis. Journal of Thrombosis and Haemostasis2012;10(5):833‐9. ">Rathbun 2012</a> reported two episodes of cutaneous rash with LMWH. In addition, there was a significant reduction in pain with both LMWH and NSAIDs with no differences between the groups. </p> <p>One study compared LMWH alone versus LMWH combined with the anti‐inflammatory agent acemetacin (<a href="./references#CD004982-bbs2-0031" title="UncuH . A comparison of low‐molecular‐weight heparin and combined therapy of low‐molecular‐weight heparin with an anti‐inflammatory agent in the treatment of superficial vein thrombosis. Phlebology2009;24(2):56‐60. ">Uncu 2009</a>). There were no cases of VTE, extension of ST, or major bleeding in either group. The effects on signs and symptoms of ST were not statistically different (<a href="./references#CD004982-fig-0090" title="">Analysis 14.4</a>; <a href="./references#CD004982-fig-0091" title="">Analysis 14.5</a>; <a href="./references#CD004982-fig-0092" title="">Analysis 14.6</a>; <a href="./references#CD004982-fig-0093" title="">Analysis 14.7</a>). </p> <p>Three studies compared different regimens of LMWH head‐to‐head but without using a placebo or inactive control group (<a href="./references#CD004982-bbs2-0010" title="CosmiB . Risk factors for recurrent events in subjects with superficial vein thrombosis in the randomized clinical trial SteFlux (Superficial Thromboembolism Fluxum). Thrombosis Research2014;133(2):196‐202. CosmiB , FilippiniM , TontiD , AvruscioG , GhirarduzziA , BucheriniE , et al. A randomized double‐blind study of low‐molecular‐weight heparin (parnaparin) for superficial vein thrombosis: STEFLUX (Superficial ThromboEmbolism and Fluxum). Journal of Thrombosis and Haemostasis2012;10(6):1026‐35. CosmiB , FilippiniM , TontiD , GhirarduzziA , AvruscioG , ImbertiD , et al. Risk factors for recurrent events in subjects with superficial vein thrombosis in the randomized clinical trial Steflux (Superficial Thromboembolism Fluxum). Hamostaseologie2012;32:A29. CosmiB , FilippiniM , TontiD , GhirarduzziA , AvruscioG , ImbertiD , et al. The Steflux (Superficial Thromboembolism and Fluxum) randomized double blind clinical study of different treatment doses and duration of low molecular weight heparin (parnaparin) in superficial vein thrombosis. Hamostaseologie2012;32:A28. ">Cosmi 2012</a>; <a href="./references#CD004982-bbs2-0028" title="SpirkoskaA , JezovnikMK , PoredosP . Time course and the recanalization rate of superficial vein thrombosis treated with low‐molecular‐weight heparin. Angiology2015;66:381‐6. ">Spirkoska 2015</a>; <a href="./references#CD004982-bbs2-0032" title="PrandoniP . High versus low doses of low‐molecular‐weight heparin for the treatment of superficial vein thrombosis of the legs. A double‐blind, randomized trial. Journal of Thrombosis and Haemostasis2005;3 (Suppl 1):Abstract number OR145. [http://onlinelibrary.wiley.com/doi/10.1111/j.1538‐7836.2005.0300b.x/full] PrandoniP , TormeneD , PesaventoR , Vesalio Investigators Group. High vs. low doses of low‐molecular‐weight heparin for the treatment of superficial vein thrombosis of the legs: a double‐blind, randomized trial. Journal of Thrombosis and Haemostasis2005;3(6):1152‐7. ">Vesalio Group 2005</a>). In <a href="./references#CD004982-bbs2-0010" title="CosmiB . Risk factors for recurrent events in subjects with superficial vein thrombosis in the randomized clinical trial SteFlux (Superficial Thromboembolism Fluxum). Thrombosis Research2014;133(2):196‐202. CosmiB , FilippiniM , TontiD , AvruscioG , GhirarduzziA , BucheriniE , et al. A randomized double‐blind study of low‐molecular‐weight heparin (parnaparin) for superficial vein thrombosis: STEFLUX (Superficial ThromboEmbolism and Fluxum). Journal of Thrombosis and Haemostasis2012;10(6):1026‐35. CosmiB , FilippiniM , TontiD , GhirarduzziA , AvruscioG , ImbertiD , et al. Risk factors for recurrent events in subjects with superficial vein thrombosis in the randomized clinical trial Steflux (Superficial Thromboembolism Fluxum). Hamostaseologie2012;32:A29. CosmiB , FilippiniM , TontiD , GhirarduzziA , AvruscioG , ImbertiD , et al. The Steflux (Superficial Thromboembolism and Fluxum) randomized double blind clinical study of different treatment doses and duration of low molecular weight heparin (parnaparin) in superficial vein thrombosis. Hamostaseologie2012;32:A28. ">Cosmi 2012</a> (the STEFLUX study), the incidence of symptomatic VTE at the end of treatment and at the three‐month follow‐up was not different in the 30‐day intermediate‐dose LMWH and 30‐day prophylactic dose LMWH groups (<a href="./references#CD004982-fig-0036" title="">Analysis 5.1</a>; <a href="./references#CD004982-fig-0037" title="">Analysis 5.2</a>), and it was lower in the 30‐day intermediate‐dose LMWH compared with the 10‐day intermediate‐dose LMWH (VTE end‐of‐treatment: 0.46% with 30‐day intermediate‐dose LMWH versus 4.72% with 10‐day intermediate‐dose LMWH, RR 0.10, 95% CI 0.01 to 0.75; VTE 3‐month follow‐up: 1.82% with 30‐day intermediate‐dose LMWH versus 5.19% with 10‐day intermediate‐dose LMWH, RR 0.35, 95% CI 0.11 to 1.09; <a href="./references#CD004982-fig-0048" title="">Analysis 7.1</a>; <a href="./references#CD004982-fig-0049" title="">Analysis 7.2</a>). At the three‐month follow‐up, symptomatic PE had occurred in none of the participants of the 30‐day intermediate‐dose group and in one participant of both the 10‐day intermediate‐dose and 30‐day prophylactic‐dose LMWH groups. The incidence of symptomatic DVT did not differ between the three groups (<a href="./references#CD004982-fig-0039" title="">Analysis 5.4</a>; <a href="./references#CD004982-fig-0045" title="">Analysis 6.4</a>; <a href="./references#CD004982-fig-0051" title="">Analysis 7.4</a>). ST extension at three months was significantly reduced by the 30‐day intermediate‐dose LMWH in comparison to both the 30‐day prophylactic (2.28% with 30‐day intermediate‐dose versus 8.29% with 30‐day prophylactic dose LMWH; RR 0.28, 95% CI 0.10 to 0.73) and 10‐day intermediate dose LMWH (10.38%, RR 0.22, 95% CI 0.08 to 0.57), while recurrence of ST was similar in the 30‐day intermediate‐dose LMWH and the other two groups (<a href="./references#CD004982-fig-0041" title="">Analysis 5.6</a>; <a href="./references#CD004982-fig-0053" title="">Analysis 7.6</a>). There were no cases of major bleeding or HIT. The intensity of local symptoms evaluated by visual analogue scales (VAS) was comparable in the 30‐day intermediate‐dose, 10‐day intermediate‐dose, and the 30‐day prophylactic‐dose LMWH at the start of treatment (5.0 with 30‐day intermediate‐dose, 5.1 with 10‐day intermediate‐dose, 5.1 with 30‐day prophylactic‐dose; P = 0.97) as well as at the end of treatment (0.7 with 30‐day intermediate‐dose, 0.6 with 10‐day intermediate‐dose, 0.8 with 30‐day prophylactic‐dose; P = 0.10) and at three months (0.2 with 30‐day intermediate‐dose, 0.3 with 10‐day intermediate‐dose, 0.4 with 30‐day prophylactic‐dose; P = 0.47). Allergic reactions occurred in 0.4% with 30‐day intermediate‐dose, 1.4% with 10‐day intermediate‐dose, and 0% with 30‐day prophylactic‐dose. </p> <p>In <a href="./references#CD004982-bbs2-0028" title="SpirkoskaA , JezovnikMK , PoredosP . Time course and the recanalization rate of superficial vein thrombosis treated with low‐molecular‐weight heparin. Angiology2015;66:381‐6. ">Spirkoska 2015</a>, one participant in the intermediate‐dose LMWH group developed a symptomatic PE versus none in the prophylactic‐dose LMWH group. Asymptomatic ST progression into DVT occurred in one participant in each group. There were no major bleeding events. The authors reported a regression of the thrombus at the end of the study period in 66% of participants receiving the prophylactic‐dose LMWH compared to 80% in the intermediate‐dose LMWH and a complete thrombus resolution with recanalisation in three participants (9.7%) in the prophylactic‐dose LMWH and six (19.4%) participants in the intermediate‐dose LMWH. These differences were not statistically significant. </p> <p>In the <a href="./references#CD004982-bbs2-0032" title="PrandoniP . High versus low doses of low‐molecular‐weight heparin for the treatment of superficial vein thrombosis of the legs. A double‐blind, randomized trial. Journal of Thrombosis and Haemostasis2005;3 (Suppl 1):Abstract number OR145. [http://onlinelibrary.wiley.com/doi/10.1111/j.1538‐7836.2005.0300b.x/full] PrandoniP , TormeneD , PesaventoR , Vesalio Investigators Group. High vs. low doses of low‐molecular‐weight heparin for the treatment of superficial vein thrombosis of the legs: a double‐blind, randomized trial. Journal of Thrombosis and Haemostasis2005;3(6):1152‐7. ">Vesalio Group 2005</a>, one month of weight‐adjusted full therapeutic dose of LMWH or fixed prophylactic‐dose LMWH led to a similar reduction in ST extension or recurrence, or VTE (RR 1.20, 95% CI 0.42 to 3.40) over a three‐month follow‐up. In the prophylactic‐dose LMWH group most of the VTE events (77%) occurred while participants were still on treatment, whereas only 33% of participants on therapeutic‐dose LMWH developed VTE during LMWH administration. This advantage was lost after drug discontinuation with no difference at the end of the study period. There was no major bleeding or HIT during the study. Local symptoms and signs regressed faster with therapeutic dose LMWH although the difference was not statistically significant. </p> <p>Two studies used sc UFH at prophylactic doses as the comparator treatment (<a href="./references#CD004982-bbs2-0006" title="BelcaroG , NicolaidesAN , ErrichiBM , CesaroneMR , DeSanctisMT , IncandelaL , et al. Superficial thrombophlebitis of the legs: a randomized, controlled, follow‐up study. Angiology1999;50(7):523‐9. ">Belcaro 1999</a>; <a href="./references#CD004982-bbs2-0021" title="MarchioriA , VerlatoF , SabbionP , CamporeseG , RossoF , MosenaL , et al. High versus low doses of unfractionated heparin for the treatment of superficial thrombophlebitis of the leg. A prospective, controlled, randomized study. Haematologica2002;87(5):523‐7. ">Marchiori 2002</a>). Relative to elastic stockings alone, prophylactic sc UFH plus elastic stockings was associated with a statistically non‐significant lower VTE rate (RR 0.08, 95% CI 0.00 to 1.47) and a 83% reduction in ST extension or recurrence (RR 0.17, 95% CI 0.04 to 0.72) (<a href="./references#CD004982-bbs2-0006" title="BelcaroG , NicolaidesAN , ErrichiBM , CesaroneMR , DeSanctisMT , IncandelaL , et al. Superficial thrombophlebitis of the legs: a randomized, controlled, follow‐up study. Angiology1999;50(7):523‐9. ">Belcaro 1999</a>). One study compared high‐ versus low‐dose sc UFH. There was a non‐significant 83% reduction in VTE (RR 0.17, 95% CI 0.02 to 1.30) and a 27% (RR 0.73, 95% CI 0.34 to 1.55) reduced rate of ST extension or recurrence among participants treated with high‐dose UFH (<a href="./references#CD004982-bbs2-0021" title="MarchioriA , VerlatoF , SabbionP , CamporeseG , RossoF , MosenaL , et al. High versus low doses of unfractionated heparin for the treatment of superficial thrombophlebitis of the leg. A prospective, controlled, randomized study. Haematologica2002;87(5):523‐7. ">Marchiori 2002</a>). There were no episodes of major bleeding or HIT in either study group. </p> <p>Two studies evaluated sc heparin calcium (<a href="./references#CD004982-bbs2-0004" title="BelcaroG , ErrichiBM , LauroraG , CesaroneMR , CandianiC . Treatment of acute superficial thrombosis and follow‐up by computerized thermography. VASA. Zeitschrift fur Gefasskrankheiten. Journal for Vascular Diseases1989;18(3):227‐34. ">Belcaro 1989</a>; <a href="./references#CD004982-bbs2-0005" title="BelcaroG . Evolution of superficial vein thrombosis treated with defibrotide: comparison with low dose subcutaneous heparin. International Journal of Tissue Reactions1990;12(5):319‐24. ">Belcaro 1990</a>). The combination of elastic stockings plus heparin calcium did not significantly improve local symptoms and signs compared with elastic stockings alone. Treatment with heparin calcium was correlated with a faster reduction of the analogue score and the area at maximum temperature than with defibrotide, although the difference was not significant. There were no adverse effects. </p> </section> <section id="CD004982-sec-0066"> <h4 class="title">Non‐steroidal anti‐inflammatory drugs</h4> <p>Six studies included an NSAID group (<a href="./references#CD004982-bbs2-0002" title="Anonymous . Indomethacin in superficial thrombophlebitis. Practitioner1970;205(227):369‐72. ">Anonymous 1970</a>; <a href="./references#CD004982-bbs2-0013" title="FerrariE , PratesiC , ScaricabarozziI , TrezzaniR . A clinical study of efficacy and tolerability of nimesulide compared with diclofenac sodium in the treatment of acute superficial thrombophlebitis [Studio clinico sull'efficacia terapeutica e la tollerabilità della nimesulide in confronto a diclofenac sodio nel trattamento delle tromboflebiti acute superficiali]. Minerva Cardioangiologica1992;40(11):455‐60. ">Ferrari 1992</a>; <a href="./references#CD004982-bbs2-0025" title="NusserC‐J , SchareW , BernardI . The treatment of superficial thrombophlebitis with nonsteroidal antiphlogistic agents [Therapie superfizieller thrombophlebitiden mit nichtsteroidalen antiphlogistika]. Therapiewoche1991;41(9):541‐4. ">Nusser 1991</a>; <a href="./references#CD004982-bbs2-0027" title="RathbunSW , AstonCE , WhitsettTL . A randomized trial of dalteparin compared with ibuprofen for the treatment of superficial thrombophlebitis. Journal of Thrombosis and Haemostasis2012;10(5):833‐9. ">Rathbun 2012</a>; <a href="./references#CD004982-bbs2-0029" title="Superficial Thrombophlebitis Treated by Enoxaparin Study Group. A pilot randomized double‐blind comparison of a low‐molecular‐weight heparin, a nonsteroidal anti‐inflammatory agent, and placebo in the treatment of superficial vein thrombosis. Archives of Internal Medicine2003;163(14):1657‐63. ">Stenox Group 2003</a>; <a href="./references#CD004982-bbs2-0030" title="TitonJP , AugerD , GrangeP , HecquetJP , RemondA , UlliacP , et al. Therapeutic management of superficial venous thrombosis with calcium nadroparin. Dosage testing and comparison with an non‐steroidal anti‐inflammatory agent [Traitement curatif des thromboses veineuses superficielles par nadroparine calcique. Recherche posologique et comparaison à un anti‐inflammatoire non stéroidien]. Annales de Cardiologie et d'Angeiologie1994;43(3):160‐6. ">Titon 1994</a>). Of these, two compared NSAIDs with placebo (<a href="./references#CD004982-bbs2-0002" title="Anonymous . Indomethacin in superficial thrombophlebitis. Practitioner1970;205(227):369‐72. ">Anonymous 1970</a>; <a href="./references#CD004982-bbs2-0029" title="Superficial Thrombophlebitis Treated by Enoxaparin Study Group. A pilot randomized double‐blind comparison of a low‐molecular‐weight heparin, a nonsteroidal anti‐inflammatory agent, and placebo in the treatment of superficial vein thrombosis. Archives of Internal Medicine2003;163(14):1657‐63. ">Stenox Group 2003</a>), three NSAID with LMWH (<a href="./references#CD004982-bbs2-0027" title="RathbunSW , AstonCE , WhitsettTL . A randomized trial of dalteparin compared with ibuprofen for the treatment of superficial thrombophlebitis. Journal of Thrombosis and Haemostasis2012;10(5):833‐9. ">Rathbun 2012</a>; <a href="./references#CD004982-bbs2-0029" title="Superficial Thrombophlebitis Treated by Enoxaparin Study Group. A pilot randomized double‐blind comparison of a low‐molecular‐weight heparin, a nonsteroidal anti‐inflammatory agent, and placebo in the treatment of superficial vein thrombosis. Archives of Internal Medicine2003;163(14):1657‐63. ">Stenox Group 2003</a>; <a href="./references#CD004982-bbs2-0030" title="TitonJP , AugerD , GrangeP , HecquetJP , RemondA , UlliacP , et al. Therapeutic management of superficial venous thrombosis with calcium nadroparin. Dosage testing and comparison with an non‐steroidal anti‐inflammatory agent [Traitement curatif des thromboses veineuses superficielles par nadroparine calcique. Recherche posologique et comparaison à un anti‐inflammatoire non stéroidien]. Annales de Cardiologie et d'Angeiologie1994;43(3):160‐6. ">Titon 1994</a>), and two randomised participants to two different NSAIDs (<a href="./references#CD004982-bbs2-0013" title="FerrariE , PratesiC , ScaricabarozziI , TrezzaniR . A clinical study of efficacy and tolerability of nimesulide compared with diclofenac sodium in the treatment of acute superficial thrombophlebitis [Studio clinico sull'efficacia terapeutica e la tollerabilità della nimesulide in confronto a diclofenac sodio nel trattamento delle tromboflebiti acute superficiali]. Minerva Cardioangiologica1992;40(11):455‐60. ">Ferrari 1992</a>; <a href="./references#CD004982-bbs2-0025" title="NusserC‐J , SchareW , BernardI . The treatment of superficial thrombophlebitis with nonsteroidal antiphlogistic agents [Therapie superfizieller thrombophlebitiden mit nichtsteroidalen antiphlogistika]. Therapiewoche1991;41(9):541‐4. ">Nusser 1991</a>). The trials comparing NSAIDs versus LMWH have been discussed previously (<a href="./references#CD004982-bbs2-0027" title="RathbunSW , AstonCE , WhitsettTL . A randomized trial of dalteparin compared with ibuprofen for the treatment of superficial thrombophlebitis. Journal of Thrombosis and Haemostasis2012;10(5):833‐9. ">Rathbun 2012</a>; <a href="./references#CD004982-bbs2-0029" title="Superficial Thrombophlebitis Treated by Enoxaparin Study Group. A pilot randomized double‐blind comparison of a low‐molecular‐weight heparin, a nonsteroidal anti‐inflammatory agent, and placebo in the treatment of superficial vein thrombosis. Archives of Internal Medicine2003;163(14):1657‐63. ">Stenox Group 2003</a>; <a href="./references#CD004982-bbs2-0030" title="TitonJP , AugerD , GrangeP , HecquetJP , RemondA , UlliacP , et al. Therapeutic management of superficial venous thrombosis with calcium nadroparin. Dosage testing and comparison with an non‐steroidal anti‐inflammatory agent [Traitement curatif des thromboses veineuses superficielles par nadroparine calcique. Recherche posologique et comparaison à un anti‐inflammatoire non stéroidien]. Annales de Cardiologie et d'Angeiologie1994;43(3):160‐6. ">Titon 1994</a>). </p> <p>NSAIDs significantly reduced the risk of ST extension or recurrence, or both, by 54% compared with placebo (RR 0.46, 95% CI 0.27 to 0.78) (<a href="./references#CD004982-bbs2-0029" title="Superficial Thrombophlebitis Treated by Enoxaparin Study Group. A pilot randomized double‐blind comparison of a low‐molecular‐weight heparin, a nonsteroidal anti‐inflammatory agent, and placebo in the treatment of superficial vein thrombosis. Archives of Internal Medicine2003;163(14):1657‐63. ">Stenox Group 2003</a>). However, there were no differences in the incidence of VTE or in the resolution of local symptoms and signs. While there were no major bleeding episodes recorded in any of the NSAID or placebo groups, indomethacin tended to increase the rate of adverse effects compared with placebo (RR 2.60, 95% CI 0.95 to 7.08) (<a href="./references#CD004982-bbs2-0002" title="Anonymous . Indomethacin in superficial thrombophlebitis. Practitioner1970;205(227):369‐72. ">Anonymous 1970</a>). </p> <p>In one study, oral acemetacin led to a better resolution of the local clinical picture than diclofenac (<a href="./references#CD004982-bbs2-0025" title="NusserC‐J , SchareW , BernardI . The treatment of superficial thrombophlebitis with nonsteroidal antiphlogistic agents [Therapie superfizieller thrombophlebitiden mit nichtsteroidalen antiphlogistika]. Therapiewoche1991;41(9):541‐4. ">Nusser 1991</a>). Another trial compared nimesulide with diclofenac sodium (<a href="./references#CD004982-bbs2-0013" title="FerrariE , PratesiC , ScaricabarozziI , TrezzaniR . A clinical study of efficacy and tolerability of nimesulide compared with diclofenac sodium in the treatment of acute superficial thrombophlebitis [Studio clinico sull'efficacia terapeutica e la tollerabilità della nimesulide in confronto a diclofenac sodio nel trattamento delle tromboflebiti acute superficiali]. Minerva Cardioangiologica1992;40(11):455‐60. ">Ferrari 1992</a>). Local symptoms were similarly improved by both treatments. In the group of participants randomised to nimesulide, there was a lower incidence of gastric pain episodes (RR 0.25, 95% CI 0.03 to 2.08) although this difference was not statistically significant (<a href="./references#CD004982-bbs2-0013" title="FerrariE , PratesiC , ScaricabarozziI , TrezzaniR . A clinical study of efficacy and tolerability of nimesulide compared with diclofenac sodium in the treatment of acute superficial thrombophlebitis [Studio clinico sull'efficacia terapeutica e la tollerabilità della nimesulide in confronto a diclofenac sodio nel trattamento delle tromboflebiti acute superficiali]. Minerva Cardioangiologica1992;40(11):455‐60. ">Ferrari 1992</a>). </p> </section> <section id="CD004982-sec-0067"> <h4 class="title">Topical treatment</h4> <p>Nine studies included a topical treatment group (<a href="./references#CD004982-bbs2-0007" title="BelcaroG , CesaroneMR , DugallM , FeragalliB , IppolitoE , CorsiM , et al. Topical formulation of heparin is effective in reducing the symptoms of superficial venous thrombosis: a monocenter, observer‐blind, placebo‐controlled randomized study. Panminerva Medica2011;53(3 Suppl 1):3‐11. ">Belcaro 2011</a>; <a href="./references#CD004982-bbs2-0012" title="DeSanctisMT , CesaroneMR , IncandelaL , BelcaroG , GriffinM . Treatment of superficial vein thrombosis with standardized application of Essaven gel ‐ a placebo‐controlled, randomized study. Angiology2001;52 Suppl 3:S57‐62. ">De Sanctis 2001</a>; <a href="./references#CD004982-bbs2-0014" title="GorskiG , SzopinskiP , MichalakJ , MarianowskaA , BorkowskiM , GeremekM , et al. Liposomal heparin spray: a new formula in adjunctive treatment of superficial venous thrombosis. Angiology2005;56(1):9‐17. ">Gorski 2005</a>; <a href="./references#CD004982-bbs2-0015" title="HolzgreveA , KleineW , StegmannW . Local treatment of superficial thrombophlebitis with nonsteroidal antiinflammatory agents. Zeitschrift fur Allgemeinmedizin1989;65(27):663‐7. ">Holzgreve 1989</a>; <a href="./references#CD004982-bbs2-0016" title="IncandelaL , DeSanctisMT , CesaroneMR , RicciA , ErrichiBM , DugalM , et al. Treatment of superficial vein thrombosis: clinical evaluation of essaven gel ‐ a placebo‐controlled, 8‐week, randomized study. Angiology2001;52 Suppl 3:69‐72. ">Incandela 2001</a>; <a href="./references#CD004982-bbs2-0017" title="KatzenschlagerR , UgurluogluA , MinarE , HirschlM . Liposomal heparin‐spraygel in comparison with subcutaneous low molecular weight heparin in patients with superficial venous thrombosis. A randomized, controlled, open multicentre study. Journal fur Kardiologie2003;10(9):375‐8. ">Katzenschlager 2003</a>; <a href="./references#CD004982-bbs2-0024" title="DiebschlagW , NockerW . Lokal treatment for superficial thrombophlebitis. Die Medizinische Welt1990;41:651‐5. NockerW , DiebschlagW , LehmacherW . The efficacy of a diclofenac gel compared with placebo and heparin gel in the local treatment of superficial thrombophlebitis [Lokaltherapie bei oberflachlicher thrombophlebitis. Wirksamkeit eines diclofenac‐natrium‐gels im vergleich zu placebo‐ und heparin‐gel]. Zeitschrift fur Allgemeinmedizin1991;67:2214‐22. ">Nocker 1991</a>; <a href="./references#CD004982-bbs2-0026" title="PintoG , GalatiD , BompianiGD , CorcioneF , CalifanoG , ColucciS , et al. Topical 5'‐methylthioadenosine in the treatment of symptomatic chronic venous insufficiency, haemorrhoids and superficial phlebitis. A double‐blind placebo‐controlled trial. Drug Investigation1992;4(3):205‐14. ">Pinto 1992</a>; <a href="./references#CD004982-bbs2-0033" title="WinterWR , RauhutK , ArnoldS , BabiakD , StoidnerB . Local therapy of thrombophlebitis superficialis ‐ an inter‐individual comparison of Voltaren‐Emulgel versus a gel containing heparin [Lokale therapie der thrombophlebitis superficialis ‐ Ein individueller vergleich von Voltaren‐emulgel versus ein heparin‐haltiges gel]. Zeitschrift fur Rheumatologie1986;45:180‐1. ">Winter 1986</a>). The comparison of heparin spray gel versus LMWH has been discussed earlier (see Low molecular weight heparin and unfractionated heparin section; <a href="./references#CD004982-bbs2-0014" title="GorskiG , SzopinskiP , MichalakJ , MarianowskaA , BorkowskiM , GeremekM , et al. Liposomal heparin spray: a new formula in adjunctive treatment of superficial venous thrombosis. Angiology2005;56(1):9‐17. ">Gorski 2005</a>; <a href="./references#CD004982-bbs2-0017" title="KatzenschlagerR , UgurluogluA , MinarE , HirschlM . Liposomal heparin‐spraygel in comparison with subcutaneous low molecular weight heparin in patients with superficial venous thrombosis. A randomized, controlled, open multicentre study. Journal fur Kardiologie2003;10(9):375‐8. ">Katzenschlager 2003</a>). </p> <p><a href="./references#CD004982-bbs2-0007" title="BelcaroG , CesaroneMR , DugallM , FeragalliB , IppolitoE , CorsiM , et al. Topical formulation of heparin is effective in reducing the symptoms of superficial venous thrombosis: a monocenter, observer‐blind, placebo‐controlled randomized study. Panminerva Medica2011;53(3 Suppl 1):3‐11. ">Belcaro 2011</a> randomised participants to three doses of heparin spray gel versus placebo for seven to 14 days. After one week, there was a significant reduction in pain assessed by the VAS with heparin spray gel (‐93.13% reduction with heparin spray gel versus ‐61.35% reduction with placebo; P &lt; 0.0001), a lower erythema extension (‐92% with heparin spray gel versus ‐26% with placebo; P &lt; 0.012), and thrombus length (‐40.81 with heparin spray gel versus ‐4.22 with placebo; P &lt; 0.0001). There were no adverse events or drug‐related reactions reported. </p> <p>One study randomised participants to receive topical methylthioadenosine or placebo (<a href="./references#CD004982-bbs2-0026" title="PintoG , GalatiD , BompianiGD , CorcioneF , CalifanoG , ColucciS , et al. Topical 5'‐methylthioadenosine in the treatment of symptomatic chronic venous insufficiency, haemorrhoids and superficial phlebitis. A double‐blind placebo‐controlled trial. Drug Investigation1992;4(3):205‐14. ">Pinto 1992</a>). Methylthioadenosine was associated with a non‐significant reduction in local signs and symptoms relative to placebo. </p> <p>A significant improvement in the local symptomatology was observed with diclofenac gel (<a href="./references#CD004982-bbs2-0024" title="DiebschlagW , NockerW . Lokal treatment for superficial thrombophlebitis. Die Medizinische Welt1990;41:651‐5. NockerW , DiebschlagW , LehmacherW . The efficacy of a diclofenac gel compared with placebo and heparin gel in the local treatment of superficial thrombophlebitis [Lokaltherapie bei oberflachlicher thrombophlebitis. Wirksamkeit eines diclofenac‐natrium‐gels im vergleich zu placebo‐ und heparin‐gel]. Zeitschrift fur Allgemeinmedizin1991;67:2214‐22. ">Nocker 1991</a>) and essaven gel (<a href="./references#CD004982-bbs2-0012" title="DeSanctisMT , CesaroneMR , IncandelaL , BelcaroG , GriffinM . Treatment of superficial vein thrombosis with standardized application of Essaven gel ‐ a placebo‐controlled, randomized study. Angiology2001;52 Suppl 3:S57‐62. ">De Sanctis 2001</a>; <a href="./references#CD004982-bbs2-0016" title="IncandelaL , DeSanctisMT , CesaroneMR , RicciA , ErrichiBM , DugalM , et al. Treatment of superficial vein thrombosis: clinical evaluation of essaven gel ‐ a placebo‐controlled, 8‐week, randomized study. Angiology2001;52 Suppl 3:69‐72. ">Incandela 2001</a>) compared with placebo. </p> <p><a href="./references#CD004982-bbs2-0015" title="HolzgreveA , KleineW , StegmannW . Local treatment of superficial thrombophlebitis with nonsteroidal antiinflammatory agents. Zeitschrift fur Allgemeinmedizin1989;65(27):663‐7. ">Holzgreve 1989</a> and <a href="./references#CD004982-bbs2-0033" title="WinterWR , RauhutK , ArnoldS , BabiakD , StoidnerB . Local therapy of thrombophlebitis superficialis ‐ an inter‐individual comparison of Voltaren‐Emulgel versus a gel containing heparin [Lokale therapie der thrombophlebitis superficialis ‐ Ein individueller vergleich von Voltaren‐emulgel versus ein heparin‐haltiges gel]. Zeitschrift fur Rheumatologie1986;45:180‐1. ">Winter 1986</a> compared two different types of gel. <a href="./references#CD004982-bbs2-0015" title="HolzgreveA , KleineW , StegmannW . Local treatment of superficial thrombophlebitis with nonsteroidal antiinflammatory agents. Zeitschrift fur Allgemeinmedizin1989;65(27):663‐7. ">Holzgreve 1989</a> evaluated diclofenac gel versus etofenak gel and showed a comparable efficacy profile of the two topical medications. <a href="./references#CD004982-bbs2-0033" title="WinterWR , RauhutK , ArnoldS , BabiakD , StoidnerB . Local therapy of thrombophlebitis superficialis ‐ an inter‐individual comparison of Voltaren‐Emulgel versus a gel containing heparin [Lokale therapie der thrombophlebitis superficialis ‐ Ein individueller vergleich von Voltaren‐emulgel versus ein heparin‐haltiges gel]. Zeitschrift fur Rheumatologie1986;45:180‐1. ">Winter 1986</a> compared diclofenac gel and heparin gel and found a better efficacy with diclofenac gel. </p> <p>None of the studies evaluating a topical treatment reported data on VTE or ST recurrence.</p> </section> <section id="CD004982-sec-0068"> <h4 class="title">Surgery</h4> <p>Three studies included a surgical treatment (<a href="./references#CD004982-bbs2-0004" title="BelcaroG , ErrichiBM , LauroraG , CesaroneMR , CandianiC . Treatment of acute superficial thrombosis and follow‐up by computerized thermography. VASA. Zeitschrift fur Gefasskrankheiten. Journal for Vascular Diseases1989;18(3):227‐34. ">Belcaro 1989</a>; <a href="./references#CD004982-bbs2-0006" title="BelcaroG , NicolaidesAN , ErrichiBM , CesaroneMR , DeSanctisMT , IncandelaL , et al. Superficial thrombophlebitis of the legs: a randomized, controlled, follow‐up study. Angiology1999;50(7):523‐9. ">Belcaro 1999</a>; <a href="./references#CD004982-bbs2-0020" title="LozanoFS , AlmazanA . Low‐molecular‐weight heparin versus saphenofemoral disconnection for the treatment of above‐knee greater saphenous thrombophlebitis: a prospective study. Vascular and Endovascular Surgery2003;37(6):415‐20. ">Lozano 2003</a>). One study compared surgery (saphenofemoral disconnection) with LMWH (see Low molecular weight heparin and unfractionated heparin section; <a href="./references#CD004982-bbs2-0020" title="LozanoFS , AlmazanA . Low‐molecular‐weight heparin versus saphenofemoral disconnection for the treatment of above‐knee greater saphenous thrombophlebitis: a prospective study. Vascular and Endovascular Surgery2003;37(6):415‐20. ">Lozano 2003</a>). The remaining two studies compared surgery combined with elastic stockings with elastic stockings alone (<a href="./references#CD004982-bbs2-0004" title="BelcaroG , ErrichiBM , LauroraG , CesaroneMR , CandianiC . Treatment of acute superficial thrombosis and follow‐up by computerized thermography. VASA. Zeitschrift fur Gefasskrankheiten. Journal for Vascular Diseases1989;18(3):227‐34. ">Belcaro 1989</a>; <a href="./references#CD004982-bbs2-0006" title="BelcaroG , NicolaidesAN , ErrichiBM , CesaroneMR , DeSanctisMT , IncandelaL , et al. Superficial thrombophlebitis of the legs: a randomized, controlled, follow‐up study. Angiology1999;50(7):523‐9. ">Belcaro 1999</a>). </p> <p>One trial found that thrombectomy plus elastic stockings with or without venoruton led to an improvement of the local clinical signs and a greater reduction in the number of veins with ST compared with elastic compression bandages alone (<a href="./references#CD004982-bbs2-0004" title="BelcaroG , ErrichiBM , LauroraG , CesaroneMR , CandianiC . Treatment of acute superficial thrombosis and follow‐up by computerized thermography. VASA. Zeitschrift fur Gefasskrankheiten. Journal for Vascular Diseases1989;18(3):227‐34. ">Belcaro 1989</a>). There were no cases of DVT in either group. One trial found that ligation of the vein plus elastic stockings was associated with a non‐significant reduction in VTE events (RR 0.33, 95% CI 0.07 to 1.60) and ST recurrence and extension (RR 0.46, 95% CI 0.18 to 1.15) relative to the control treatment (<a href="./references#CD004982-bbs2-0006" title="BelcaroG , NicolaidesAN , ErrichiBM , CesaroneMR , DeSanctisMT , IncandelaL , et al. Superficial thrombophlebitis of the legs: a randomized, controlled, follow‐up study. Angiology1999;50(7):523‐9. ">Belcaro 1999</a>). </p> <p>Compared with elastic stockings alone, venous stripping plus elastic stockings decreased the risk of ST extension and recurrence (RR 0.09, 95% CI 0.01 to 0.64) and seemed to be associated with a lower, non‐significant, incidence of VTE (RR 0.37, 95% CI 0.08 to 1.78) (<a href="./references#CD004982-bbs2-0006" title="BelcaroG , NicolaidesAN , ErrichiBM , CesaroneMR , DeSanctisMT , IncandelaL , et al. Superficial thrombophlebitis of the legs: a randomized, controlled, follow‐up study. Angiology1999;50(7):523‐9. ">Belcaro 1999</a>). </p> </section> <section id="CD004982-sec-0069"> <h4 class="title">Other</h4> <p>Nine studies evaluated an oral (<a href="./references#CD004982-bbs2-0003" title="ArcherDS , FowlerPD . Comparison of oxyphenbutazone and placebo in the treatment of superficial thrombophlebitis: an object lesson in clinical trial design. Practitioner1977;218:712‐75. ">Archer 1977</a>; <a href="./references#CD004982-bbs2-0004" title="BelcaroG , ErrichiBM , LauroraG , CesaroneMR , CandianiC . Treatment of acute superficial thrombosis and follow‐up by computerized thermography. VASA. Zeitschrift fur Gefasskrankheiten. Journal for Vascular Diseases1989;18(3):227‐34. ">Belcaro 1989</a>; <a href="./references#CD004982-bbs2-0006" title="BelcaroG , NicolaidesAN , ErrichiBM , CesaroneMR , DeSanctisMT , IncandelaL , et al. Superficial thrombophlebitis of the legs: a randomized, controlled, follow‐up study. Angiology1999;50(7):523‐9. ">Belcaro 1999</a>; <a href="./references#CD004982-bbs2-0018" title="KoshkinVM , KirienkoAI . Systemic enzyme therapy in the treatment of acute thrombosis of superficial veins in the lower extremities and postthrombophlebitic disease. International Journal of Immunotherapy2001;17(2‐4):121‐4. ">Koshkin 2001</a>; <a href="./references#CD004982-bbs2-0019" title="KuhlweinA . Drug treatment of superficial thrombophlebitides [Medikamentose behandlung oberflachlicher thrombophlebitiden]. Therapiewoche1985;35(36):4067‐70. ">Kuhlwein 1985</a>; <a href="./references#CD004982-bbs2-0023" title="MessaG , LaPlacaG , PuccettiL , DiPerriT . Heparansulphate. Effectiveness and tolerability of heparan sulphate in the treatment of superficial thrombophlebitis. Controlled clinical study vs sulodexide [Efficacia e tollerabilità dell'eparansolfato nel trattamento della tromboflebite superficiale. Studio clinico controllato vs sulodexide]. Minerva Cardioangiologica1997;45(4):147‐53. ">Messa 1997</a>), intramuscular (<a href="./references#CD004982-bbs2-0001" title="AndreozziGM , SignorelliS , DiPinoL , MartiniR , MarchitelliE , PintoA , et al. Tolerability and clinical efficacy of desmin in the treatment of superficial varicothrombophlebitis. Angiology1996;47(9):887‐94. ">Andreozzi 1996</a>), intravenous (<a href="./references#CD004982-bbs2-0022" title="MarshallM , KleineM‐W . Efficacy and tolerability of an oral enzyme therapy in the treatment of painful acute superficial thrombophlebitis [Wirksamkeit und vertraglichkeit einer oralen enzymtherapie bei der schmerzhaften akuten thrombophlebitis superficialis]. Phlebologie2001;30(2):36‐43. ">Marshall 2001</a>), or non‐pharmacological (<a href="./references#CD004982-bbs2-0009" title="BoehlerK , KittlerH , StolkovichS , TzanevaS . Therapeutic effect of compression stockings versus no compression on isolated superficial vein thrombosis of the legs: a randomized clinical trial. European Journal of Vascular and Endovascular Surgery2014;48(4):465‐71. ">Boehler 2014</a>) treatment. <a href="./references#CD004982-bbs2-0008" title="Beyer‐WestendorfJ , SchellongSM , GerlachH , RabeE , WeitzJI , JersemannK , et al. Prevention of thromboembolic complications in patients with superficial‐vein thrombosis given rivaroxaban or fondaparinux: the open‐label, randomised, non‐inferiority SURPRISE phase 3b trial. Lancet Haematology2017;4(3):e105‐13. WerthS , BauersachsR , GerlachH , RabeE , SchellongS , Beyer‐WestendorfJ . Superficial vein thrombosis treated for 45 days with rivaroxaban versus fondaparinux: rationale and design of the SURPRISE trial. Journal of Thrombosis and Thrombolysis2016;42(2):197‐204. ">Beyer‐Westendorf 2017</a> compared oral rivaroxaban with fondaparinux and has been presented above (see Fondaparinux section). </p> <p>Compared with placebo, oral vasotonin was associated with a higher proportion of participants who were cured or improved (<a href="./references#CD004982-bbs2-0019" title="KuhlweinA . Drug treatment of superficial thrombophlebitides [Medikamentose behandlung oberflachlicher thrombophlebitiden]. Therapiewoche1985;35(36):4067‐70. ">Kuhlwein 1985</a>). The criteria to determine the response to study treatment were not described. Vasotonin seemed to be well tolerated, with one case of poor tolerability among participants treated with vasotonin (3%) versus five cases (13%) in the placebo arm (RR 0.20, 95% CI 0.02 to 1.63). </p> <p>The combination of venoruton, thrombectomy, and elastic stockings versus elastic stockings alone has been discussed above (see Low molecular weight heparin and unfractionated heparin section; <a href="./references#CD004982-bbs2-0004" title="BelcaroG , ErrichiBM , LauroraG , CesaroneMR , CandianiC . Treatment of acute superficial thrombosis and follow‐up by computerized thermography. VASA. Zeitschrift fur Gefasskrankheiten. Journal for Vascular Diseases1989;18(3):227‐34. ">Belcaro 1989</a>). In the same trial, venoruton combined with elastic stockings led to an improvement of local symptoms compared with elastic stockings alone. </p> <p>One study evaluating oral heparansulphate versus oral sulodexide suggested a greater decrease in local pain, itching, and redness in participants receiving oral heparansulphate than in the group receiving sulodexide (<a href="./references#CD004982-bbs2-0023" title="MessaG , LaPlacaG , PuccettiL , DiPerriT . Heparansulphate. Effectiveness and tolerability of heparan sulphate in the treatment of superficial thrombophlebitis. Controlled clinical study vs sulodexide [Efficacia e tollerabilità dell'eparansolfato nel trattamento della tromboflebite superficiale. Studio clinico controllato vs sulodexide]. Minerva Cardioangiologica1997;45(4):147‐53. ">Messa 1997</a>). </p> <p>Compared with placebo, oxyphenbutazone reduced local tenderness four‐fold and halved the intensity of pain and erythema (<a href="./references#CD004982-bbs2-0003" title="ArcherDS , FowlerPD . Comparison of oxyphenbutazone and placebo in the treatment of superficial thrombophlebitis: an object lesson in clinical trial design. Practitioner1977;218:712‐75. ">Archer 1977</a>). </p> <p>One study evaluated oral vitamin K antagonists in combination with elastic stockings, which suggested a non‐significant reduction in VTE events (RR 0.08, 95% CI 0.00 to 1.47) and ST extension or recurrence (RR 0.42, 95% CI 0.16 to 1.13) with vitamin K antagonists plus elastic stockings compared with elastic stockings alone (<a href="./references#CD004982-bbs2-0006" title="BelcaroG , NicolaidesAN , ErrichiBM , CesaroneMR , DeSanctisMT , IncandelaL , et al. Superficial thrombophlebitis of the legs: a randomized, controlled, follow‐up study. Angiology1999;50(7):523‐9. ">Belcaro 1999</a>). </p> <p>Two studies addressed the use of enzyme therapy versus placebo (<a href="./references#CD004982-bbs2-0018" title="KoshkinVM , KirienkoAI . Systemic enzyme therapy in the treatment of acute thrombosis of superficial veins in the lower extremities and postthrombophlebitic disease. International Journal of Immunotherapy2001;17(2‐4):121‐4. ">Koshkin 2001</a>; <a href="./references#CD004982-bbs2-0022" title="MarshallM , KleineM‐W . Efficacy and tolerability of an oral enzyme therapy in the treatment of painful acute superficial thrombophlebitis [Wirksamkeit und vertraglichkeit einer oralen enzymtherapie bei der schmerzhaften akuten thrombophlebitis superficialis]. Phlebologie2001;30(2):36‐43. ">Marshall 2001</a>). Enzyme treatment seemed to improve local symptoms although the criteria to evaluate the response to study treatment were not reported. </p> <p>One trial assessed the efficacy of three doses of desmin (<a href="./references#CD004982-bbs2-0001" title="AndreozziGM , SignorelliS , DiPinoL , MartiniR , MarchitelliE , PintoA , et al. Tolerability and clinical efficacy of desmin in the treatment of superficial varicothrombophlebitis. Angiology1996;47(9):887‐94. ">Andreozzi 1996</a>). There was a better control of local symptoms with higher doses of desmin without any increase in the risk of adverse events. </p> <p>One study evaluated LMWH plus compression stockings versus LMWH alone (<a href="./references#CD004982-bbs2-0009" title="BoehlerK , KittlerH , StolkovichS , TzanevaS . Therapeutic effect of compression stockings versus no compression on isolated superficial vein thrombosis of the legs: a randomized clinical trial. European Journal of Vascular and Endovascular Surgery2014;48(4):465‐71. ">Boehler 2014</a>). At the three‐week follow‐up, there was no difference between the two groups with regard to pain intensity (mean difference ‐0.15 cm, 95% CI ‐0.95 to 0.65), skin erythema (‐6.54 cm<sup>2</sup>, 95% CI ‐17.94 to 4.86), or quality of life evaluated through the 36‐item Short Form (SF‐36) Physical score (mean difference 2.92, 95% CI ‐1.04 to 6.88) and SF‐36 Mental score (‐2.98, 95% CI ‐7.30 to 1.34). There was no DVT or HIT. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD004982-sec-0070" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD004982-sec-0070"></div> <p>Uncertainty still exists around the optimal treatment of ST of the legs. The therapeutic approach for ST should aim at the resolution or improvement of the local symptoms but also, and even more importantly, at preventing the possible extension of the superficial vein thrombosis into the deep venous system (<a href="./references#CD004982-bbs2-0108" title="WichersIM , DiNisioM , BullerHR , MiddeldorpS . Treatment of superficial vein thrombosis to prevent deep vein thrombosis and pulmonary embolism: a systematic review. Haematologica2005;90(5):672‐7. ">Wichers 2005</a>). </p> <p>This review summarised data from 7296 people with ST of the legs. About half of the participants were included in the CALISTO study, which compared 45 days of fondaparinux versus placebo using a double‐blind method (<a href="./references#CD004982-bbs2-0011" title="BauersachsRM . The CALISTO‐study. Phlebologie2011;40(2):79‐83. DecoususH . Fondaparinux reduced a composite of VTE complications or death in superficial leg‐vein thrombosis. Annals of Internal Medicine2011;154(4):JC2‐3. DecoususH , PrandoniP , MismettiP , BauersachsRM , BodaZ , BrennerB , et al. CALISTO Study Group. Fondaparinux for the treatment of superficial‐vein thrombosis in the legs. New England Journal of Medicine2010;363(13):1222‐32. LeizoroviczA , BeckerF , BuchmullerA , QuereI , PrandoniP , DecoususH , et al. Clinical relevance of symptomatic superficial‐vein thrombosis extension: lessons from the CALISTO study. Blood2013;122(10):1724‐9. LeizoroviczA , PrandoniP , DecoususH . Fondaparinux reduces all types of symptomatic thromboembolic complications in patients with superficial‐vein thrombosis in the legs: data from the CALISTO study. ASH Annual Meeting Abstracts2011;118:2310. ">Decousus 2010b</a>). Fondaparinux reduced the incidence of symptomatic VTE by 85%, ST extension by 92%, and the recurrence of ST by 79%. A total of 88 participants would need to be treated with fondaparinux to prevent one PE or DVT. These benefits were achieved without apparently increasing the risk of bleeding and they were maintained at one‐month follow‐up after discontinuation of treatment. However, CIs around bleeding estimate were broad and did not exclude a significantly higher risk with the drug. In the SURPRISE study, people with ST and one or more risk factors for thromboembolic complications were randomised to 45 days of fondaparinux or rivaroxaban 10 mg (<a href="./references#CD004982-bbs2-0008" title="Beyer‐WestendorfJ , SchellongSM , GerlachH , RabeE , WeitzJI , JersemannK , et al. Prevention of thromboembolic complications in patients with superficial‐vein thrombosis given rivaroxaban or fondaparinux: the open‐label, randomised, non‐inferiority SURPRISE phase 3b trial. Lancet Haematology2017;4(3):e105‐13. WerthS , BauersachsR , GerlachH , RabeE , SchellongS , Beyer‐WestendorfJ . Superficial vein thrombosis treated for 45 days with rivaroxaban versus fondaparinux: rationale and design of the SURPRISE trial. Journal of Thrombosis and Thrombolysis2016;42(2):197‐204. ">Beyer‐Westendorf 2017</a>). The results suggested that rivaroxaban was as effective as fondaparinux; however, the study was not powered to prove non‐inferiority. In addition, the authors observed a non‐statistically significant increase of the primary composite outcome as well as of clinically relevant non‐major bleedings in the rivaroxaban group which require further evaluation in appropriately sized studies. In contrast to the CALISTO study, the risk of thromboembolic events seemed to increase after treatment withdrawal at 45 days suggesting that a longer treatment may be required for people at high risk. </p> <p>Compared with placebo or topical treatments, both NSAIDs and LMWH could help preventing ST extension while effectively controlling local symptoms (<a href="./references#CD004982-bbs2-0029" title="Superficial Thrombophlebitis Treated by Enoxaparin Study Group. A pilot randomized double‐blind comparison of a low‐molecular‐weight heparin, a nonsteroidal anti‐inflammatory agent, and placebo in the treatment of superficial vein thrombosis. Archives of Internal Medicine2003;163(14):1657‐63. ">Stenox Group 2003</a>; <a href="./references#CD004982-bbs2-0030" title="TitonJP , AugerD , GrangeP , HecquetJP , RemondA , UlliacP , et al. Therapeutic management of superficial venous thrombosis with calcium nadroparin. Dosage testing and comparison with an non‐steroidal anti‐inflammatory agent [Traitement curatif des thromboses veineuses superficielles par nadroparine calcique. Recherche posologique et comparaison à un anti‐inflammatoire non stéroidien]. Annales de Cardiologie et d'Angeiologie1994;43(3):160‐6. ">Titon 1994</a>). When compared with each other, LMWH and NSAIDs seemed to be associated with a similar reduction in the incidence of VTE and worsening of ST. However, these conclusions need to be taken cautiously due to the methodological drawbacks, the low incidence of VTE, and the sample size of the available studies, which did not have enough power for a direct comparison between LMWH and NSAIDs. Thus, these data remain preliminary and further research is required to determine which treatment works better in terms of VTE prevention, and whether a combination may be more effective. Moreover, the benefits of LMWH and NSAIDs should be balanced against the associated adverse effects such as bleeding and gastric complications. None of the studies reported major bleeding episodes in participants randomised to LMWH. NSAIDs increased the risk of gastric pain three‐fold compared with placebo. To date, no study has evaluated NSAIDs versus surgery whereas one trial directly compared LMWH with surgical treatment, showing a comparable efficacy and safety (<a href="./references#CD004982-bbs2-0020" title="LozanoFS , AlmazanA . Low‐molecular‐weight heparin versus saphenofemoral disconnection for the treatment of above‐knee greater saphenous thrombophlebitis: a prospective study. Vascular and Endovascular Surgery2003;37(6):415‐20. ">Lozano 2003</a>). Despite the methodological limitations of this study, the results would suggest that a medical approach with LMWH would be as effective and safe as an invasive surgical treatment. </p> <p><a href="./references#CD004982-bbs2-0010" title="CosmiB . Risk factors for recurrent events in subjects with superficial vein thrombosis in the randomized clinical trial SteFlux (Superficial Thromboembolism Fluxum). Thrombosis Research2014;133(2):196‐202. CosmiB , FilippiniM , TontiD , AvruscioG , GhirarduzziA , BucheriniE , et al. A randomized double‐blind study of low‐molecular‐weight heparin (parnaparin) for superficial vein thrombosis: STEFLUX (Superficial ThromboEmbolism and Fluxum). Journal of Thrombosis and Haemostasis2012;10(6):1026‐35. CosmiB , FilippiniM , TontiD , GhirarduzziA , AvruscioG , ImbertiD , et al. Risk factors for recurrent events in subjects with superficial vein thrombosis in the randomized clinical trial Steflux (Superficial Thromboembolism Fluxum). Hamostaseologie2012;32:A29. CosmiB , FilippiniM , TontiD , GhirarduzziA , AvruscioG , ImbertiD , et al. The Steflux (Superficial Thromboembolism and Fluxum) randomized double blind clinical study of different treatment doses and duration of low molecular weight heparin (parnaparin) in superficial vein thrombosis. Hamostaseologie2012;32:A28. ">Cosmi 2012</a> and <a href="./references#CD004982-bbs2-0032" title="PrandoniP . High versus low doses of low‐molecular‐weight heparin for the treatment of superficial vein thrombosis of the legs. A double‐blind, randomized trial. Journal of Thrombosis and Haemostasis2005;3 (Suppl 1):Abstract number OR145. [http://onlinelibrary.wiley.com/doi/10.1111/j.1538‐7836.2005.0300b.x/full] PrandoniP , TormeneD , PesaventoR , Vesalio Investigators Group. High vs. low doses of low‐molecular‐weight heparin for the treatment of superficial vein thrombosis of the legs: a double‐blind, randomized trial. Journal of Thrombosis and Haemostasis2005;3(6):1152‐7. ">Vesalio Group 2005</a> compared different regimens of LMWH head‐to‐head. While symptomatic VTE occurred at a similar rate with prophylactic and higher (intermediate or therapeutic) dose LMWH, the higher‐dose LMWH seemed to be associated with a significant 70% reduction in ST progression (<a href="./references#CD004982-bbs2-0010" title="CosmiB . Risk factors for recurrent events in subjects with superficial vein thrombosis in the randomized clinical trial SteFlux (Superficial Thromboembolism Fluxum). Thrombosis Research2014;133(2):196‐202. CosmiB , FilippiniM , TontiD , AvruscioG , GhirarduzziA , BucheriniE , et al. A randomized double‐blind study of low‐molecular‐weight heparin (parnaparin) for superficial vein thrombosis: STEFLUX (Superficial ThromboEmbolism and Fluxum). Journal of Thrombosis and Haemostasis2012;10(6):1026‐35. CosmiB , FilippiniM , TontiD , GhirarduzziA , AvruscioG , ImbertiD , et al. Risk factors for recurrent events in subjects with superficial vein thrombosis in the randomized clinical trial Steflux (Superficial Thromboembolism Fluxum). Hamostaseologie2012;32:A29. CosmiB , FilippiniM , TontiD , GhirarduzziA , AvruscioG , ImbertiD , et al. The Steflux (Superficial Thromboembolism and Fluxum) randomized double blind clinical study of different treatment doses and duration of low molecular weight heparin (parnaparin) in superficial vein thrombosis. Hamostaseologie2012;32:A28. ">Cosmi 2012</a>). Furthermore, the findings of <a href="./references#CD004982-bbs2-0010" title="CosmiB . Risk factors for recurrent events in subjects with superficial vein thrombosis in the randomized clinical trial SteFlux (Superficial Thromboembolism Fluxum). Thrombosis Research2014;133(2):196‐202. CosmiB , FilippiniM , TontiD , AvruscioG , GhirarduzziA , BucheriniE , et al. A randomized double‐blind study of low‐molecular‐weight heparin (parnaparin) for superficial vein thrombosis: STEFLUX (Superficial ThromboEmbolism and Fluxum). Journal of Thrombosis and Haemostasis2012;10(6):1026‐35. CosmiB , FilippiniM , TontiD , GhirarduzziA , AvruscioG , ImbertiD , et al. Risk factors for recurrent events in subjects with superficial vein thrombosis in the randomized clinical trial Steflux (Superficial Thromboembolism Fluxum). Hamostaseologie2012;32:A29. CosmiB , FilippiniM , TontiD , GhirarduzziA , AvruscioG , ImbertiD , et al. The Steflux (Superficial Thromboembolism and Fluxum) randomized double blind clinical study of different treatment doses and duration of low molecular weight heparin (parnaparin) in superficial vein thrombosis. Hamostaseologie2012;32:A28. ">Cosmi 2012</a> suggested that treatment with LMWH should be prolonged for at least 30 days to reduce the incidence of symptomatic VTE, compared to shorter usage of LMWH. However, it should be noted that neither <a href="./references#CD004982-bbs2-0010" title="CosmiB . Risk factors for recurrent events in subjects with superficial vein thrombosis in the randomized clinical trial SteFlux (Superficial Thromboembolism Fluxum). Thrombosis Research2014;133(2):196‐202. CosmiB , FilippiniM , TontiD , AvruscioG , GhirarduzziA , BucheriniE , et al. A randomized double‐blind study of low‐molecular‐weight heparin (parnaparin) for superficial vein thrombosis: STEFLUX (Superficial ThromboEmbolism and Fluxum). Journal of Thrombosis and Haemostasis2012;10(6):1026‐35. CosmiB , FilippiniM , TontiD , GhirarduzziA , AvruscioG , ImbertiD , et al. Risk factors for recurrent events in subjects with superficial vein thrombosis in the randomized clinical trial Steflux (Superficial Thromboembolism Fluxum). Hamostaseologie2012;32:A29. CosmiB , FilippiniM , TontiD , GhirarduzziA , AvruscioG , ImbertiD , et al. The Steflux (Superficial Thromboembolism and Fluxum) randomized double blind clinical study of different treatment doses and duration of low molecular weight heparin (parnaparin) in superficial vein thrombosis. Hamostaseologie2012;32:A28. ">Cosmi 2012</a> nor <a href="./references#CD004982-bbs2-0032" title="PrandoniP . High versus low doses of low‐molecular‐weight heparin for the treatment of superficial vein thrombosis of the legs. A double‐blind, randomized trial. Journal of Thrombosis and Haemostasis2005;3 (Suppl 1):Abstract number OR145. [http://onlinelibrary.wiley.com/doi/10.1111/j.1538‐7836.2005.0300b.x/full] PrandoniP , TormeneD , PesaventoR , Vesalio Investigators Group. High vs. low doses of low‐molecular‐weight heparin for the treatment of superficial vein thrombosis of the legs: a double‐blind, randomized trial. Journal of Thrombosis and Haemostasis2005;3(6):1152‐7. ">Vesalio Group 2005</a> had a placebo or inactive control group and <a href="./references#CD004982-bbs2-0010" title="CosmiB . Risk factors for recurrent events in subjects with superficial vein thrombosis in the randomized clinical trial SteFlux (Superficial Thromboembolism Fluxum). Thrombosis Research2014;133(2):196‐202. CosmiB , FilippiniM , TontiD , AvruscioG , GhirarduzziA , BucheriniE , et al. A randomized double‐blind study of low‐molecular‐weight heparin (parnaparin) for superficial vein thrombosis: STEFLUX (Superficial ThromboEmbolism and Fluxum). Journal of Thrombosis and Haemostasis2012;10(6):1026‐35. CosmiB , FilippiniM , TontiD , GhirarduzziA , AvruscioG , ImbertiD , et al. Risk factors for recurrent events in subjects with superficial vein thrombosis in the randomized clinical trial Steflux (Superficial Thromboembolism Fluxum). Hamostaseologie2012;32:A29. CosmiB , FilippiniM , TontiD , GhirarduzziA , AvruscioG , ImbertiD , et al. The Steflux (Superficial Thromboembolism and Fluxum) randomized double blind clinical study of different treatment doses and duration of low molecular weight heparin (parnaparin) in superficial vein thrombosis. Hamostaseologie2012;32:A28. ">Cosmi 2012</a> was prematurely interrupted, which may have led to an overestimation of the differences between the groups. </p> <p>In the study of <a href="./references#CD004982-bbs2-0009" title="BoehlerK , KittlerH , StolkovichS , TzanevaS . Therapeutic effect of compression stockings versus no compression on isolated superficial vein thrombosis of the legs: a randomized clinical trial. European Journal of Vascular and Endovascular Surgery2014;48(4):465‐71. ">Boehler 2014</a>, the addition of compression stockings to prophylactic dose LMWH seemed to carry no additional benefit in terms of clinical improvement. </p> <p>Preliminary data suggested that high‐dose UFH can be effective in the treatment of ST although this needs to be confirmed in larger studies (<a href="./references#CD004982-bbs2-0021" title="MarchioriA , VerlatoF , SabbionP , CamporeseG , RossoF , MosenaL , et al. High versus low doses of unfractionated heparin for the treatment of superficial thrombophlebitis of the leg. A prospective, controlled, randomized study. Haematologica2002;87(5):523‐7. ">Marchiori 2002</a>). While not directly evaluated against UFH, fondaparinux and LMWH may still be preferable due to the easier mode of administration and the more predictable response not requiring laboratory monitoring as for UFH. </p> <p>Most of the studies comparing oral treatment, topical treatment, or surgery did not report VTE, ST progression, adverse events, or treatment adverse effects. In addition, the methodological quality of these studies was often poor, with major study design flaws such as an unclear method of allocation or randomisation, the lack of a placebo as control group, or an unacceptably high dropout rate. All these limitations weaken the clinical applicability of the results and cast doubt about the actual efficacy and safety of these treatments. </p> <section id="CD004982-sec-0071"> <h3 class="title" id="CD004982-sec-0071">Summary of main results</h3> <p>Fondaparinux was associated with a significant lower incidence of VTE, ST extension, or ST recurrence relative to placebo with similar risk of bleeding. Rivaroxaban 10 mg requires further evaluation. As compared to placebo, LMWH and NSAIDs appeared to reduce the extension or recurrence of ST, or both, whereas the available data did not show any significant effect on VTE. The evidence on oral treatments, topical treatment, or surgery was too limited and did not inform clinical practice about the effects of these treatments in terms of VTE. </p> </section> <section id="CD004982-sec-0072"> <h3 class="title" id="CD004982-sec-0072">Quality of the evidence</h3> <p>Our systematic approach to searching, study selection, and data extraction followed that of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD004982-bbs2-0091" title="HigginsJPT , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org. ">Higgins 2011</a>). The methodological quality of the included studies varied from low to high (see <a href="#CD004982-fig-0002">Figure 2</a>). Poor reporting did not allow proper scoring of relevant study design features, such as sequence generation and allocation concealment, in the majority of included studies. Overall, the quality of evidence was very low for most intervention outcomes due to limitations in study design, imprecision of results and single study comparisons. The quality of evidence was low to moderate for outcomes in the two placebo‐controlled studies included in this review (<a href="./references#CD004982-bbs2-0011" title="BauersachsRM . The CALISTO‐study. Phlebologie2011;40(2):79‐83. DecoususH . Fondaparinux reduced a composite of VTE complications or death in superficial leg‐vein thrombosis. Annals of Internal Medicine2011;154(4):JC2‐3. DecoususH , PrandoniP , MismettiP , BauersachsRM , BodaZ , BrennerB , et al. CALISTO Study Group. Fondaparinux for the treatment of superficial‐vein thrombosis in the legs. New England Journal of Medicine2010;363(13):1222‐32. LeizoroviczA , BeckerF , BuchmullerA , QuereI , PrandoniP , DecoususH , et al. Clinical relevance of symptomatic superficial‐vein thrombosis extension: lessons from the CALISTO study. Blood2013;122(10):1724‐9. LeizoroviczA , PrandoniP , DecoususH . Fondaparinux reduces all types of symptomatic thromboembolic complications in patients with superficial‐vein thrombosis in the legs: data from the CALISTO study. ASH Annual Meeting Abstracts2011;118:2310. ">Decousus 2010b</a>; <a href="./references#CD004982-bbs2-0029" title="Superficial Thrombophlebitis Treated by Enoxaparin Study Group. A pilot randomized double‐blind comparison of a low‐molecular‐weight heparin, a nonsteroidal anti‐inflammatory agent, and placebo in the treatment of superficial vein thrombosis. Archives of Internal Medicine2003;163(14):1657‐63. ">Stenox Group 2003</a>). See <a href="./full#CD004982-tbl-0001">summary of findings Table for the main comparison</a>; <a href="./full#CD004982-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD004982-tbl-0003">summary of findings Table 3</a>; and <a href="./full#CD004982-tbl-0004">summary of findings Table 4</a>. </p> </section> <section id="CD004982-sec-0073"> <h3 class="title" id="CD004982-sec-0073">Potential biases in the review process</h3> <p>One limitation of this review is that, despite the relatively large number of comparisons found, only a few studies compared the same treatment on the same study outcomes. The 'no difference' findings on a specific outcome may thus be the result of insufficient power of the analysis to show a difference between treatment groups as well as the absence of a true effect. For similar reasons, it was not possible to conduct subgroup analyses for the primary efficacy outcomes to evaluate the interaction of trial characteristics with treatment effects. </p> </section> <section id="CD004982-sec-0074"> <h3 class="title" id="CD004982-sec-0074">Agreements and disagreements with other studies or reviews</h3> <p>Since our previous systematic review on the prevention of VTE in people with ST of the leg (<a href="./references#CD004982-bbs2-0108" title="WichersIM , DiNisioM , BullerHR , MiddeldorpS . Treatment of superficial vein thrombosis to prevent deep vein thrombosis and pulmonary embolism: a systematic review. Haematologica2005;90(5):672‐7. ">Wichers 2005</a>), the results of two large RCTs on the efficacy of fondaparinux for the treatment of ST have become available (<a href="./references#CD004982-bbs2-0008" title="Beyer‐WestendorfJ , SchellongSM , GerlachH , RabeE , WeitzJI , JersemannK , et al. Prevention of thromboembolic complications in patients with superficial‐vein thrombosis given rivaroxaban or fondaparinux: the open‐label, randomised, non‐inferiority SURPRISE phase 3b trial. Lancet Haematology2017;4(3):e105‐13. WerthS , BauersachsR , GerlachH , RabeE , SchellongS , Beyer‐WestendorfJ . Superficial vein thrombosis treated for 45 days with rivaroxaban versus fondaparinux: rationale and design of the SURPRISE trial. Journal of Thrombosis and Thrombolysis2016;42(2):197‐204. ">Beyer‐Westendorf 2017</a>; <a href="./references#CD004982-bbs2-0011" title="BauersachsRM . The CALISTO‐study. Phlebologie2011;40(2):79‐83. DecoususH . Fondaparinux reduced a composite of VTE complications or death in superficial leg‐vein thrombosis. Annals of Internal Medicine2011;154(4):JC2‐3. DecoususH , PrandoniP , MismettiP , BauersachsRM , BodaZ , BrennerB , et al. CALISTO Study Group. Fondaparinux for the treatment of superficial‐vein thrombosis in the legs. New England Journal of Medicine2010;363(13):1222‐32. LeizoroviczA , BeckerF , BuchmullerA , QuereI , PrandoniP , DecoususH , et al. Clinical relevance of symptomatic superficial‐vein thrombosis extension: lessons from the CALISTO study. Blood2013;122(10):1724‐9. LeizoroviczA , PrandoniP , DecoususH . Fondaparinux reduces all types of symptomatic thromboembolic complications in patients with superficial‐vein thrombosis in the legs: data from the CALISTO study. ASH Annual Meeting Abstracts2011;118:2310. ">Decousus 2010b</a>). The high methodological quality and the size of the CALISTO study (<a href="./references#CD004982-bbs2-0011" title="BauersachsRM . The CALISTO‐study. Phlebologie2011;40(2):79‐83. DecoususH . Fondaparinux reduced a composite of VTE complications or death in superficial leg‐vein thrombosis. Annals of Internal Medicine2011;154(4):JC2‐3. DecoususH , PrandoniP , MismettiP , BauersachsRM , BodaZ , BrennerB , et al. CALISTO Study Group. Fondaparinux for the treatment of superficial‐vein thrombosis in the legs. New England Journal of Medicine2010;363(13):1222‐32. LeizoroviczA , BeckerF , BuchmullerA , QuereI , PrandoniP , DecoususH , et al. Clinical relevance of symptomatic superficial‐vein thrombosis extension: lessons from the CALISTO study. Blood2013;122(10):1724‐9. LeizoroviczA , PrandoniP , DecoususH . Fondaparinux reduces all types of symptomatic thromboembolic complications in patients with superficial‐vein thrombosis in the legs: data from the CALISTO study. ASH Annual Meeting Abstracts2011;118:2310. ">Decousus 2010b</a>), which alone accounted for half of the overall review population, made it a landmark investigation in the field. The SURPRISE study was the first to compare one of the direct oral factor Xa inhibitors, rivaroxaban, with fondaparinux and to select people with ST based on their underlying risk of thromboembolic events. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD004982-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD004982-fig-0001" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/full#CD004982-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD004982-fig-0002" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/full#CD004982-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Fondaparinux versus placebo, Outcome 1 Pulmonary embolism." data-id="CD004982-fig-0003" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Fondaparinux versus placebo, Outcome 1 Pulmonary embolism.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Fondaparinux versus placebo, Outcome 2 Deep vein thrombosis." data-id="CD004982-fig-0004" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Fondaparinux versus placebo, Outcome 2 Deep vein thrombosis.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Fondaparinux versus placebo, Outcome 3 Deep vein thrombosis or pulmonary embolism." data-id="CD004982-fig-0005" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Fondaparinux versus placebo, Outcome 3 Deep vein thrombosis or pulmonary embolism. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Fondaparinux versus placebo, Outcome 4 Extension of superficial thrombophlebitis." data-id="CD004982-fig-0006" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Fondaparinux versus placebo, Outcome 4 Extension of superficial thrombophlebitis.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Fondaparinux versus placebo, Outcome 5 Recurrence of superficial thrombophlebitis." data-id="CD004982-fig-0007" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Fondaparinux versus placebo, Outcome 5 Recurrence of superficial thrombophlebitis.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Fondaparinux versus placebo, Outcome 6 Mortality." data-id="CD004982-fig-0008" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Fondaparinux versus placebo, Outcome 6 Mortality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Fondaparinux versus placebo, Outcome 7 Major bleeding." data-id="CD004982-fig-0009" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Fondaparinux versus placebo, Outcome 7 Major bleeding.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Fondaparinux versus placebo, Outcome 8 Clinically relevant non‐major bleeding." data-id="CD004982-fig-0010" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Fondaparinux versus placebo, Outcome 8 Clinically relevant non‐major bleeding. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Fondaparinux versus placebo, Outcome 9 Minor bleeding." data-id="CD004982-fig-0011" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Fondaparinux versus placebo, Outcome 9 Minor bleeding.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Fondaparinux versus placebo, Outcome 10 Arterial thromboembolic complication." data-id="CD004982-fig-0012" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Fondaparinux versus placebo, Outcome 10 Arterial thromboembolic complication.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Fondaparinux versus placebo, Outcome 11 Adverse effects of treatment." data-id="CD004982-fig-0013" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 Fondaparinux versus placebo, Outcome 11 Adverse effects of treatment.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-001-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-001-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Fondaparinux versus placebo, Outcome 12 Non‐fatal serious adverse event." data-id="CD004982-fig-0014" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-001-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1 Fondaparinux versus placebo, Outcome 12 Non‐fatal serious adverse event.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-001-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Fondaparinux versus rivaroxaban, Outcome 1 Pulmonary embolism." data-id="CD004982-fig-0015" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Fondaparinux versus rivaroxaban, Outcome 1 Pulmonary embolism.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Fondaparinux versus rivaroxaban, Outcome 2 Deep vein thrombosis." data-id="CD004982-fig-0016" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Fondaparinux versus rivaroxaban, Outcome 2 Deep vein thrombosis.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Fondaparinux versus rivaroxaban, Outcome 3 Deep vein thrombosis or pulmonary embolism." data-id="CD004982-fig-0017" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Fondaparinux versus rivaroxaban, Outcome 3 Deep vein thrombosis or pulmonary embolism. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Fondaparinux versus rivaroxaban, Outcome 4 Extension of superficial thrombophlebitis." data-id="CD004982-fig-0018" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Fondaparinux versus rivaroxaban, Outcome 4 Extension of superficial thrombophlebitis.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Fondaparinux versus rivaroxaban, Outcome 5 Recurrence of superficial thrombophlebitis." data-id="CD004982-fig-0019" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Fondaparinux versus rivaroxaban, Outcome 5 Recurrence of superficial thrombophlebitis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Fondaparinux versus rivaroxaban, Outcome 6 Mortality." data-id="CD004982-fig-0020" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 Fondaparinux versus rivaroxaban, Outcome 6 Mortality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-002-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-002-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Fondaparinux versus rivaroxaban, Outcome 7 Major bleeding." data-id="CD004982-fig-0021" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-002-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 Fondaparinux versus rivaroxaban, Outcome 7 Major bleeding.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-002-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-002-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-002-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Fondaparinux versus rivaroxaban, Outcome 8 Clinically relevant non‐major bleeding." data-id="CD004982-fig-0022" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-002-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2 Fondaparinux versus rivaroxaban, Outcome 8 Clinically relevant non‐major bleeding. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-002-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-002-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-002-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Fondaparinux versus rivaroxaban, Outcome 9 Minor bleeding." data-id="CD004982-fig-0023" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-002-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2 Fondaparinux versus rivaroxaban, Outcome 9 Minor bleeding.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-002-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-002-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-002-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Fondaparinux versus rivaroxaban, Outcome 10 Serious adverse events." data-id="CD004982-fig-0024" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-002-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.10</div> <div class="figure-caption"> <p>Comparison 2 Fondaparinux versus rivaroxaban, Outcome 10 Serious adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-002-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-002-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-002-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Fondaparinux versus rivaroxaban, Outcome 11 Adverse effects of treatment." data-id="CD004982-fig-0025" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-002-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.11</div> <div class="figure-caption"> <p>Comparison 2 Fondaparinux versus rivaroxaban, Outcome 11 Adverse effects of treatment.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-002-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Prophylactic low molecular weight heparin (LMWH) versus placebo, Outcome 1 Venous thromboembolism end‐of‐treatment." data-id="CD004982-fig-0026" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Prophylactic low molecular weight heparin (LMWH) versus placebo, Outcome 1 Venous thromboembolism end‐of‐treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Prophylactic low molecular weight heparin (LMWH) versus placebo, Outcome 2 Venous thromboembolism 3‐month follow‐up." data-id="CD004982-fig-0027" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Prophylactic low molecular weight heparin (LMWH) versus placebo, Outcome 2 Venous thromboembolism 3‐month follow‐up. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Prophylactic low molecular weight heparin (LMWH) versus placebo, Outcome 3 Extension or recurrence (or both) of superficial thrombophlebitis." data-id="CD004982-fig-0028" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Prophylactic low molecular weight heparin (LMWH) versus placebo, Outcome 3 Extension or recurrence (or both) of superficial thrombophlebitis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Prophylactic low molecular weight heparin (LMWH) versus placebo, Outcome 4 Major bleeding." data-id="CD004982-fig-0029" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 Prophylactic low molecular weight heparin (LMWH) versus placebo, Outcome 4 Major bleeding. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-003-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-003-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Prophylactic low molecular weight heparin (LMWH) versus placebo, Outcome 5 Heparin‐induced thrombocytopenia." data-id="CD004982-fig-0030" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-003-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3 Prophylactic low molecular weight heparin (LMWH) versus placebo, Outcome 5 Heparin‐induced thrombocytopenia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-003-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Therapeutic low molecular weight heparin (LMWH) versus placebo, Outcome 1 Venous thromboembolism end‐of‐treatment." data-id="CD004982-fig-0031" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Therapeutic low molecular weight heparin (LMWH) versus placebo, Outcome 1 Venous thromboembolism end‐of‐treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Therapeutic low molecular weight heparin (LMWH) versus placebo, Outcome 2 Venous thromboembolism 3‐month follow‐up." data-id="CD004982-fig-0032" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Therapeutic low molecular weight heparin (LMWH) versus placebo, Outcome 2 Venous thromboembolism 3‐month follow‐up. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-004-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-004-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Therapeutic low molecular weight heparin (LMWH) versus placebo, Outcome 3 Extension or recurrence (or both) of superficial thrombophlebitis." data-id="CD004982-fig-0033" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-004-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 Therapeutic low molecular weight heparin (LMWH) versus placebo, Outcome 3 Extension or recurrence (or both) of superficial thrombophlebitis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-004-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-004-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-004-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Therapeutic low molecular weight heparin (LMWH) versus placebo, Outcome 4 Major bleeding." data-id="CD004982-fig-0034" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-004-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4 Therapeutic low molecular weight heparin (LMWH) versus placebo, Outcome 4 Major bleeding. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-004-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-004-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-004-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Therapeutic low molecular weight heparin (LMWH) versus placebo, Outcome 5 Heparin‐induced thrombocytopenia." data-id="CD004982-fig-0035" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-004-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4 Therapeutic low molecular weight heparin (LMWH) versus placebo, Outcome 5 Heparin‐induced thrombocytopenia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-004-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Thirty‐day prophylactic low molecular weight heparin (LMWH) versus 30‐day intermediate LMWH, Outcome 1 Venous thromboembolism end‐of‐treatment." data-id="CD004982-fig-0036" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 Thirty‐day prophylactic low molecular weight heparin (LMWH) versus 30‐day intermediate LMWH, Outcome 1 Venous thromboembolism end‐of‐treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-005-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-005-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Thirty‐day prophylactic low molecular weight heparin (LMWH) versus 30‐day intermediate LMWH, Outcome 2 Venous thromboembolism 3‐month follow‐up." data-id="CD004982-fig-0037" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-005-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5 Thirty‐day prophylactic low molecular weight heparin (LMWH) versus 30‐day intermediate LMWH, Outcome 2 Venous thromboembolism 3‐month follow‐up. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-005-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-005-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-005-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Thirty‐day prophylactic low molecular weight heparin (LMWH) versus 30‐day intermediate LMWH, Outcome 3 Symptomatic deep vein thrombosis end‐of‐treatment." data-id="CD004982-fig-0038" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-005-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5 Thirty‐day prophylactic low molecular weight heparin (LMWH) versus 30‐day intermediate LMWH, Outcome 3 Symptomatic deep vein thrombosis end‐of‐treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-005-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-005-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-005-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Thirty‐day prophylactic low molecular weight heparin (LMWH) versus 30‐day intermediate LMWH, Outcome 4 Symptomatic deep vein thrombosis 3‐month follow‐up." data-id="CD004982-fig-0039" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-005-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5 Thirty‐day prophylactic low molecular weight heparin (LMWH) versus 30‐day intermediate LMWH, Outcome 4 Symptomatic deep vein thrombosis 3‐month follow‐up. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-005-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-005-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-005-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Thirty‐day prophylactic low molecular weight heparin (LMWH) versus 30‐day intermediate LMWH, Outcome 5 Extension of superficial thrombophlebitis 3‐month follow‐up." data-id="CD004982-fig-0040" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-005-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.5</div> <div class="figure-caption"> <p>Comparison 5 Thirty‐day prophylactic low molecular weight heparin (LMWH) versus 30‐day intermediate LMWH, Outcome 5 Extension of superficial thrombophlebitis 3‐month follow‐up. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-005-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-005-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-005-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Thirty‐day prophylactic low molecular weight heparin (LMWH) versus 30‐day intermediate LMWH, Outcome 6 Recurrence of superficial thrombophlebitis 3‐month follow‐up." data-id="CD004982-fig-0041" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-005-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.6</div> <div class="figure-caption"> <p>Comparison 5 Thirty‐day prophylactic low molecular weight heparin (LMWH) versus 30‐day intermediate LMWH, Outcome 6 Recurrence of superficial thrombophlebitis 3‐month follow‐up. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-005-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-006-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-006-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Thirty‐day prophylactic low molecular weight heparin (LMWH) versus 10‐day intermediate LMWH, Outcome 1 Venous thromboembolism end‐of‐treatment." data-id="CD004982-fig-0042" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-006-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6 Thirty‐day prophylactic low molecular weight heparin (LMWH) versus 10‐day intermediate LMWH, Outcome 1 Venous thromboembolism end‐of‐treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-006-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-006-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-006-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Thirty‐day prophylactic low molecular weight heparin (LMWH) versus 10‐day intermediate LMWH, Outcome 2 Venous thromboembolism 3‐month follow‐up." data-id="CD004982-fig-0043" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-006-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6 Thirty‐day prophylactic low molecular weight heparin (LMWH) versus 10‐day intermediate LMWH, Outcome 2 Venous thromboembolism 3‐month follow‐up. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-006-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-006-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-006-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Thirty‐day prophylactic low molecular weight heparin (LMWH) versus 10‐day intermediate LMWH, Outcome 3 Symptomatic deep vein thrombosis end‐of‐treatment." data-id="CD004982-fig-0044" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-006-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6 Thirty‐day prophylactic low molecular weight heparin (LMWH) versus 10‐day intermediate LMWH, Outcome 3 Symptomatic deep vein thrombosis end‐of‐treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-006-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-006-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-006-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Thirty‐day prophylactic low molecular weight heparin (LMWH) versus 10‐day intermediate LMWH, Outcome 4 Symptomatic deep vein thrombosis 3‐month follow‐up." data-id="CD004982-fig-0045" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-006-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.4</div> <div class="figure-caption"> <p>Comparison 6 Thirty‐day prophylactic low molecular weight heparin (LMWH) versus 10‐day intermediate LMWH, Outcome 4 Symptomatic deep vein thrombosis 3‐month follow‐up. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-006-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-006-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-006-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Thirty‐day prophylactic low molecular weight heparin (LMWH) versus 10‐day intermediate LMWH, Outcome 5 Extension of superficial thrombophlebitis 3‐month follow‐up." data-id="CD004982-fig-0046" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-006-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.5</div> <div class="figure-caption"> <p>Comparison 6 Thirty‐day prophylactic low molecular weight heparin (LMWH) versus 10‐day intermediate LMWH, Outcome 5 Extension of superficial thrombophlebitis 3‐month follow‐up. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-006-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-006-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-006-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Thirty‐day prophylactic low molecular weight heparin (LMWH) versus 10‐day intermediate LMWH, Outcome 6 Recurrence of superficial thrombophlebitis 3‐month follow‐up." data-id="CD004982-fig-0047" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-006-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.6</div> <div class="figure-caption"> <p>Comparison 6 Thirty‐day prophylactic low molecular weight heparin (LMWH) versus 10‐day intermediate LMWH, Outcome 6 Recurrence of superficial thrombophlebitis 3‐month follow‐up. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-006-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-007-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-007-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Thirty‐day intermediate low molecular weight heparin (LMWH) versus 10‐day intermediate LMWH, Outcome 1 Venous thromboembolism end‐of‐treatment." data-id="CD004982-fig-0048" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-007-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7 Thirty‐day intermediate low molecular weight heparin (LMWH) versus 10‐day intermediate LMWH, Outcome 1 Venous thromboembolism end‐of‐treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-007-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-007-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-007-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Thirty‐day intermediate low molecular weight heparin (LMWH) versus 10‐day intermediate LMWH, Outcome 2 Venous thromboembolism 3‐month follow‐up." data-id="CD004982-fig-0049" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-007-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.2</div> <div class="figure-caption"> <p>Comparison 7 Thirty‐day intermediate low molecular weight heparin (LMWH) versus 10‐day intermediate LMWH, Outcome 2 Venous thromboembolism 3‐month follow‐up. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-007-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-007-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-007-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Thirty‐day intermediate low molecular weight heparin (LMWH) versus 10‐day intermediate LMWH, Outcome 3 Symptomatic deep vein thrombosis end‐of‐treatment." data-id="CD004982-fig-0050" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-007-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.3</div> <div class="figure-caption"> <p>Comparison 7 Thirty‐day intermediate low molecular weight heparin (LMWH) versus 10‐day intermediate LMWH, Outcome 3 Symptomatic deep vein thrombosis end‐of‐treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-007-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-007-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-007-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Thirty‐day intermediate low molecular weight heparin (LMWH) versus 10‐day intermediate LMWH, Outcome 4 Symptomatic deep vein thrombosis 3‐month follow‐up." data-id="CD004982-fig-0051" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-007-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.4</div> <div class="figure-caption"> <p>Comparison 7 Thirty‐day intermediate low molecular weight heparin (LMWH) versus 10‐day intermediate LMWH, Outcome 4 Symptomatic deep vein thrombosis 3‐month follow‐up. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-007-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-007-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-007-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Thirty‐day intermediate low molecular weight heparin (LMWH) versus 10‐day intermediate LMWH, Outcome 5 Extension of superficial thrombophlebitis 3‐month follow‐up." data-id="CD004982-fig-0052" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-007-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.5</div> <div class="figure-caption"> <p>Comparison 7 Thirty‐day intermediate low molecular weight heparin (LMWH) versus 10‐day intermediate LMWH, Outcome 5 Extension of superficial thrombophlebitis 3‐month follow‐up. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-007-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-007-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-007-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Thirty‐day intermediate low molecular weight heparin (LMWH) versus 10‐day intermediate LMWH, Outcome 6 Recurrence of superficial thrombophlebitis 3‐month follow‐up." data-id="CD004982-fig-0053" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-007-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.6</div> <div class="figure-caption"> <p>Comparison 7 Thirty‐day intermediate low molecular weight heparin (LMWH) versus 10‐day intermediate LMWH, Outcome 6 Recurrence of superficial thrombophlebitis 3‐month follow‐up. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-007-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-008-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-008-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Six‐week prophylactic low molecular weight heparin (LMWH) versus six‐week intermediate LMWH, Outcome 1 Symptomatic venous thromboembolism." data-id="CD004982-fig-0054" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-008-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8 Six‐week prophylactic low molecular weight heparin (LMWH) versus six‐week intermediate LMWH, Outcome 1 Symptomatic venous thromboembolism. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-008-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0055"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-008-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-008-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Six‐week prophylactic low molecular weight heparin (LMWH) versus six‐week intermediate LMWH, Outcome 2 Symptomatic pulmonary embolism." data-id="CD004982-fig-0055" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-008-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.2</div> <div class="figure-caption"> <p>Comparison 8 Six‐week prophylactic low molecular weight heparin (LMWH) versus six‐week intermediate LMWH, Outcome 2 Symptomatic pulmonary embolism. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0055">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-008-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0056"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-008-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-008-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Six‐week prophylactic low molecular weight heparin (LMWH) versus six‐week intermediate LMWH, Outcome 3 Superficial thrombophlebitis progression into deep vein thrombosis." data-id="CD004982-fig-0056" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-008-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.3</div> <div class="figure-caption"> <p>Comparison 8 Six‐week prophylactic low molecular weight heparin (LMWH) versus six‐week intermediate LMWH, Outcome 3 Superficial thrombophlebitis progression into deep vein thrombosis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0056">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-008-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0057"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-008-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-008-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Six‐week prophylactic low molecular weight heparin (LMWH) versus six‐week intermediate LMWH, Outcome 4 Major bleeding." data-id="CD004982-fig-0057" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-008-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.4</div> <div class="figure-caption"> <p>Comparison 8 Six‐week prophylactic low molecular weight heparin (LMWH) versus six‐week intermediate LMWH, Outcome 4 Major bleeding. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0057">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-008-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0058"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-009-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-009-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Fixed‐dose low molecular weight heparin (LMWH) versus weight‐adjusted LMWH, Outcome 1 Superficial thrombophlebitis or venous thromboembolism." data-id="CD004982-fig-0058" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-009-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.1</div> <div class="figure-caption"> <p>Comparison 9 Fixed‐dose low molecular weight heparin (LMWH) versus weight‐adjusted LMWH, Outcome 1 Superficial thrombophlebitis or venous thromboembolism. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0058">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-009-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0059"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-009-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-009-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Fixed‐dose low molecular weight heparin (LMWH) versus weight‐adjusted LMWH, Outcome 2 Venous thromboembolism." data-id="CD004982-fig-0059" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-009-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.2</div> <div class="figure-caption"> <p>Comparison 9 Fixed‐dose low molecular weight heparin (LMWH) versus weight‐adjusted LMWH, Outcome 2 Venous thromboembolism. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0059">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-009-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0060"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-009-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-009-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Fixed‐dose low molecular weight heparin (LMWH) versus weight‐adjusted LMWH, Outcome 3 Superficial thrombophlebitis." data-id="CD004982-fig-0060" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-009-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.3</div> <div class="figure-caption"> <p>Comparison 9 Fixed‐dose low molecular weight heparin (LMWH) versus weight‐adjusted LMWH, Outcome 3 Superficial thrombophlebitis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0060">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-009-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0061"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-009-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-009-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Fixed‐dose low molecular weight heparin (LMWH) versus weight‐adjusted LMWH, Outcome 4 Swelling disappearance." data-id="CD004982-fig-0061" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-009-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.4</div> <div class="figure-caption"> <p>Comparison 9 Fixed‐dose low molecular weight heparin (LMWH) versus weight‐adjusted LMWH, Outcome 4 Swelling disappearance. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0061">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-009-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0062"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-009-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-009-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Fixed‐dose low molecular weight heparin (LMWH) versus weight‐adjusted LMWH, Outcome 5 Tenderness disappearance." data-id="CD004982-fig-0062" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-009-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.5</div> <div class="figure-caption"> <p>Comparison 9 Fixed‐dose low molecular weight heparin (LMWH) versus weight‐adjusted LMWH, Outcome 5 Tenderness disappearance. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0062">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-009-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0063"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-009-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-009-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Fixed‐dose low molecular weight heparin (LMWH) versus weight‐adjusted LMWH, Outcome 6 Pain disappearance." data-id="CD004982-fig-0063" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-009-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.6</div> <div class="figure-caption"> <p>Comparison 9 Fixed‐dose low molecular weight heparin (LMWH) versus weight‐adjusted LMWH, Outcome 6 Pain disappearance. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0063">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-009-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0064"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-009-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-009-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Fixed‐dose low molecular weight heparin (LMWH) versus weight‐adjusted LMWH, Outcome 7 Pitting oedema disappearance." data-id="CD004982-fig-0064" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-009-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.7</div> <div class="figure-caption"> <p>Comparison 9 Fixed‐dose low molecular weight heparin (LMWH) versus weight‐adjusted LMWH, Outcome 7 Pitting oedema disappearance. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0064">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-009-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0065"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-009-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-009-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Fixed‐dose low molecular weight heparin (LMWH) versus weight‐adjusted LMWH, Outcome 8 Collateral veins disappearance." data-id="CD004982-fig-0065" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-009-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.8</div> <div class="figure-caption"> <p>Comparison 9 Fixed‐dose low molecular weight heparin (LMWH) versus weight‐adjusted LMWH, Outcome 8 Collateral veins disappearance. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0065">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-009-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0066"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-009-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-009-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Fixed‐dose low molecular weight heparin (LMWH) versus weight‐adjusted LMWH, Outcome 9 Redness disappearance." data-id="CD004982-fig-0066" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-009-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.9</div> <div class="figure-caption"> <p>Comparison 9 Fixed‐dose low molecular weight heparin (LMWH) versus weight‐adjusted LMWH, Outcome 9 Redness disappearance. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0066">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-009-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0067"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-009-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-009-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Fixed‐dose low molecular weight heparin (LMWH) versus weight‐adjusted LMWH, Outcome 10 Palpable cord disappearance." data-id="CD004982-fig-0067" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-009-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.10</div> <div class="figure-caption"> <p>Comparison 9 Fixed‐dose low molecular weight heparin (LMWH) versus weight‐adjusted LMWH, Outcome 10 Palpable cord disappearance. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0067">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-009-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0068"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-009-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-009-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Fixed‐dose low molecular weight heparin (LMWH) versus weight‐adjusted LMWH, Outcome 11 Major bleeding." data-id="CD004982-fig-0068" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-009-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.11</div> <div class="figure-caption"> <p>Comparison 9 Fixed‐dose low molecular weight heparin (LMWH) versus weight‐adjusted LMWH, Outcome 11 Major bleeding. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0068">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-009-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0069"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-009-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-009-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Fixed‐dose low molecular weight heparin (LMWH) versus weight‐adjusted LMWH, Outcome 12 Heparin‐induced thrombocytopenia." data-id="CD004982-fig-0069" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-009-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.12</div> <div class="figure-caption"> <p>Comparison 9 Fixed‐dose low molecular weight heparin (LMWH) versus weight‐adjusted LMWH, Outcome 12 Heparin‐induced thrombocytopenia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0069">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-009-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0070"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-010-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-010-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Therapeutic low molecular weight heparin (LMWH) versus saphenofemoral disconnection, Outcome 1 Venous thromboembolism." data-id="CD004982-fig-0070" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-010-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.1</div> <div class="figure-caption"> <p>Comparison 10 Therapeutic low molecular weight heparin (LMWH) versus saphenofemoral disconnection, Outcome 1 Venous thromboembolism. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0070">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-010-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0071"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-010-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-010-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Therapeutic low molecular weight heparin (LMWH) versus saphenofemoral disconnection, Outcome 2 Extension or recurrence (or both) of superficial thrombophlebitis." data-id="CD004982-fig-0071" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-010-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.2</div> <div class="figure-caption"> <p>Comparison 10 Therapeutic low molecular weight heparin (LMWH) versus saphenofemoral disconnection, Outcome 2 Extension or recurrence (or both) of superficial thrombophlebitis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0071">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-010-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0072"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-010-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-010-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Therapeutic low molecular weight heparin (LMWH) versus saphenofemoral disconnection, Outcome 3 Major bleeding." data-id="CD004982-fig-0072" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-010-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.3</div> <div class="figure-caption"> <p>Comparison 10 Therapeutic low molecular weight heparin (LMWH) versus saphenofemoral disconnection, Outcome 3 Major bleeding. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0072">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-010-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0073"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-010-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-010-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Therapeutic low molecular weight heparin (LMWH) versus saphenofemoral disconnection, Outcome 4 Complications." data-id="CD004982-fig-0073" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-010-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.4</div> <div class="figure-caption"> <p>Comparison 10 Therapeutic low molecular weight heparin (LMWH) versus saphenofemoral disconnection, Outcome 4 Complications. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0073">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-010-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0074"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-011-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-011-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 Fixed‐dose low molecular weight heparin (LMWH) versus non‐steroidal anti‐inflammatory drugs (NSAIDs), Outcome 1 Venous thromboembolism." data-id="CD004982-fig-0074" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-011-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.1</div> <div class="figure-caption"> <p>Comparison 11 Fixed‐dose low molecular weight heparin (LMWH) versus non‐steroidal anti‐inflammatory drugs (NSAIDs), Outcome 1 Venous thromboembolism. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0074">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-011-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0075"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-011-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-011-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 Fixed‐dose low molecular weight heparin (LMWH) versus non‐steroidal anti‐inflammatory drugs (NSAIDs), Outcome 2 Extension or recurrence (or both) of superficial thrombophlebitis." data-id="CD004982-fig-0075" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-011-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.2</div> <div class="figure-caption"> <p>Comparison 11 Fixed‐dose low molecular weight heparin (LMWH) versus non‐steroidal anti‐inflammatory drugs (NSAIDs), Outcome 2 Extension or recurrence (or both) of superficial thrombophlebitis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0075">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-011-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0076"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-011-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-011-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 Fixed‐dose low molecular weight heparin (LMWH) versus non‐steroidal anti‐inflammatory drugs (NSAIDs), Outcome 3 Major bleeding." data-id="CD004982-fig-0076" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-011-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.3</div> <div class="figure-caption"> <p>Comparison 11 Fixed‐dose low molecular weight heparin (LMWH) versus non‐steroidal anti‐inflammatory drugs (NSAIDs), Outcome 3 Major bleeding. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0076">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-011-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0077"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-011-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-011-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 Fixed‐dose low molecular weight heparin (LMWH) versus non‐steroidal anti‐inflammatory drugs (NSAIDs), Outcome 4 Heparin‐induced thrombocytopenia." data-id="CD004982-fig-0077" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-011-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.4</div> <div class="figure-caption"> <p>Comparison 11 Fixed‐dose low molecular weight heparin (LMWH) versus non‐steroidal anti‐inflammatory drugs (NSAIDs), Outcome 4 Heparin‐induced thrombocytopenia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0077">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-011-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0078"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-012-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-012-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 12 Weight‐adjusted low molecular weight heparin (LMWH) versus non‐steroidal anti‐inflammatory drugs (NSAIDs), Outcome 1 Venous thromboembolism." data-id="CD004982-fig-0078" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-012-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.1</div> <div class="figure-caption"> <p>Comparison 12 Weight‐adjusted low molecular weight heparin (LMWH) versus non‐steroidal anti‐inflammatory drugs (NSAIDs), Outcome 1 Venous thromboembolism. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0078">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-012-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0079"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-012-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-012-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 12 Weight‐adjusted low molecular weight heparin (LMWH) versus non‐steroidal anti‐inflammatory drugs (NSAIDs), Outcome 2 Extension or recurrence (or both) of superficial thrombophlebitis." data-id="CD004982-fig-0079" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-012-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.2</div> <div class="figure-caption"> <p>Comparison 12 Weight‐adjusted low molecular weight heparin (LMWH) versus non‐steroidal anti‐inflammatory drugs (NSAIDs), Outcome 2 Extension or recurrence (or both) of superficial thrombophlebitis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0079">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-012-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0080"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-012-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-012-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 12 Weight‐adjusted low molecular weight heparin (LMWH) versus non‐steroidal anti‐inflammatory drugs (NSAIDs), Outcome 3 Major bleeding." data-id="CD004982-fig-0080" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-012-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.3</div> <div class="figure-caption"> <p>Comparison 12 Weight‐adjusted low molecular weight heparin (LMWH) versus non‐steroidal anti‐inflammatory drugs (NSAIDs), Outcome 3 Major bleeding. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0080">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-012-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0081"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-012-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-012-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 12 Weight‐adjusted low molecular weight heparin (LMWH) versus non‐steroidal anti‐inflammatory drugs (NSAIDs), Outcome 4 Heparin‐induced thrombocytopenia." data-id="CD004982-fig-0081" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-012-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.4</div> <div class="figure-caption"> <p>Comparison 12 Weight‐adjusted low molecular weight heparin (LMWH) versus non‐steroidal anti‐inflammatory drugs (NSAIDs), Outcome 4 Heparin‐induced thrombocytopenia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0081">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-012-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0082"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-013-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-013-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 13 Prophylactic low molecular weight heparin (LMWH) versus non‐steroidal anti‐inflammatory drugs (NSAIDs), Outcome 1 Venous thromboembolism end‐of‐treatment." data-id="CD004982-fig-0082" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-013-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.1</div> <div class="figure-caption"> <p>Comparison 13 Prophylactic low molecular weight heparin (LMWH) versus non‐steroidal anti‐inflammatory drugs (NSAIDs), Outcome 1 Venous thromboembolism end‐of‐treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0082">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-013-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0083"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-013-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-013-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 13 Prophylactic low molecular weight heparin (LMWH) versus non‐steroidal anti‐inflammatory drugs (NSAIDs), Outcome 2 Venous thromboembolism 3‐month follow‐up." data-id="CD004982-fig-0083" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-013-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.2</div> <div class="figure-caption"> <p>Comparison 13 Prophylactic low molecular weight heparin (LMWH) versus non‐steroidal anti‐inflammatory drugs (NSAIDs), Outcome 2 Venous thromboembolism 3‐month follow‐up. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0083">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-013-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0084"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-013-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-013-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 13 Prophylactic low molecular weight heparin (LMWH) versus non‐steroidal anti‐inflammatory drugs (NSAIDs), Outcome 3 Extension or recurrence (or both) of superficial thrombophlebitis." data-id="CD004982-fig-0084" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-013-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.3</div> <div class="figure-caption"> <p>Comparison 13 Prophylactic low molecular weight heparin (LMWH) versus non‐steroidal anti‐inflammatory drugs (NSAIDs), Outcome 3 Extension or recurrence (or both) of superficial thrombophlebitis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0084">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-013-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0085"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-013-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-013-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 13 Prophylactic low molecular weight heparin (LMWH) versus non‐steroidal anti‐inflammatory drugs (NSAIDs), Outcome 4 Major bleeding." data-id="CD004982-fig-0085" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-013-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.4</div> <div class="figure-caption"> <p>Comparison 13 Prophylactic low molecular weight heparin (LMWH) versus non‐steroidal anti‐inflammatory drugs (NSAIDs), Outcome 4 Major bleeding. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0085">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-013-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0086"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-013-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-013-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 13 Prophylactic low molecular weight heparin (LMWH) versus non‐steroidal anti‐inflammatory drugs (NSAIDs), Outcome 5 Heparin‐induced thrombocytopenia." data-id="CD004982-fig-0086" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-013-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.5</div> <div class="figure-caption"> <p>Comparison 13 Prophylactic low molecular weight heparin (LMWH) versus non‐steroidal anti‐inflammatory drugs (NSAIDs), Outcome 5 Heparin‐induced thrombocytopenia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0086">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-013-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0087"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-014-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-014-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 14 Low molecular weight heparin (LMWH) versus LMWH plus acemetacin, Outcome 1 Pulmonary embolism." data-id="CD004982-fig-0087" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-014-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.1</div> <div class="figure-caption"> <p>Comparison 14 Low molecular weight heparin (LMWH) versus LMWH plus acemetacin, Outcome 1 Pulmonary embolism. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0087">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-014-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0088"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-014-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-014-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 14 Low molecular weight heparin (LMWH) versus LMWH plus acemetacin, Outcome 2 Deep vein thrombosis." data-id="CD004982-fig-0088" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-014-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.2</div> <div class="figure-caption"> <p>Comparison 14 Low molecular weight heparin (LMWH) versus LMWH plus acemetacin, Outcome 2 Deep vein thrombosis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0088">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-014-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0089"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-014-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-014-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 14 Low molecular weight heparin (LMWH) versus LMWH plus acemetacin, Outcome 3 Extension of superficial thrombophlebitis." data-id="CD004982-fig-0089" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-014-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.3</div> <div class="figure-caption"> <p>Comparison 14 Low molecular weight heparin (LMWH) versus LMWH plus acemetacin, Outcome 3 Extension of superficial thrombophlebitis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0089">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-014-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0090"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-014-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-014-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 14 Low molecular weight heparin (LMWH) versus LMWH plus acemetacin, Outcome 4 Pain reduction." data-id="CD004982-fig-0090" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-014-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.4</div> <div class="figure-caption"> <p>Comparison 14 Low molecular weight heparin (LMWH) versus LMWH plus acemetacin, Outcome 4 Pain reduction. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0090">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-014-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0091"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-014-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-014-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 14 Low molecular weight heparin (LMWH) versus LMWH plus acemetacin, Outcome 5 Hyperaemia reduction." data-id="CD004982-fig-0091" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-014-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.5</div> <div class="figure-caption"> <p>Comparison 14 Low molecular weight heparin (LMWH) versus LMWH plus acemetacin, Outcome 5 Hyperaemia reduction. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0091">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-014-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0092"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-014-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-014-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 14 Low molecular weight heparin (LMWH) versus LMWH plus acemetacin, Outcome 6 Tenderness reduction." data-id="CD004982-fig-0092" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-014-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.6</div> <div class="figure-caption"> <p>Comparison 14 Low molecular weight heparin (LMWH) versus LMWH plus acemetacin, Outcome 6 Tenderness reduction. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0092">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-014-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0093"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-014-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-014-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 14 Low molecular weight heparin (LMWH) versus LMWH plus acemetacin, Outcome 7 Palpable cord reduction." data-id="CD004982-fig-0093" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-014-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.7</div> <div class="figure-caption"> <p>Comparison 14 Low molecular weight heparin (LMWH) versus LMWH plus acemetacin, Outcome 7 Palpable cord reduction. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0093">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-014-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0094"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-014-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-014-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 14 Low molecular weight heparin (LMWH) versus LMWH plus acemetacin, Outcome 8 Mortality." data-id="CD004982-fig-0094" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-014-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.8</div> <div class="figure-caption"> <p>Comparison 14 Low molecular weight heparin (LMWH) versus LMWH plus acemetacin, Outcome 8 Mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0094">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-014-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0095"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-014-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-014-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 14 Low molecular weight heparin (LMWH) versus LMWH plus acemetacin, Outcome 9 Major bleeding." data-id="CD004982-fig-0095" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-014-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.9</div> <div class="figure-caption"> <p>Comparison 14 Low molecular weight heparin (LMWH) versus LMWH plus acemetacin, Outcome 9 Major bleeding. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0095">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-014-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0096"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-014-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-014-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 14 Low molecular weight heparin (LMWH) versus LMWH plus acemetacin, Outcome 10 Minor bleeding." data-id="CD004982-fig-0096" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-014-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.10</div> <div class="figure-caption"> <p>Comparison 14 Low molecular weight heparin (LMWH) versus LMWH plus acemetacin, Outcome 10 Minor bleeding. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0096">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-014-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0097"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-014-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-014-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 14 Low molecular weight heparin (LMWH) versus LMWH plus acemetacin, Outcome 11 Adverse events." data-id="CD004982-fig-0097" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-014-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.11</div> <div class="figure-caption"> <p>Comparison 14 Low molecular weight heparin (LMWH) versus LMWH plus acemetacin, Outcome 11 Adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0097">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-014-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0098"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-015-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-015-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 15 Prophylactic low molecular weight heparin (LMWH) plus elastic compression stockings (ECS) versus ECS alone, Outcome 1 Venous thromboembolism." data-id="CD004982-fig-0098" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-015-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.1</div> <div class="figure-caption"> <p>Comparison 15 Prophylactic low molecular weight heparin (LMWH) plus elastic compression stockings (ECS) versus ECS alone, Outcome 1 Venous thromboembolism. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0098">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-015-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0099"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-015-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-015-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 15 Prophylactic low molecular weight heparin (LMWH) plus elastic compression stockings (ECS) versus ECS alone, Outcome 2 Extension or recurrence (or both) of superficial thrombophlebitis." data-id="CD004982-fig-0099" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-015-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.2</div> <div class="figure-caption"> <p>Comparison 15 Prophylactic low molecular weight heparin (LMWH) plus elastic compression stockings (ECS) versus ECS alone, Outcome 2 Extension or recurrence (or both) of superficial thrombophlebitis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0099">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-015-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0100"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-016-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-016-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 16 Low molecular weight heparin (LMWH) versus heparin spray gel, Outcome 1 Deep vein thrombosis." data-id="CD004982-fig-0100" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-016-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.1</div> <div class="figure-caption"> <p>Comparison 16 Low molecular weight heparin (LMWH) versus heparin spray gel, Outcome 1 Deep vein thrombosis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0100">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-016-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0101"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-016-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-016-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 16 Low molecular weight heparin (LMWH) versus heparin spray gel, Outcome 2 Participants with thrombus at 21 days." data-id="CD004982-fig-0101" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-016-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.2</div> <div class="figure-caption"> <p>Comparison 16 Low molecular weight heparin (LMWH) versus heparin spray gel, Outcome 2 Participants with thrombus at 21 days. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0101">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-016-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0102"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-016-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-016-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 16 Low molecular weight heparin (LMWH) versus heparin spray gel, Outcome 3 Allergic reaction or elevated sedimentation rate." data-id="CD004982-fig-0102" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-016-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.3</div> <div class="figure-caption"> <p>Comparison 16 Low molecular weight heparin (LMWH) versus heparin spray gel, Outcome 3 Allergic reaction or elevated sedimentation rate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0102">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-016-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0103"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-017-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-017-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 17 High‐dose unfractionated heparin (UFH) versus low‐dose UFH, Outcome 1 Incidence of venous thromboembolism." data-id="CD004982-fig-0103" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-017-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.1</div> <div class="figure-caption"> <p>Comparison 17 High‐dose unfractionated heparin (UFH) versus low‐dose UFH, Outcome 1 Incidence of venous thromboembolism. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0103">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-017-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0104"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-017-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-017-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 17 High‐dose unfractionated heparin (UFH) versus low‐dose UFH, Outcome 2 Extension or recurrence (or both) of superficial thrombophlebitis." data-id="CD004982-fig-0104" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-017-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.2</div> <div class="figure-caption"> <p>Comparison 17 High‐dose unfractionated heparin (UFH) versus low‐dose UFH, Outcome 2 Extension or recurrence (or both) of superficial thrombophlebitis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0104">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-017-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0105"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-017-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-017-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 17 High‐dose unfractionated heparin (UFH) versus low‐dose UFH, Outcome 3 Major bleeding." data-id="CD004982-fig-0105" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-017-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.3</div> <div class="figure-caption"> <p>Comparison 17 High‐dose unfractionated heparin (UFH) versus low‐dose UFH, Outcome 3 Major bleeding. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0105">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-017-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0106"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-017-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-017-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 17 High‐dose unfractionated heparin (UFH) versus low‐dose UFH, Outcome 4 Heparin‐induced thrombocytopenia." data-id="CD004982-fig-0106" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-017-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.4</div> <div class="figure-caption"> <p>Comparison 17 High‐dose unfractionated heparin (UFH) versus low‐dose UFH, Outcome 4 Heparin‐induced thrombocytopenia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0106">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-017-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0107"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-018-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-018-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 18 Heparin calcium plus elastic compression bandage (ECB) versus ECB alone, Outcome 1 Deep vein thrombosis." data-id="CD004982-fig-0107" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-018-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 18.1</div> <div class="figure-caption"> <p>Comparison 18 Heparin calcium plus elastic compression bandage (ECB) versus ECB alone, Outcome 1 Deep vein thrombosis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0107">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-018-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0108"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-019-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-019-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 19 Heparin subcutaneous (sc) versus defibrotide, Outcome 1 Decrease in the analogue score." data-id="CD004982-fig-0108" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-019-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 19.1</div> <div class="figure-caption"> <p>Comparison 19 Heparin subcutaneous (sc) versus defibrotide, Outcome 1 Decrease in the analogue score. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0108">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-019-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0109"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-019-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-019-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 19 Heparin subcutaneous (sc) versus defibrotide, Outcome 2 Adverse effects of treatment." data-id="CD004982-fig-0109" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-019-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 19.2</div> <div class="figure-caption"> <p>Comparison 19 Heparin subcutaneous (sc) versus defibrotide, Outcome 2 Adverse effects of treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0109">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-019-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0110"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-020-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-020-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 20 Non‐steroidal anti‐inflammatory drugs (NSAIDs) versus placebo, Outcome 1 Venous thromboembolism." data-id="CD004982-fig-0110" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-020-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 20.1</div> <div class="figure-caption"> <p>Comparison 20 Non‐steroidal anti‐inflammatory drugs (NSAIDs) versus placebo, Outcome 1 Venous thromboembolism. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0110">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-020-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0111"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-020-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-020-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 20 Non‐steroidal anti‐inflammatory drugs (NSAIDs) versus placebo, Outcome 2 Extension or recurrence (or both) of superficial thrombophlebitis." data-id="CD004982-fig-0111" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-020-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 20.2</div> <div class="figure-caption"> <p>Comparison 20 Non‐steroidal anti‐inflammatory drugs (NSAIDs) versus placebo, Outcome 2 Extension or recurrence (or both) of superficial thrombophlebitis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0111">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-020-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0112"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-020-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-020-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 20 Non‐steroidal anti‐inflammatory drugs (NSAIDs) versus placebo, Outcome 3 Major bleeding." data-id="CD004982-fig-0112" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-020-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 20.3</div> <div class="figure-caption"> <p>Comparison 20 Non‐steroidal anti‐inflammatory drugs (NSAIDs) versus placebo, Outcome 3 Major bleeding. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0112">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-020-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0113"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-020-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-020-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 20 Non‐steroidal anti‐inflammatory drugs (NSAIDs) versus placebo, Outcome 4 Heparin‐induced thrombocytopenia." data-id="CD004982-fig-0113" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-020-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 20.4</div> <div class="figure-caption"> <p>Comparison 20 Non‐steroidal anti‐inflammatory drugs (NSAIDs) versus placebo, Outcome 4 Heparin‐induced thrombocytopenia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0113">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-020-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0114"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-021-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-021-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 21 Indomethacin versus placebo, Outcome 1 Adverse effects." data-id="CD004982-fig-0114" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-021-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 21.1</div> <div class="figure-caption"> <p>Comparison 21 Indomethacin versus placebo, Outcome 1 Adverse effects.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0114">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-021-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0115"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-022-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-022-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 22 Nimesulide versus diclofenac sodium, Outcome 1 Gastric pain." data-id="CD004982-fig-0115" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-022-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 22.1</div> <div class="figure-caption"> <p>Comparison 22 Nimesulide versus diclofenac sodium, Outcome 1 Gastric pain.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0115">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-022-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0116"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-023-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-023-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 23 Essaven gel versus placebo, Outcome 1 Intolerance." data-id="CD004982-fig-0116" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-023-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 23.1</div> <div class="figure-caption"> <p>Comparison 23 Essaven gel versus placebo, Outcome 1 Intolerance.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0116">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-023-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0117"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-024-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-024-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 24 Thrombectomy plus venoruton plus elastic compression bandage (ECB) versus ECB alone, Outcome 1 Deep vein thrombosis." data-id="CD004982-fig-0117" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-024-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 24.1</div> <div class="figure-caption"> <p>Comparison 24 Thrombectomy plus venoruton plus elastic compression bandage (ECB) versus ECB alone, Outcome 1 Deep vein thrombosis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0117">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-024-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0118"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-025-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-025-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 25 Thrombectomy plus elastic compression bandage (ECB) versus ECB alone, Outcome 1 Deep vein thrombosis." data-id="CD004982-fig-0118" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-025-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 25.1</div> <div class="figure-caption"> <p>Comparison 25 Thrombectomy plus elastic compression bandage (ECB) versus ECB alone, Outcome 1 Deep vein thrombosis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0118">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-025-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0119"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-026-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-026-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 26 Ligation plus elastic compression stockings (ECS) versus ECS alone, Outcome 1 Venous thromboembolism." data-id="CD004982-fig-0119" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-026-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 26.1</div> <div class="figure-caption"> <p>Comparison 26 Ligation plus elastic compression stockings (ECS) versus ECS alone, Outcome 1 Venous thromboembolism. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0119">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-026-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0120"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-026-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-026-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 26 Ligation plus elastic compression stockings (ECS) versus ECS alone, Outcome 2 Extension or recurrence (or both) of superficial thrombophlebitis." data-id="CD004982-fig-0120" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-026-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 26.2</div> <div class="figure-caption"> <p>Comparison 26 Ligation plus elastic compression stockings (ECS) versus ECS alone, Outcome 2 Extension or recurrence (or both) of superficial thrombophlebitis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0120">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-026-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0121"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-027-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-027-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 27 Prophylactic unfractionated heparin (UFH) plus elastic compression stockings (ECS) versus ECS alone, Outcome 1 Venous thromboembolism." data-id="CD004982-fig-0121" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-027-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 27.1</div> <div class="figure-caption"> <p>Comparison 27 Prophylactic unfractionated heparin (UFH) plus elastic compression stockings (ECS) versus ECS alone, Outcome 1 Venous thromboembolism. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0121">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-027-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0122"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-027-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-027-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 27 Prophylactic unfractionated heparin (UFH) plus elastic compression stockings (ECS) versus ECS alone, Outcome 2 Extension or recurrence (or both) of superficial thrombophlebitis." data-id="CD004982-fig-0122" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-027-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 27.2</div> <div class="figure-caption"> <p>Comparison 27 Prophylactic unfractionated heparin (UFH) plus elastic compression stockings (ECS) versus ECS alone, Outcome 2 Extension or recurrence (or both) of superficial thrombophlebitis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0122">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-027-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0123"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-028-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-028-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 28 Oral vasotonin versus placebo, Outcome 1 Cured or substantially better." data-id="CD004982-fig-0123" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-028-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 28.1</div> <div class="figure-caption"> <p>Comparison 28 Oral vasotonin versus placebo, Outcome 1 Cured or substantially better.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0123">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-028-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0124"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-028-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-028-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 28 Oral vasotonin versus placebo, Outcome 2 Poor tolerability." data-id="CD004982-fig-0124" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-028-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 28.2</div> <div class="figure-caption"> <p>Comparison 28 Oral vasotonin versus placebo, Outcome 2 Poor tolerability.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0124">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-028-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0125"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-029-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-029-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 29 Elastic compression bandage (ECB) plus venoruton versus ECB alone, Outcome 1 Deep vein thrombosis." data-id="CD004982-fig-0125" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-029-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 29.1</div> <div class="figure-caption"> <p>Comparison 29 Elastic compression bandage (ECB) plus venoruton versus ECB alone, Outcome 1 Deep vein thrombosis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0125">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-029-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0126"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-030-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-030-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 30 Oral heparansulphate versus oral sulodexide, Outcome 1 Redness disappearance." data-id="CD004982-fig-0126" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-030-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 30.1</div> <div class="figure-caption"> <p>Comparison 30 Oral heparansulphate versus oral sulodexide, Outcome 1 Redness disappearance.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0126">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-030-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0127"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-030-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-030-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 30 Oral heparansulphate versus oral sulodexide, Outcome 2 Pain disappearance." data-id="CD004982-fig-0127" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-030-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 30.2</div> <div class="figure-caption"> <p>Comparison 30 Oral heparansulphate versus oral sulodexide, Outcome 2 Pain disappearance.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0127">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-030-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0128"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-030-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-030-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 30 Oral heparansulphate versus oral sulodexide, Outcome 3 Disappearance of itching." data-id="CD004982-fig-0128" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-030-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 30.3</div> <div class="figure-caption"> <p>Comparison 30 Oral heparansulphate versus oral sulodexide, Outcome 3 Disappearance of itching. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0128">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-030-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0129"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-030-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-030-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 30 Oral heparansulphate versus oral sulodexide, Outcome 4 Oedema improvement." data-id="CD004982-fig-0129" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-030-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 30.4</div> <div class="figure-caption"> <p>Comparison 30 Oral heparansulphate versus oral sulodexide, Outcome 4 Oedema improvement.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0129">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-030-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0130"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-030-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-030-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 30 Oral heparansulphate versus oral sulodexide, Outcome 5 Trophism improvement." data-id="CD004982-fig-0130" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-030-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 30.5</div> <div class="figure-caption"> <p>Comparison 30 Oral heparansulphate versus oral sulodexide, Outcome 5 Trophism improvement.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0130">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-030-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0131"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-031-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-031-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 31 Oxyphenbutazone versus placebo, Outcome 1 Tenderness improvement." data-id="CD004982-fig-0131" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-031-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 31.1</div> <div class="figure-caption"> <p>Comparison 31 Oxyphenbutazone versus placebo, Outcome 1 Tenderness improvement.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0131">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-031-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0132"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-032-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-032-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 32 Vitamin K antagonist (VKA) plus elastic compression stockings (ECS) versus ECS alone, Outcome 1 Venous thromboembolism." data-id="CD004982-fig-0132" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-032-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 32.1</div> <div class="figure-caption"> <p>Comparison 32 Vitamin K antagonist (VKA) plus elastic compression stockings (ECS) versus ECS alone, Outcome 1 Venous thromboembolism. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0132">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-032-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0133"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-032-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-032-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 32 Vitamin K antagonist (VKA) plus elastic compression stockings (ECS) versus ECS alone, Outcome 2 Extension or recurrence (or both) of superficial thrombophlebitis." data-id="CD004982-fig-0133" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-032-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 32.2</div> <div class="figure-caption"> <p>Comparison 32 Vitamin K antagonist (VKA) plus elastic compression stockings (ECS) versus ECS alone, Outcome 2 Extension or recurrence (or both) of superficial thrombophlebitis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0133">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-032-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0134"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-033-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-033-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 33 Stripping plus elastic compression stockings (ECS) versus ECS alone, Outcome 1 Venous thromboembolism." data-id="CD004982-fig-0134" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-033-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 33.1</div> <div class="figure-caption"> <p>Comparison 33 Stripping plus elastic compression stockings (ECS) versus ECS alone, Outcome 1 Venous thromboembolism. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0134">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-033-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0135"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-033-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-033-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 33 Stripping plus elastic compression stockings (ECS) versus ECS alone, Outcome 2 Extension or recurrence (or both) of superficial thrombophlebitis." data-id="CD004982-fig-0135" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-033-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 33.2</div> <div class="figure-caption"> <p>Comparison 33 Stripping plus elastic compression stockings (ECS) versus ECS alone, Outcome 2 Extension or recurrence (or both) of superficial thrombophlebitis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0135">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-033-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0136"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-034-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-034-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 34 Enzyme therapy versus placebo, Outcome 1 Pain reduction." data-id="CD004982-fig-0136" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-034-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 34.1</div> <div class="figure-caption"> <p>Comparison 34 Enzyme therapy versus placebo, Outcome 1 Pain reduction.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0136">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-034-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0137"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-034-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-034-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 34 Enzyme therapy versus placebo, Outcome 2 Responders." data-id="CD004982-fig-0137" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-034-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 34.2</div> <div class="figure-caption"> <p>Comparison 34 Enzyme therapy versus placebo, Outcome 2 Responders.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0137">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-034-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0138"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-035-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-035-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 35 Desmin intramuscular (im) 200 versus desmin 100, Outcome 1 Adverse events." data-id="CD004982-fig-0138" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-035-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 35.1</div> <div class="figure-caption"> <p>Comparison 35 Desmin intramuscular (im) 200 versus desmin 100, Outcome 1 Adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0138">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-035-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0139"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-035-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-035-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 35 Desmin intramuscular (im) 200 versus desmin 100, Outcome 2 Adverse drug reactions." data-id="CD004982-fig-0139" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-035-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 35.2</div> <div class="figure-caption"> <p>Comparison 35 Desmin intramuscular (im) 200 versus desmin 100, Outcome 2 Adverse drug reactions. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0139">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-035-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0140"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-036-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-036-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 36 Desmin subcutaneous (sc) 2 × 100 versus desmin 100, Outcome 1 Adverse events." data-id="CD004982-fig-0140" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-036-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 36.1</div> <div class="figure-caption"> <p>Comparison 36 Desmin subcutaneous (sc) 2 × 100 versus desmin 100, Outcome 1 Adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0140">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-036-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0141"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-036-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-036-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 36 Desmin subcutaneous (sc) 2 × 100 versus desmin 100, Outcome 2 Adverse drug reactions." data-id="CD004982-fig-0141" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-036-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 36.2</div> <div class="figure-caption"> <p>Comparison 36 Desmin subcutaneous (sc) 2 × 100 versus desmin 100, Outcome 2 Adverse drug reactions. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0141">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-036-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0142"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-037-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-037-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 37 Prophylactic low molecular weight heparin (LMWH) plus elastic compression stockings (ECS) versus prophylactic LMWH, Outcome 1 Pain (VAS, cm) at 3 weeks." data-id="CD004982-fig-0142" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-037-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 37.1</div> <div class="figure-caption"> <p>Comparison 37 Prophylactic low molecular weight heparin (LMWH) plus elastic compression stockings (ECS) versus prophylactic LMWH, Outcome 1 Pain (VAS, cm) at 3 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0142">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-037-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0143"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-037-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-037-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 37 Prophylactic low molecular weight heparin (LMWH) plus elastic compression stockings (ECS) versus prophylactic LMWH, Outcome 2 Skin erythema (cm2) at 3 weeks." data-id="CD004982-fig-0143" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-037-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 37.2</div> <div class="figure-caption"> <p>Comparison 37 Prophylactic low molecular weight heparin (LMWH) plus elastic compression stockings (ECS) versus prophylactic LMWH, Outcome 2 Skin erythema (cm<sup>2</sup>) at 3 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0143">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-037-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0144"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-037-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-037-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 37 Prophylactic low molecular weight heparin (LMWH) plus elastic compression stockings (ECS) versus prophylactic LMWH, Outcome 3 SF‐36 physical score at 3 weeks." data-id="CD004982-fig-0144" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-037-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 37.3</div> <div class="figure-caption"> <p>Comparison 37 Prophylactic low molecular weight heparin (LMWH) plus elastic compression stockings (ECS) versus prophylactic LMWH, Outcome 3 SF‐36 physical score at 3 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0144">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-037-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004982-fig-0145"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/urn:x-wiley:14651858:media:CD004982:CD004982-CMP-037-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_t/tCD004982-CMP-037-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 37 Prophylactic low molecular weight heparin (LMWH) plus elastic compression stockings (ECS) versus prophylactic LMWH, Outcome 4 SF‐36 mental score at 3 weeks." data-id="CD004982-fig-0145" src="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-037-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 37.4</div> <div class="figure-caption"> <p>Comparison 37 Prophylactic low molecular weight heparin (LMWH) plus elastic compression stockings (ECS) versus prophylactic LMWH, Outcome 4 SF‐36 mental score at 3 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-fig-0145">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/media/CDSR/CD004982/image_n/nCD004982-CMP-037-04.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD004982-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Fondaparinux compared to placebo for superficial thrombophlebitis of the leg</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Fondaparinux compared to placebo for superficial thrombophlebitis of the leg</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with ST of the leg<br/> <b>Settings:</b> hospitalised or non‐hospitalised<br/> <b>Intervention:</b> fondaparinux<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Fondaparinux</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Symptomatic VTE</b><br/> Ventilation‐perfusion scanning, helical computed tomography, pulmonary angiography, autopsy, ultrasonography, or venography<br/> Follow‐up: 77 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>13 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>2 per 1000</b><br/> (1 to 7) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.15</b> <br/> (0.04 to 0.5) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3002<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Major bleeding</b><br/> Follow‐up: 77 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>1 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>1 per 1000</b><br/> (0 to 11) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.99</b> <br/> (0.06 to 15.86) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2987<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Extension of ST</b><br/> Ultrasonography<br/> Follow‐up: 77 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>34 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>3 per 1000</b><br/> (1 to 7) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.08</b> <br/> (0.03 to 0.22) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3002<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Recurrence of ST</b><br/> Ultrasonography<br/> Follow‐up: 77 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>16 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>3 per 1000</b><br/> (1 to 9) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.21</b> <br/> (0.08 to 0.54) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3002<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mortality</b><br/> Follow‐up: 77 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1 per 1000</b><br/> (0 to 15) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2</b> <br/> (0.18 to 22) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3002<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Minor bleeding</b><br/> Follow‐up: 77 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>4 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>6 per 1000</b><br/> (2 to 17) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.49</b> <br/> (0.53 to 4.17) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2987<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate<sup>1</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects of treatment</b><br/> Follow‐up: 77 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>33 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>37 per 1000</b><br/> (26 to 54) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.13</b> <br/> (0.78 to 1.65) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2987<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>ST:</b> superficial thrombophlebitis; <b>VTE:</b> venous thromboembolism. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Evidence downgraded one level for imprecision due to a low number of events. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Fondaparinux compared to placebo for superficial thrombophlebitis of the leg</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/full#CD004982-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD004982-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Prophylactic LMWH versus placebo for superficial thrombophlebitis of the leg</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Prophylactic LMWH versus placebo for superficial thrombophlebitis of the leg</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with ST of the leg<br/> <b>Settings:</b> hospitalised and non‐hospitalised<br/> <b>Intervention:</b> prophylactic LMWH versus placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Prophylactic LMWH</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Symptomatic VTE</b><br/> Follow‐up: 97 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>45 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>54 per 1000</b><br/> (17 to 174) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.22</b> <br/> (0.38 to 3.89) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>222<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Major bleeding</b><br/> Follow‐up: 97 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>222<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 episodes of major bleeding</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Extension or recurrence (or both) of ST</b><br/> Follow‐up: 97 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>330 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>145 per 1000</b><br/> (86 to 244) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.44</b> <br/> (0.26 to 0.74) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>222<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data not available</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Minor bleeding</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data not available</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects of treatment</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data not available</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>LMWH:</b> low molecular weight heparin; <b>RR:</b> risk ratio; <b>ST:</b> superficial thrombophlebitis; <b>VTE:</b> venous thromboembolism. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Evidence downgraded one level due to unclear random sequence generation and incomplete outcome data.<br/> <sup>2</sup>Evidence downgraded one level for imprecision due to a low number of events. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Prophylactic LMWH versus placebo for superficial thrombophlebitis of the leg</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/full#CD004982-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD004982-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Therapeutic LMWH versus placebo for superficial thrombophlebitis of the leg</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Therapeutic LMWH versus placebo for superficial thrombophlebitis of the leg</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with ST of the leg<br/> <b>Settings:</b> hospitalised and non‐hospitalised<br/> <b>Intervention:</b> therapeutic LMWH versus placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>Placebo</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>Therapeutic LMWH</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Symptomatic VTE</b><br/> Follow‐up: 97 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>45 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>38 per 1000</b> </p> <p>(10 to 137)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.85</b> <br/> (0.23 to 3.06) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>218<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Major bleeding</b><br/> Follow‐up: 97 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>218<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No episodes of major bleeding</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Extension or recurrence (or both) of ST</b><br/> Follow‐up: 97 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>330 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>152 per 1000</b> </p> <p>(89 to 254)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.46</b> <br/> (0.27 to 0.77) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>218<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data not available</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Minor bleeding</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data not available</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects of treatment</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data not available</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>LMWH:</b> low molecular weight heparin; <b>RR:</b> risk ratio; <b>ST:</b> superficial thrombophlebitis; <b>VTE:</b> venous thromboembolism. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Evidence downgraded one level due to an unclear random sequence generation and incomplete outcome data.<br/> <sup>2</sup>Evidence downgraded one level for imprecision due to a low number of events. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Therapeutic LMWH versus placebo for superficial thrombophlebitis of the leg</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/full#CD004982-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD004982-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">NSAIDs versus placebo for superficial thrombophlebitis of the leg</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>NSAIDs versus placebo for superficial thrombophlebitis of the leg</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with superficial thrombophlebitis of the leg<br/> <b>Settings:</b> hospitalised and non‐hospitalised<br/> <b>Intervention:</b> NSAIDs versus placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>NSAIDs</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Symptomatic VTE</b><br/> Follow‐up: 97 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>45 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>41 per 1000</b><br/> (11 to 146) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.91</b> <br/> (0.25 to 3.28) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>211<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Major bleeding</b><br/> Follow‐up: 97 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>211<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 episodes of major bleeding</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Extension or recurrence (or both) of ST</b><br/> Follow‐up: 97 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>330 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>152 per 1000</b><br/> (89 to 258) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.46</b> <br/> (0.27 to 0.78) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>211<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data not available</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Minor bleeding</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data not available</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects of treatment</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data not available</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>NSAIDs:</b> non‐steroidal anti‐inflammatory drugs; <b>RR:</b> risk ratio; <b>ST:</b> superficial thrombophlebitis; <b>VTE:</b> venous thromboembolism. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Evidence downgraded one level due to an unclear random sequence generation and incomplete outcome data.<br/> <sup>2</sup>Evidence downgraded one level for imprecision due to a low number of events. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">NSAIDs versus placebo for superficial thrombophlebitis of the leg</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/full#CD004982-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004982-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Fondaparinux versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Pulmonary embolism <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Deep vein thrombosis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Deep vein thrombosis or pulmonary embolism <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Extension of superficial thrombophlebitis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Recurrence of superficial thrombophlebitis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Major bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Clinically relevant non‐major bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Minor bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Arterial thromboembolic complication <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Adverse effects of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Non‐fatal serious adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Fondaparinux versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004982-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Fondaparinux versus rivaroxaban</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Pulmonary embolism <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Deep vein thrombosis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Deep vein thrombosis or pulmonary embolism <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Extension of superficial thrombophlebitis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Recurrence of superficial thrombophlebitis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Major bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Clinically relevant non‐major bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Minor bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Adverse effects of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Fondaparinux versus rivaroxaban</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004982-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Prophylactic low molecular weight heparin (LMWH) versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Venous thromboembolism end‐of‐treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Venous thromboembolism 3‐month follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Extension or recurrence (or both) of superficial thrombophlebitis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Major bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Heparin‐induced thrombocytopenia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Prophylactic low molecular weight heparin (LMWH) versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004982-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Therapeutic low molecular weight heparin (LMWH) versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Venous thromboembolism end‐of‐treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Venous thromboembolism 3‐month follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Extension or recurrence (or both) of superficial thrombophlebitis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Major bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Heparin‐induced thrombocytopenia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Therapeutic low molecular weight heparin (LMWH) versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004982-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Thirty‐day prophylactic low molecular weight heparin (LMWH) versus 30‐day intermediate LMWH</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Venous thromboembolism end‐of‐treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Venous thromboembolism 3‐month follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Symptomatic deep vein thrombosis end‐of‐treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Symptomatic deep vein thrombosis 3‐month follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Extension of superficial thrombophlebitis 3‐month follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Recurrence of superficial thrombophlebitis 3‐month follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Thirty‐day prophylactic low molecular weight heparin (LMWH) versus 30‐day intermediate LMWH</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004982-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Thirty‐day prophylactic low molecular weight heparin (LMWH) versus 10‐day intermediate LMWH</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Venous thromboembolism end‐of‐treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Venous thromboembolism 3‐month follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Symptomatic deep vein thrombosis end‐of‐treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Symptomatic deep vein thrombosis 3‐month follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Extension of superficial thrombophlebitis 3‐month follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Recurrence of superficial thrombophlebitis 3‐month follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Thirty‐day prophylactic low molecular weight heparin (LMWH) versus 10‐day intermediate LMWH</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004982-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Thirty‐day intermediate low molecular weight heparin (LMWH) versus 10‐day intermediate LMWH</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Venous thromboembolism end‐of‐treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Venous thromboembolism 3‐month follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Symptomatic deep vein thrombosis end‐of‐treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Symptomatic deep vein thrombosis 3‐month follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Extension of superficial thrombophlebitis 3‐month follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Recurrence of superficial thrombophlebitis 3‐month follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Thirty‐day intermediate low molecular weight heparin (LMWH) versus 10‐day intermediate LMWH</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004982-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Six‐week prophylactic low molecular weight heparin (LMWH) versus six‐week intermediate LMWH</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Symptomatic venous thromboembolism <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Symptomatic pulmonary embolism <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Superficial thrombophlebitis progression into deep vein thrombosis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Major bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Six‐week prophylactic low molecular weight heparin (LMWH) versus six‐week intermediate LMWH</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004982-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Fixed‐dose low molecular weight heparin (LMWH) versus weight‐adjusted LMWH</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Superficial thrombophlebitis or venous thromboembolism <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Venous thromboembolism <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>238</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.10, 2.72]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Superficial thrombophlebitis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Swelling disappearance <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Tenderness disappearance <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Pain disappearance <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Pitting oedema disappearance <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Collateral veins disappearance <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Redness disappearance <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Palpable cord disappearance <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Major bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>238</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Heparin‐induced thrombocytopenia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>238</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.07, 16.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Fixed‐dose low molecular weight heparin (LMWH) versus weight‐adjusted LMWH</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004982-tbl-0014"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Therapeutic low molecular weight heparin (LMWH) versus saphenofemoral disconnection</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Venous thromboembolism <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Extension or recurrence (or both) of superficial thrombophlebitis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Major bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Complications <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Therapeutic low molecular weight heparin (LMWH) versus saphenofemoral disconnection</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004982-tbl-0015"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">Fixed‐dose low molecular weight heparin (LMWH) versus non‐steroidal anti‐inflammatory drugs (NSAIDs)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Venous thromboembolism <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>278</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.24, 3.63]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Extension or recurrence (or both) of superficial thrombophlebitis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>331</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.58, 1.78]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Major bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>335</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Heparin‐induced thrombocytopenia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>278</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">Fixed‐dose low molecular weight heparin (LMWH) versus non‐steroidal anti‐inflammatory drugs (NSAIDs)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-tbl-0015">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004982-tbl-0016"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">Weight‐adjusted low molecular weight heparin (LMWH) versus non‐steroidal anti‐inflammatory drugs (NSAIDs)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Venous thromboembolism <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Extension or recurrence (or both) of superficial thrombophlebitis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Major bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Heparin‐induced thrombocytopenia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">Weight‐adjusted low molecular weight heparin (LMWH) versus non‐steroidal anti‐inflammatory drugs (NSAIDs)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-tbl-0016">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004982-tbl-0017"> <div class="table-heading"><span class="table-label">Comparison 13.</span> <span class="table-title">Prophylactic low molecular weight heparin (LMWH) versus non‐steroidal anti‐inflammatory drugs (NSAIDs)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Venous thromboembolism end‐of‐treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Venous thromboembolism 3‐month follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Extension or recurrence (or both) of superficial thrombophlebitis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Major bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Heparin‐induced thrombocytopenia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 13.</span> <span class="table-title">Prophylactic low molecular weight heparin (LMWH) versus non‐steroidal anti‐inflammatory drugs (NSAIDs)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-tbl-0017">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004982-tbl-0018"> <div class="table-heading"><span class="table-label">Comparison 14.</span> <span class="table-title">Low molecular weight heparin (LMWH) versus LMWH plus acemetacin</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Pulmonary embolism <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Deep vein thrombosis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Extension of superficial thrombophlebitis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Pain reduction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Hyperaemia reduction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Tenderness reduction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Palpable cord reduction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Major bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Minor bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 14.</span> <span class="table-title">Low molecular weight heparin (LMWH) versus LMWH plus acemetacin</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-tbl-0018">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004982-tbl-0019"> <div class="table-heading"><span class="table-label">Comparison 15.</span> <span class="table-title">Prophylactic low molecular weight heparin (LMWH) plus elastic compression stockings (ECS) versus ECS alone</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Venous thromboembolism <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Extension or recurrence (or both) of superficial thrombophlebitis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 15.</span> <span class="table-title">Prophylactic low molecular weight heparin (LMWH) plus elastic compression stockings (ECS) versus ECS alone</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-tbl-0019">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004982-tbl-0020"> <div class="table-heading"><span class="table-label">Comparison 16.</span> <span class="table-title">Low molecular weight heparin (LMWH) versus heparin spray gel</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Deep vein thrombosis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [0.03, 2.70]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Participants with thrombus at 21 days <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Allergic reaction or elevated sedimentation rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 16.</span> <span class="table-title">Low molecular weight heparin (LMWH) versus heparin spray gel</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-tbl-0020">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004982-tbl-0021"> <div class="table-heading"><span class="table-label">Comparison 17.</span> <span class="table-title">High‐dose unfractionated heparin (UFH) versus low‐dose UFH</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Incidence of venous thromboembolism <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Extension or recurrence (or both) of superficial thrombophlebitis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Major bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Heparin‐induced thrombocytopenia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 17.</span> <span class="table-title">High‐dose unfractionated heparin (UFH) versus low‐dose UFH</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-tbl-0021">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004982-tbl-0022"> <div class="table-heading"><span class="table-label">Comparison 18.</span> <span class="table-title">Heparin calcium plus elastic compression bandage (ECB) versus ECB alone</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Deep vein thrombosis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 18.</span> <span class="table-title">Heparin calcium plus elastic compression bandage (ECB) versus ECB alone</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-tbl-0022">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004982-tbl-0023"> <div class="table-heading"><span class="table-label">Comparison 19.</span> <span class="table-title">Heparin subcutaneous (sc) versus defibrotide</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Decrease in the analogue score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Adverse effects of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 19.</span> <span class="table-title">Heparin subcutaneous (sc) versus defibrotide</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-tbl-0023">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004982-tbl-0024"> <div class="table-heading"><span class="table-label">Comparison 20.</span> <span class="table-title">Non‐steroidal anti‐inflammatory drugs (NSAIDs) versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Venous thromboembolism <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Extension or recurrence (or both) of superficial thrombophlebitis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Major bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Heparin‐induced thrombocytopenia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 20.</span> <span class="table-title">Non‐steroidal anti‐inflammatory drugs (NSAIDs) versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-tbl-0024">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004982-tbl-0025"> <div class="table-heading"><span class="table-label">Comparison 21.</span> <span class="table-title">Indomethacin versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 21.</span> <span class="table-title">Indomethacin versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-tbl-0025">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004982-tbl-0026"> <div class="table-heading"><span class="table-label">Comparison 22.</span> <span class="table-title">Nimesulide versus diclofenac sodium</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Gastric pain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 22.</span> <span class="table-title">Nimesulide versus diclofenac sodium</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-tbl-0026">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004982-tbl-0027"> <div class="table-heading"><span class="table-label">Comparison 23.</span> <span class="table-title">Essaven gel versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Intolerance <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 23.</span> <span class="table-title">Essaven gel versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-tbl-0027">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004982-tbl-0028"> <div class="table-heading"><span class="table-label">Comparison 24.</span> <span class="table-title">Thrombectomy plus venoruton plus elastic compression bandage (ECB) versus ECB alone</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Deep vein thrombosis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 24.</span> <span class="table-title">Thrombectomy plus venoruton plus elastic compression bandage (ECB) versus ECB alone</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-tbl-0028">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004982-tbl-0029"> <div class="table-heading"><span class="table-label">Comparison 25.</span> <span class="table-title">Thrombectomy plus elastic compression bandage (ECB) versus ECB alone</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Deep vein thrombosis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 25.</span> <span class="table-title">Thrombectomy plus elastic compression bandage (ECB) versus ECB alone</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-tbl-0029">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004982-tbl-0030"> <div class="table-heading"><span class="table-label">Comparison 26.</span> <span class="table-title">Ligation plus elastic compression stockings (ECS) versus ECS alone</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Venous thromboembolism <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Extension or recurrence (or both) of superficial thrombophlebitis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 26.</span> <span class="table-title">Ligation plus elastic compression stockings (ECS) versus ECS alone</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-tbl-0030">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004982-tbl-0031"> <div class="table-heading"><span class="table-label">Comparison 27.</span> <span class="table-title">Prophylactic unfractionated heparin (UFH) plus elastic compression stockings (ECS) versus ECS alone</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Venous thromboembolism <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Extension or recurrence (or both) of superficial thrombophlebitis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 27.</span> <span class="table-title">Prophylactic unfractionated heparin (UFH) plus elastic compression stockings (ECS) versus ECS alone</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-tbl-0031">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004982-tbl-0032"> <div class="table-heading"><span class="table-label">Comparison 28.</span> <span class="table-title">Oral vasotonin versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Cured or substantially better <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Poor tolerability <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 28.</span> <span class="table-title">Oral vasotonin versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-tbl-0032">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004982-tbl-0033"> <div class="table-heading"><span class="table-label">Comparison 29.</span> <span class="table-title">Elastic compression bandage (ECB) plus venoruton versus ECB alone</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Deep vein thrombosis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 29.</span> <span class="table-title">Elastic compression bandage (ECB) plus venoruton versus ECB alone</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-tbl-0033">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004982-tbl-0034"> <div class="table-heading"><span class="table-label">Comparison 30.</span> <span class="table-title">Oral heparansulphate versus oral sulodexide</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Redness disappearance <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Pain disappearance <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Disappearance of itching <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Oedema improvement <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Trophism improvement <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 30.</span> <span class="table-title">Oral heparansulphate versus oral sulodexide</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-tbl-0034">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004982-tbl-0035"> <div class="table-heading"><span class="table-label">Comparison 31.</span> <span class="table-title">Oxyphenbutazone versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Tenderness improvement <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 31.</span> <span class="table-title">Oxyphenbutazone versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-tbl-0035">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004982-tbl-0036"> <div class="table-heading"><span class="table-label">Comparison 32.</span> <span class="table-title">Vitamin K antagonist (VKA) plus elastic compression stockings (ECS) versus ECS alone</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Venous thromboembolism <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Extension or recurrence (or both) of superficial thrombophlebitis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 32.</span> <span class="table-title">Vitamin K antagonist (VKA) plus elastic compression stockings (ECS) versus ECS alone</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-tbl-0036">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004982-tbl-0037"> <div class="table-heading"><span class="table-label">Comparison 33.</span> <span class="table-title">Stripping plus elastic compression stockings (ECS) versus ECS alone</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Venous thromboembolism <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Extension or recurrence (or both) of superficial thrombophlebitis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 33.</span> <span class="table-title">Stripping plus elastic compression stockings (ECS) versus ECS alone</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-tbl-0037">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004982-tbl-0038"> <div class="table-heading"><span class="table-label">Comparison 34.</span> <span class="table-title">Enzyme therapy versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Pain reduction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Responders <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 34.</span> <span class="table-title">Enzyme therapy versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-tbl-0038">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004982-tbl-0039"> <div class="table-heading"><span class="table-label">Comparison 35.</span> <span class="table-title">Desmin intramuscular (im) 200 versus desmin 100</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Adverse drug reactions <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 35.</span> <span class="table-title">Desmin intramuscular (im) 200 versus desmin 100</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-tbl-0039">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004982-tbl-0040"> <div class="table-heading"><span class="table-label">Comparison 36.</span> <span class="table-title">Desmin subcutaneous (sc) 2 × 100 versus desmin 100</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Adverse drug reactions <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 36.</span> <span class="table-title">Desmin subcutaneous (sc) 2 × 100 versus desmin 100</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-tbl-0040">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004982-tbl-0041"> <div class="table-heading"><span class="table-label">Comparison 37.</span> <span class="table-title">Prophylactic low molecular weight heparin (LMWH) plus elastic compression stockings (ECS) versus prophylactic LMWH</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Pain (VAS, cm) at 3 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Skin erythema (cm<sup>2</sup>) at 3 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 SF‐36 physical score at 3 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 SF‐36 mental score at 3 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 37.</span> <span class="table-title">Prophylactic low molecular weight heparin (LMWH) plus elastic compression stockings (ECS) versus prophylactic LMWH</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004982.pub6/references#CD004982-tbl-0041">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD004982.pub6&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD004982-note-0003">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD004982-note-0004">فارسی</a> </li> <li class="section-language"> <a class="" href="ms#CD004982-note-0002">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pt#CD004982-note-0001">Português</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD004982-note-0011">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004982\x2epub6\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004982\x2epub6\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004982\x2epub6\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004982\x2epub6"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004982\x2epub6\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004982\x2epub6\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004982\x2epub6\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004982\x2epub6\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004982\x2epub6\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004982\x2epub6"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004982\x2epub6\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004982\x2epub6\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004982\x2epub6\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004982\x2epub6"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004982\x2epub6\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004982\x2epub6\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004982\x2epub6\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004982\x2epub6"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=k5rEBE5b&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004982.pub6&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD004982.pub6';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD004982.pub6/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD004982.pub6/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004982.pub6%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740711466433"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD004982.pub6/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740711466437"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD004982.pub6/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d26203c1d9377',t:'MTc0MDcxMTQ2Ni4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 